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Abstract 
In this thesis branched/hyperbranched polymers were synthesised and used 
for the formulation of drug nanoparticles via bottom-up techniques as well as for the 
encapsulation and release of water-insoluble drugs. In the first Chapter current bot-
tom-up techniques and encapsulation techniques are reviewed. A special focus was 
put on polymer architectures used for drug release and encapsulation and their syn-
thesis.  
In Chapter 2, branched polymers have been synthesised by conventional rad-
ical polymerisation. Three different core forming monomers and cross-linkers were 
used and the branched polymer products were tested for their ability to stabilise 
emulsions for emulsion freeze-drying. Nanoparticles of two model water-insoluble 
drugs were successfully produced and the optimal polymer and set-up was ascer-
tained and used to form nanoparticles of triclosan, an antimicrobial agent. Enhanced 
activity was subsequently tested against Candida albicans. The influence of core 
composition on the emulsion freeze-drying process i.e. stability, nanoparticle yield 
and size, was investigated as well by varying the cross-linkage ratio. Drug nanopar-
ticles with narrow particle size distribution, small uniform sizes and long storage 
stability could successfully be obtained using emulsion freeze-drying under with 
different branched polymers.  
In Chapter 3, these polymers were tested for a simple solvent evaporation 
technique to obtain drug nanoparticles. Drug nanoparticles of below 250 nm with 
narrow particle size distribution and long storage stability were obtained, by simply 
evaporating an ethanolic solution of branched polymers and drugs in ratios as high 
as 1:1. The obtained drug nanoparticles exhibited very favourable dissolution behav-
iour compared to non-processed drugs.  
Atom-transfer radical-polymerisation, a reversible-deactivation radical 
polymerisation technique was used in Chapter 4 to afford better polymerisation con-
trol and thermoresponsive polymers were synthesised. These polymers were tested 
for their ability to form and stabilise drug nanoparticle suspensions in dependence of 
core compositions. Nanosuspensions with high drug to polymer ratios of 1:1, high 
nanoparticle yields, and small particle sizes could be obtained.  
In Chapter 5 reversible addition-fragmentation chain transfer polymerisation 
was used to synthesise star hyperbranched polymers by a ‘core-first’ approach with 
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a pH responsive core and thermoresponsive arms. The influence of core composition 
on pH and temperature responsive behaviour was systematically investigated. The 
polymer with the most favourable core composition was chosen and investigated for 
drug encapsulation and release. A higher encapsulation efficiency as well as pro-
longed and continues release was found in comparison to a diblock analogue. Z-
group reduction via aminolysis to a thiol was used for post-polymerisation surface 
modifications. A fluorescent dye was successfully ‘clicked’ on by thiol-ene ‘click’ 
chemistry. The thiol end-group was subsequently used for gelation via the formation 
of disulphide bonds.  
In the following work it was possible to successfully show the versatility of 
branched polymers for the use in different bottom-up techniques, as well as nanocar-
riers for biomedical applications. Due to their better encapsulation efficiency and 
favourable release profiles, as well as their ability to be form and stabilise drug na-
noparticles, making further additives redundant, the use of branched polymers for 
biomedical application is a favourable alternative to what is currently found on the 
market.    
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1.1. Introduction 
A survey done in 1988 over a period of 20 years demonstrated that 40 % of all 
pharmaceutical drugs produced in major companies in the United Kingdom showed 
low bioavailabilty.1 Bioavailability is defined as the fraction of an administered drug 
that reaches systematic circulation.2 Drugs with low bioavailability are prone to either 
accumulate in tissue due to their high lipophilicity or be eliminated via a first-pass 
metabolism in the intestines or liver, due to low solubility and inability to pass the 
intestinal walls. Hence, many water-insoluble drugs need to be administered intrave-
nously and in high quantities to reach target sites in suitable concentrations, which 
often goes hand in hand with discomfort for patients. Estimation in 2000 put the cost 
of drug development, from first discovery to approval for a single drug at 800 million3, 
4, with one of the reasons being that only one in ten developed drugs achieve final 
approval.5 Methods like high-throughput screening,6 computer-aided and structure-
based drug design 7 as well as fragment-based lead discovery 8 increased the rate of 
success in pharmaceutical research. Due to the adoption of these methods, drugs 
showing low bioavailability may be identified early on. Hence, the percentage of 
drugs not passing Phase I testing because of low bioavailability decreased from 40 % 
to 10 % between 1991 and 2000.5 However, 40 % of approved drugs as well as an 
estimate of 90 % of developed drugs in the pipeline still exhibit poor water solubility9 
and highly efficient drugs are still being abandoned early on because of low solubility. 
As an example of this, a list of essential drugs compiled by the world health organi-
sation in 2004 cited that only 23.6 % of the listed drugs were Biopharmaceutics Clas-
sification System (BCS) Class I 
drugs (high solubility and high 
permeability, Figure 1.1.), as de-
fined by Amidon,10 and thus 
showed high bioavailability.11 
Over the past years, much re-
search efforts went into tackling 
the poor water solubility prob-
lem. Various methods have been Figure 1.1. Biopharmaceutics Classification System  
3 
 
developed, for example, cyclodextrin complexation12, crystal modification,13 solid 
dispersions,14 polymeric micelles,15 lipid-based delivery,16 and hot melt extrusion.17 
Another highly researched topic is the prodrug design approach, where the 
drug is kept in an inactive state exhibiting better solubility or permeability. However, 
this approach relies on specific metabolic mechanisms to change the inactive prodrug 
to an active one.18 Prodrugs can either consist of a drug linked to a carrier or antibody 
that is cleaved off by a metabolic mechanism or be a precursor that is turned into the 
active form by hydrolyses, oxidation or other metabolic reactions.19-22 In addition to 
the difficulty in synthesis, in-vitro testing is done in rodents and other animals, which 
exhibit slightly different metabolistic conditions compared to humans, e.g., enzymes 
or level of transporters, metabolites from carriers, or metabolic intermediates during 
activation.23 Another highly researched area is the formulation by nanotechnology, 
where the size of drug particles is decreased to the nanometre range. By downsizing 
the poorly water-soluble drug particles, thermodynamic and kinetic characteristics 
change, giving rise to new attributes like water solubility and applications such as dry 
powder inhalation. 24,25 Solubility is increased based on the Ostwald-Freundlich equa-
tion (1.1) 26-28: 
log
𝑐𝑆
𝑐∞
=
2𝜎𝑉
2.303𝑅𝑇𝜌𝑟
      (𝟏. 𝟏) 
With 𝑐𝑆 = saturation solubility, 𝑐∞= solubility of large particles, σ = interfacial tension, 
V = atomic volume, R = gas constant, T = absolute temperature, ρ = density of the 
solid, r = radius. 
The dissolution rate increases at the same time due to the decrease in size and 
subsequent increase in surface area as shown in the Noyes-Whitney equation (1.2) 29: 
𝑑𝑐
𝑑𝑡
= 𝐷 × 𝐴 (
𝑐𝑠 − 𝑐𝑥
ℎ
)      (𝟏. 𝟐) 
With D = diffusion coefficient, A = surface area of the particle, 𝑐𝑆 = saturation solu-
bility, 𝑐𝑥 = bulk concentration and h = diffusional distance.
30  
There are two major strategies in nanoparticle formulation: top-down and bot-
tom-up approaches. That is, the drug material can either function as a nanoparticle by 
being downsized from large particles (top-down) or grown from molecules in solution 
(bottom-up). Drugs may be also encapsulated in nanoparticle forming material (e.g., 
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liposomes, dendrimers, polymers). These encapsulation methods may be classified in 
the bottom-up category.  
In this Chapter, the working principles and recent development of various 
methods developed for bottom-up techniques and encapsulation in nanoparticles will 
be reviewed. Due to recent excellent reviews on top-down approaches,31,32 we focus 
on bottom-up techniques (particularly the novel cryogenic methods, supercritical 
fluid-related methods) and encapsulation approaches, discuss how solvents and addi-
tives may be selected to achieve stable and uniform nanoparticles dispersions, and 
also describe the applications of such poorly water-soluble drug nanoparticles. An-
other focus will be on encapsulation techniques using polymeric nanoparticles. A brief 
overview will be given of structures being used for encapsulation and polymerisation 
techniques. We conclude the review with a summary and perspective on the develop-
ment and challenges of nanoformulation techniques.  
1.2. Bottom-up techniques 
Methods starting from solutions to afford nanoparticles are categorized as bot-
tom-up techniques. In the following section, different approaches are described, and 
an overview of advantages and disadvantages is given in Table 1.1.  
1.2.1. Nanoparticle formation by precipitation techniques 
1.2.1.1. Solvent anti-solvent precipitation 
Solvent anti-solvent precipitation is the most straight forward bottom-up tech-
nique for producing nanoparticles. In the solvent anti-solvent process a water insolu-
ble drug is dissolved in an organic solvent. The solution is then mixed with a solvent 
in which the drug is not soluble (antisolvent), containing stabilisers. The chosen sol-
vents need to be miscible with each other. Precipitation of nanoparticle sized drug is 
immediate.33 Formation of nanoparticles is due to the Marangoni effect and directly 
dependent on interfacial turbulence of the phase interface and flow, diffusion and sur-
face tension.34 These are influenced by the speed of mixing, solvent, stabiliser, and 
temperature. Studies on mixing have shown that an increase of mixing speed de-
creases particle size. Higher mixing speed leads to greater micromixing i.e. the mixing 
on molecular level, between two phases. As a result, mass transfer and diffusion from 
one phase to the other increases and a higher supersaturation of drug in the antisolvent 
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phase is reached. This causes faster nucleation and subsequently a narrower particle 
size distribution (PSD). 35  
Stabilisers prevent Ostwald ripening by covering the surface of the formed 
nanoparticles. Surfactants can also be used as surface wetting agents for orally admin-
istered drugs to make them more bioavailable.36 Generally, an increase in surfactant 
concentration leads to a decrease in particle size, till a plateau is reached where the 
size does not change anymore. In certain cases, it has been found that stabilisers were 
more effective when dissolved in the solvent phase. Although the particle size was 
slightly bigger it was possible to use less stabiliser since being dissolved in the same 
medium as the drug made the stabiliser more readily available.37 Another factor de-
termining size is temperature. Lower temperatures in general lead to smaller sizes. At 
lower temperatures, the solubility of drug decreases and the metastable zone gets nar-
rower. Simultaneously an increase in nucleation can be observed since nucleation is a 
process of free energy and heat release.38  
In the solvent anti-solvent process the obtained nanoparticles need to be dried 
immediately to prevent crystal growth. Due to this, research has focused on combining 
different bottom-up techniques. Hu et al.38 presented an industrially applicable pro-
cess which combined the solvent anti-solvent precipitation followed by a freeze-dry-
ing step for continuous and scalable nanosizing of fenofibrate. It was found that short 
stirring time in the Solvent anti-solvent step and immediate freeze drying minimized 
the Ostwald ripening and led to faster dissolution in water. Homayouni and colleagues 
39 incorporated a high-pressure homogenizing step between Solvent anti-solvent pre-
cipitation and freeze drying. With Soluplus as stabiliser, celecoxib nanoparticles 
around 440 nm were produced with a 4 times higher solubility than raw celecoxib. 
Unexpectedly, crystalline samples dissolved better than amorphous samples, which 
could be attributed to the devitrification of amorphous celecobix when in contact with 
water. Using only the solvent anti-solvent technique, Zu et al. 40 produced taxifolin 
nanoparticles, a water insoluble antioxidant. By reducing the size to 24.6 nm, they 
found that the solubility increased two times compared to the raw material, as well as 
the bioavailability and antioxidative ability. Another approach using ionic liquids as 
antisolvent and phosphate buffer as solvent was done by Viҫosa et al. 41, producing 
amorphous rifamipicin particles with a mean size of 280-360 nm at room temperature.  
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A variation of the solvent anti-solvent precipitation process is high gravity re-
active precipitation (HGRP). On the basics of the Higee technology,42 a rotating 
packed bed (RPB) 43, 44 is used to form nanoparticles. Solvent and antisolvent are 
added to the rotating RBP. Centrifugal forces and high gravity in the chamber generate 
a thin liquid film or fine droplets. This in turn intensifies micromixing as well as mass 
transfer.45,46  
1.2.1.2. Sonoprecipitation  
Most solvent anti-solvent processes struggle with poor micromixing. This 
problem may be solved by the use of ultrasonic waves in a sonoprecipitation process. 
This process leads to rapid and more thorough mixing. Consequently, maximal super-
saturation and crystal growth arrest are reached faster. Initial cavitation and size re-
duction occur during the negative period of the sound wave, which generates cavita-
tion bubbles. Implosion of bubbles results in localized spikes in temperature and pres-
sure, leading to the creation of shock waves. The consequence for crystallisation is 
immediate formation of primary nucleation, reduction in crystal size, and inhibition 
of agglomeration.47,48 Particle size, particle size distribution, and particle morphology 
are dependent on duration of sonication. Dhumal and colleagues 49 prepared amor-
phous cefuroxime axetil particles by sonoprecipitation. It was observed that by low-
ering the temperature, cefuroxime axetil precipitated faster with a higher yield and a 
smaller size. The same result was obtained when increasing the sonication amplitude. 
A comparison study for cefuroxime axetil nanoparticles produced by spray drying and 
sonoprecipitation demonstrated similarity in both lower yields, decreased size and 
broader particle size distribution for both processes. With sonoprecipitation it is pos-
sible to not only influence size but also morphology of particles, which has an impact 
on dissolution. Tran et al.50 studied the influence of three polymer types and ultra-
sonication conditions on the shape and size of curcumin nanoparticles. It was found 
that by changing drug to polymer ratio and reaction conditions the molecular interac-
tion of the curcumin hydroxyl groups changed and subsequent size and dissolution 
rate could be modulated.  
1.2.1.3. Supercritical fluid precipitation 
Most drugs produced by precipitation techniques employing organic solvents 
show trace amounts of solvents even after purification. Using supercritical fluids as 
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solvents could overcome this issue. Supercritical fluids, where both the temperature 
and pressure of the fluids are higher than the critical temperature and pressure respec-
tively, exhibit the density of a liquid but the mass transfer ability between gas and 
liquid, making them ideal candidates to be used as solvents for precipitation pro-
cesses.51 The supercritical fluid can be removed from the nanoparticles simply by de-
pressurisation. Due to its mild critical points, non-toxicity and non-flammability, CO2 
has been the most widely used supercritical fluid.52 When a low temperature is fa-
voured (i.e. < 31 oC), compressed CO2 can be also used as solvent or medium for 
reaction or processing.53 The major techniques to produce drug nanoparticles utilizing 
supercritical fluids are rapid expansion of supercritical solution (RESS), rapid expan-
sion of supercritical solutions into a liquid solvent (RESOLV), supercritical antisol-
vent precipitation (SAS), gas antisolvent (GAS), and precipitation with a compressed 
fluid (PCA).  
Supercritical fluid acting as a solvent 
In the RESS and RESOLV processes, the supercritical fluid acts as a solvent. 
In the RESS process a supercritical liquid with dissolved drug passes through a thin 
nozzle into a low pressure vessel, where the drug precipitates.54 The rapid expansion 
of the supercritical fluid via the reduction in pressure leads to a high supersaturation 
of drug in the fluid droplets and the subsequent homogenous nucleation. The size of 
the particles depends on expansion temperature, pressure, nozzle geometry and 
lengths, solute-solvent interaction, and solubility of compound in supercritical liquid. 
Most RESS processes employ supercritical CO2 as solvent. Although there are exam-
ples for nanosized particles, the RESS process produced mainly particles in the mi-
crometre range.55 To overcome this problem, the RESS process was extended by ex-
pansion of supercritical fluid into a liquid solvent rather than air. This process is called 
RESOLV. It is rationalized that the liquid solvent inhibits crystal growth in the ex-
pansion jet. The nanoparticles may be further prevented from accumulating by adding 
stabiliser to the solvent phase. For example, using the RESOLV process, Pathak et 
al.55 prepared ibuprofen nanoparticles at 40 nm.  
Supercritical fluid as an antisolvent 
Supercritical fluids can be introduced as anti-solvent for the SAS, GAS, and 
PCA processes. The common feature is that the drugs are dissolved in organic solvents 
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(usually CO2-miscible) and then precipitate as a result of anti-solvent impact from the 
introduced compressed or supercritical fluid. For example, in the SAS process, the 
supercritical fluid is introduced into a high-pressure vessel which already contains a 
liquid solution, like in the common SAS precipitation technique (see 1.2.1.1.). How-
ever, the high diffusion ability of the supercritical fluid leads to rapid diffusion/mixing 
at the interface and hence rapid supersaturation and precipitation. The supercritical 
fluid acts as an anti-solvent as well as a ‘spray enhancer’. The homogeneity of the 
precipitated particles may be tuned by flow rate, temperature and pressure of the sys-
tem.  
In contrast to the SAS process in the GAS process, a supercritical gas (the 
temperature is higher than the critical temperature, but the pressure is lower than the 
critical pressure) is introduced instead of a supercritical fluid into the liquid solution. 
Quite often, the SAS and GAS process are not distinguished clearly during applica-
tions. Yeo and colleagues56 utilised the GAS technique to downsize macromolecules, 
such as insulin, showing that the conditions of this process were mild enough to down-
size complex biological structures. The same was shown on insulin and catalase by 
Tom and co-workers.57 They micronized both proteins for the formation of drug-pol-
ymer microspheres for controlled release.  
The PCA process is similar to SAS in that a compressed fluid (usually higher 
than the critical pressure but lower than the critical temperature) is introduced into a 
drug solution. The solution may also be sprayed into the compressed fluid for the 
solute precipitation to occur. The compressed fluid is miscible with the solvent, but 
functions as an anti-solvent to the solute. It can diffuse into the solution and increase 
the supersaturation whereupon the solute precipitates.58-60 Gentamicin-loaded bioad-
hesive microspheres were produced using compressed CO2. In addition to high en-
trapment efficiency, homogeneous distribution of drug within polymer microspheres 
and continuous release of the drug were achieved.61 In a recent study, aerogel silica 
particles with loaded drug were coated with polymer by the PCA process, which 
slowed down the release of the loaded drug.62 The PCA process could also be applied 
to precipitate lysozyme in reverse micelles by introducing compressed CO2 into the 
reverse micellar solution.63 
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1.2.1.4. Spray drying 
Spray drying is a one-step solvent evaporation process directly from liquid 
solution to powder. The process can be divided into four steps. In the first step, a 
substance is dissolved in an organic solvent, which is then pumped through a nozzle 
and atomized into hot air in the second step. Thirdly the solvent evaporates and a dry 
powder forms. The last step is the separation of dried product from gas.64 Atomization 
of solution is achieved using pressure, rotating, or two fluids nozzle. Higher atomiza-
tion pressure leads to smaller droplets and hence smaller particles. A high ratio of 
surface to volume favours rapid and effective drying. With regard to the spray from 
the nozzle, there are three different air current systems (Figure 1.2.). If hot air is flow-
ing in the same direction of the feed, it is termed co-current. The advantages and dis-
advantages of co-current lie in the short contact between substance and hot air, since 
the air cools down rapidly further down in the chamber. Although not the whole cham-
ber is used for drying, thermo sensitive substances have minimal heat contact. Most 
food powders are produced using co-current spray drying. If air is let into the systems 
from the sides or from below it is called mixed flow and counter-current, respectively. 
In both processes the whole chamber is used for drying.65,66 
Size is directly proportional to feed rate and not concentration, although higher 
concentrated solutions can lead to higher viscosity and slower feed rate. Particle mor-
phology and size are dependent on the drying conditions and solvent evaporation rate. 
The Péclet number (Pe) 
is the ratio between con-
vection time for drying 
and diffusion coeffi-
cient in the solid and 
can give a trend for 
morphology and size. 
For Pe < 1, small and 
dense particles can be 
expected. Fast drying 
can lead to large and 
hollow particles, while 
slow drying may result 
Figure 1.2. Schematic representation of spray drying apparatus with 
different currents. 
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in small and dense particles.67 In spite of a continuous, potentially easily scalable and 
fast process, there are some drawbacks and limitations to the spray drying technique. 
One is that thermolabile substances are difficult to process, due to the potential of 
decomposition or change in property. Another factor is the poor thermal efficiency of 
the process which leads to a low cost-efficiency.64,68 Despite these limitations spray 
drying is widely used in food production and in the pharmaceutical industry. This is 
mainly due to the possibility of adding additives to the feed mixture. Hence it is pos-
sible to produce encapsulated microparticles for release or better storage in one-step, 
by adding polymers to the feed solution. Another possibility is adding agents to tune 
particle size and shape, as well as ease the granulation.69 The spray drying technique 
is often used for encapsulation in particles. For example, Rizi and co-workers70 inves-
tigated the encapsulation of three model drugs in the pH-responsive polymer Eudragit 
L100. Similar drug encapsulation and drug release effects were observed by Kola-
kovic et. al.71. They produced microparticles with nanofibre cellulose (NFC) and 
could form a tight fibre network with amorphous drug present in the matrix. Sustained 
drug release was dependent on the substance used and, on its solubility, and affinity 
for NFC under the same experimental conditions. Another interesting study was done 
by Al-Qadi and co-workers,72 who produced insulin-loaded chitosan nanoparticles for 
inhalation into deep lung tissue as an alternative absorption route into systematic cir-
culation. In vivo tests in rats showed an increased and prolonged hypoglycaemic ef-
fect.  
1.2.2. Cryogenic Methods 
1.2.2.1. Freeze-drying  
In a freeze-drying process, a solution (or suspension) is frozen and the solvent 
is sublimated under reduced pressure and low temperatures. Freeze drying on its own 
is mainly used to achieve more stability in storage, since dry powder formulations 
tend to exhibit longer shelf lives and the freeze-drying process does not cause shrink-
age or toughening and leaves micropores in the material behind, which makes rehy-
dration easier.72-76 Nanosuspensions produced by other top-down or bottom-up tech-
niques can be freeze-dried into more stable powders without the risk of agglomeration 
as is often encountered in other drying methods. Protective agents such as cryopro-
tectants like sugars can be added to avoid possible decomposition or loss of activity 
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during the freezing stage.77 For example, fenofibrate dissolved in tertiary butyl alco-
hol, was mixed with a water solution of mannitol. The resulting solution was imme-
diately frozen and freeze-dried. Mannitol functioned as a nucleation seed in this case. 
After freeze drying, dispersions of the crystalline drug nanoparticles could be ob-
tained, which showed an increase in dissolution behaviour 78. In recent years, ice crys-
tals formed during the freezing stage have been explored as templates to produce po-
rous polymers and ceramics.79,80 In the case of porous polymers, the concentration of 
the solution had a significant impact on pore morphology, i.e. by freeze-drying diluted 
aqueous polymer solutions, polymer nanofibers could be readily formed.81 Incorpora-
tion of small molecules or proteins could easily be achieved by simply mixing them 
with the initial aqueous solution.82 In a more complicated procedure, curcumin and 
curcumin-loaded silica microspheres were incorporated via freeze-drying into porous 
chitosan scaffolds with varied morphologies. A dual-tuned drug release profile was 
achieved with fast initial release and sustainable release at later stage.83 Freeze-dried 
porous materials from polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG) and sur-
factant sodium dodecyl sulphate (SDS) could be used as scaffold to form poorly wa-
ter-soluble drug nanoparticles. By soaking the porous materials in organic drug solu-
tion and subsequent evaporation of the solvent, drug nanoparticles formed within the 
porous material, which could be re-dissolved in water to give aqueous nanoparticle 
dispersion.84  
1.2.2.2. Spray freeze-drying 
In a spray freeze drying (SFD) process, a drug or more often a protein solution 
is sprayed through a thin nozzle into a vessel containing liquid nitrogen at its bottom. 
The nozzle types used are the same as used in spray drying. Nucleation starts while 
the solution droplets are travelling through the cold nitrogen gas phase to the liquid 
phase, where they freeze. After recovery of the frozen droplets with a thin sieve, the 
solvent is removed by lyophilisation. Because of the freeze-drying process, in contrast 
to air drying, the obtained particles are porous while maintaining the droplet size and 
shape. SFD is a popular method for downsizing protein powders for inhalation since 
the low processing temperature thwarts denaturation.24,85 As with other processes it is 
possible to add stabilisers, although a slight increase in size as well as some loss of 
activity for proteins can be the consequence.86,87 The main difference between spray 
drying and spray freeze drying is the drying process. A comparison study of the spray 
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drying, and spray freeze drying processes for the production of lipid-polymer hybrid 
nanoparticles made from PVA, lecithin and levofloxacin for inhalation was con-
ducted. It was found that particles produced by SFD were superior in terms of flowa-
bility, physical handling and yield.88 Although the particle size and shape mainly de-
pended on droplet size and solution concentration, the use of additives during the pro-
cess was found to have an impact. This was improved by utilising a thermal-ink-jet 
printer as head of a spray freeze dry apparatus. Droplets with volumes as low as 2 –
180 pL could be continuously formed. The resulting particles showed good stability 
in storage even without any excipients.89,90 Murugappan et al.91 reported the prepara-
tion of dry powder for inhalation by immobilizing live influenza virus on inulin, dex-
tran or dextran/trehalose. Activity tests showed that storage at 30 °C for up to three 
months after the SFD did not influence the receptor binding properties or biochemical 
integrity while the activity of unprocessed live vaccination decreased by 100-fold. 
An extension of SFD is spraying directly into the liquid nitrogen by submerg-
ing the nozzle into the nitrogen, rather than across the cold nitrogen gas. In this pro-
cess, an insulated nozzle is submerged, and the solution is sprayed directly into liquid 
nitrogen. The solution gets atomized by passing through a small nozzle at high pres-
sure.92-94 High atomization rate is furthermore a consequence of high Weber and 
Reynolds numbers at liquid-liquid collision.95 The rapid freezing of solvent droplets 
leads to fast nucleation with arrested crystal growth. For proteins, the rapid freezing 
and hence fast passing of the critical temperature (the temperature between crystalli-
sation and glass transition of the solution) can avoid the formation of large ice crystals 
which leads to denaturisation. Rapid freezing limits the time available for the drug 
molecules to crystallize, thus leading to the formation of amorphous drug particles.  
1.2.2.3. Emulsion freeze-drying 
Emulsions are mixtures of two immiscible liquids, with one droplet phase dis-
persed in a continuous phase, stabilised by a surfactant. Emulsions usually consist of 
a water phase and an oil phase. When the oil phase is emulsified as droplets in aqueous 
phase, the formed emulsion is called an oil-in-water (O/W) emulsion. Vice versa, a 
water-in-oil emulsion (W/O) can be formed.96  
In an emulsion-freeze-drying process (Figure 1.3.), a poorly water-soluble 
drug is dissolved in an organic solvent (oil phase) which is then dispersed into an 
aqueous polymer/surfactant solution (usually by stirring or homogenization) to form 
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an O/W emulsion. The whole emulsion is frozen in liquid nitrogen and then freeze-
dried to remove both water and the organic solvent. During the freeze-drying process, 
drug nanoparticles are formed in situ in the porous polymer scaffold. Entrapment of 
nanoparticles in the porous polymer structure prevents nanoparticle aggregation, 
which enables easy handling, transport, and storage of the nanoparticles composites. 
More importantly, the highly porous nature of the hydrophilic polymer scaffold en-
sures the fast re-dissolution in water when required and produce stable aqueous nano-
particle dispersions.97  
 
Figure 1.3. Schematic representation of the emulsion freeze-drying process. 
In an emulsion, the number of droplets or the volume percentage can be varied. 
A high internal phase emulsion is formed when the volume percentage of the internal 
phase is greater than 74.05 %. These can be used as templates to prepare highly inter-
connected porous polymers.96,98 Additives such as surfactants to stabilise the droplet 
phase can decrease the droplet size and hence pore size and narrower pore size distri-
bution.99,100 An increase in polymer concentration generally leads to a decrease in po-
rosity.101 Pore morphology and pore size can also be tuned by varying the freezing 
rate. Rapid freezing in liquid nitrogen for instance produces smaller pores and higher 
order, whilst slower freezing rate favours disordered structures with larger pores.99 
Wang and co-workers102 formed emulsions containing sucrose in the aqueous phase 
and phospholipids and PEG in the oil phase. After lyophilisation and re-suspension in 
water, liposomes formed with a mean size smaller than 200 nm that showed high en-
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trapment efficiency for selected water insoluble drugs. Grant et al.103 produced amor-
phous indomethacin nanoparticles below 300 nm within porous PVA. Size and load-
ing of indomethacin nanoparticles could be tuned by varying the emulsion composi-
tions. Furthermore, a one-step procedure was developed to generate protein-encapsu-
lated poly(lactide-co-glycolide) (PLGA) microspheres in chitosan by freeze drying a 
W/O/W double emulsion, where previously a two-step method consisting of a micro-
sphere preparation step followed by incorporating in a pre-formed scaffold had to be 
employed. Due to the mild processing conditions and non-chemistry specificity, this 
method may be applied to a wide variety of proteins and polymers. Porosity and mor-
phology, both crucial factors for release profiles, can easily be tuned by changing stir-
ring time and concentration.104 Mc Donald et al.105 produced efavirenz particles with 
sizes of around 300 nm by the emulsion-freeze-drying approach. These particles 
showed reduced cytotoxicity, increased in vitro transport and a fourfold higher phar-
macokinetic exposure in vivo. Giardiello and colleagues 106,107 presented the formation 
of two and three component nanoparticles. The two component particles were made 
up of FRET dyes and subsequently used for better cell imaging. For the three compo-
nent particles it was possible to combine polymer, drug and magnetic nanoparticles, 
giving rise to the possibility of tracing and sensing particles to enhance targeted drug 
delivery.     
1.2.3. Emulsion/Microemulsion 
Emulsions are formed from two immiscible phases by energy input (i.e., stir-
ring, homogenization) in the presence of surfactants to reduce surface tension and 
stabilise the droplets. Emulsions are thermodynamically unstable. As such, phase sep-
aration occurs in emulsions to revert back to two immiscible phases. This happens via 
flocculation, creaming, coalescence or Ostwald ripening.108,109 Surfactants and co-sur-
factant are added to increase kinetic 
stability. One way to prepare drug 
particles is by solvent extraction of 
an emulsion. Usually, a drug is dis-
solved in a non-polar solvent and is 
emulsified into an aqueous contin-
ues phase containing polymers or Figure 1.4. Schematic representation of an emulsion 
droplet with dissolved drug molecules 
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surfactants (Figure 1.4.). The emulsion is then quenched with water. After stirring, the 
resulting particles can be filtered out. A second method is by single emulsion solvent 
evaporation. After an O/W emulsion is formed, the volatile oil phase is evaporated to 
produce aqueous nanoparticle dispersions. Final particle size may be controlled via 
droplet size and use of suitable surfactants.110,111  
Microemulsions form a sub-class of emulsions with droplets in the nanometer 
range (< 100 nm). Schuman and colleagues112,113 first observed the formation of mi-
croemulsions in 1943 by titrating a milky emulsion with hexanol and subsequently 
coined the term microemulsion in 1959. Although many definitions of microemul-
sions can be found, the most commonly used is by Danielsson.114 He defined a micro-
emulsion as ‘a system of water, oil and amphiphile which is a single optically isotropic 
and thermodynamically stable liquid solution.’ Because of their liquid form and their 
sub-micron droplet sizes microemulsions are ideal candidates for the transdermal de-
livery of drugs.115-117 Due to the nature of microemulsions, dermal and oral drug de-
liveries are the two most favoured delivery routes. High solubility potential in the oil 
droplet phase resulting in high drug concentration in microemulsion can be beneficial 
for potential therapeutic treatment. High concentration of surfactants and co-surfac-
tants contained in the emulsion may enhance permeation by reducing the diffusional 
barrier of the stratum corneum.118-120 For example, cyclosporin A, an immunosuppres-
sant,121 docetaxel,122 an anti-cancer drug and biphenyl dimethyl dicarboxylate,123 a 
treatment drug for liver diseases, have been investigated for microemulsion delivery. 
Microemulsions for oral delivery are usually encapsulated to prolong storage. Mostly 
this is done in gelatine capsules. However, due to the hydrophilic nature of gelatine, 
water containing formulations cannot be filled into a gelatine capsule, without change 
in emulsion composition.124 Self-microemulsifying drug delivery systems (SMEDDS) 
present a solution. The basic principle of SMEDDS is the ability of an oil, surfactant, 
co-surfactant and drug to form spontaneous emulsions under gentle agitation and di-
lution with water. The gastrointestinal tract provides aqueous medium and sufficient 
agitation.125,126 By virtue of high bioavailability, direct formation in the gastrointesti-
nal tract, and prolonged storage, current research in emulsion drug delivery focuses 
more on SMEDDS and SEDDS (Self-emulsifying drug delivery systems) for indus-
trial production. 
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Table 1.1. gives an overview of the advantages and disadvantages of the dis-
cussed bottom-up techniques 
Table 1.1. Bottom-up methods with advantages and disadvantages 
Method Advantages Disadvantages 
Solvent An-
tisolvent 
precipitation 
(SAS) 
• Cost and energy efficient  
• Straight forward production 
conditions 33 
• Particle agglomeration if not im-
mediately worked-up38 
• Not below specific size plateau  
• High concentrations of surfactants 
needed36 
• Drugs needs to be soluble in one 
solvent 
• Solvent and anti-solvent need to 
be miscible  
• Organic solvent residue  
 
   
High gravity 
Reactive 
precipitation 
(HGRP) 
• Intensified micromixing45 
• Smaller particles and nar-
rower size distribution 
• Drugs needs to be soluble in one 
solvent 
• Solvent and anti-solvent need to 
be miscible  
• Not below specific size plateau43 
• Organic solvent residue  
• Additives  
 
   
Rapid ex-
pansion of 
supercritical 
solution 
(RESS)/ 
Rapid ex-
pansion of 
supercritical 
solutions 
into a liquid 
solvent (RE-
SOLV) 
 
• Green chemistry52 
• Non-toxic, no solvent resi-
due52 
• Formation of Nanoparticles 
possible in RESOLV55 
• Expensive machinery and material  
• Many AIPs cannot dissolve in 
scCO2 and need an organic co-sol-
vent 
• Microparticles in RESS55 
• Additives 
 
17 
 
Supercritical 
Antisolvent 
precipitation 
(SAS)  
• mild conditions 
• AIP does not need to be mis-
cible with supercritical fluid, 
giving way to a broad range 
of materials 
• Recrystallization can be con-
trolled leading to either 
smaller or larger particles of 
a desired morphology  
 
• Solvent residue 
• Solvent needs to miscible with su-
per critical fluid 
• Immediate work up required, oth-
erwise particle can change mor-
phology 
Gas antisol-
vent (GAS) 
• mild conditions allowing the 
handling of proteins57 
• AIP does not need to be mis-
cible with supercritical fluid 
• Broad range of materials 
• Very small particles possible 
and easy particle size control 
• Recrystallization can be con-
trolled leading to either 
smaller or larger particles of 
a desired morphology  
 
• Solvent residue, which is difficult 
to strip 
• Batch technique, difficult to scale-
up 
• Difficult separation of gas and sol-
vent stream 
Spray dry-
ing 
• One –step processes64 
• Continuous and fast64 
• Additives can be mixed in 
with feed solution making 
encapsulation possible in a 
one-step process68 
 
• Efficiency loss when milder con-
ditions are needed65,66 
• Energy and thermal inefficient65,66 
Spray freeze 
drying 
• Mild conditions24,84 
• No agglomeration, due to im-
mediate freezing of particles  
• Lyophilisation leads to en-
hanced characteristics, like 
wettability, storage and han-
dling114-117 
 
• Expensive equipment  
• Freeze-drying process is time and 
energy consuming 
• Solvent residue118 
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Emulsion 
freeze-dry-
ing 
• Mild conditions 
• Particles stabilised against 
agglomeration even after 
prolonged storage73-76 
• Lyophilisation leads to en-
hanced characteristics, like 
wettability, storage and han-
dling73-77 
 
• Additives 99,100 
• Freeze-drying process is time and 
energy consuming 
• Expensive equipment  
Emulsions 
/microemul-
sions 
• Dermal application possi-
ble115-117 
•  High solubility and high 
drug concentration118-120 
•  High affinity to the internal 
emulsion phase, can be mod-
ified to increase transdermal 
flux118-120 
• high concentration of surfac-
tants and cosurfactants en-
hance permeation to the stra-
tum corneum118-120 
• SMEDDS make it possible to 
form emulsions directly in 
the intestines125,126 
• High concentrations of addi-
tives118-120 
 
• difficult to achieve long time sta-
bility125,126 
1.3. Nanocarriers for encapsulation 
1.3.1. Liposomes  
Liposomes are stable microscopic vesicles of natural or synthetic lipids (usu-
ally phospholipids), first observed in 1964 by Bangham et al. 127-129 Liposomes are 
formed when amphipathic lipids spontaneously assemble in layer form in aqueous 
medium.130 Depending on the conditions multilayer or monolayer vesicles are formed 
(Figure 1.5.).  
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Figure 1.5. Schematic representation of a) monolayer liposomes; b) bilayer liposomes and c) multilayer 
liposomes. 
In multilayer vesicles lipids are either ordered in circular rings with a head to 
tail structure with aqueous compartments in between or in a tail to tail arrangement 
with an aqueous internal department. The ability to enclose water soluble and entrap 
lipophilic drugs in the lipid layers as well as encompassing drugs with intermediate 
logP makes liposomes ideal candidates for drug delivery.131 Liposomes cannot enter 
the cell via plasma clearance or tissue disposition, but by fusion or endocytosis, which 
increases the success rate of drug delivery to cells.132 This trait makes liposomes 
highly attractive not only for drug delivery but also as carriers for enzymes and other 
proteins into the inner part of the cell.133-135 Surface charge, hydrophobicity, size, flu-
idity and packing of lipid layers heavily influence the stability and type of proteins for 
binding of liposomes.136,137 Changes in these parameters can be used for fine tuning 
of liposome properties. However, liposomes tend to be sensitive to fast elimination 
from the bloodstream as well as accumulation in tissue especially in the liver.138 To 
prevent accumulation, different strategies may be applied. For example, liposomes 
can be formed with pH sensitive materials which pass into the cell as a whole and 
release their drug load triggered by the change in pH 139 or modified with suitable 
ligands for targeted delivery.140,141 Different methods have been developed to circum-
vent fast clearance. One of the most successful is the employment of ‘stealth’ lipo-
somes. These liposomes are linked to PEG which decreased the aggregation between 
the liposomes and particle-protein interaction.143   
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1.3.2. Dendrimers 
Dendrimers belong to the family of branched polymers. Polymer arms are ra-
diating in a highly ordered fashion from a core, reminiscing of a tree. The first reports 
about dendrimers were published in the late 70s early 80s by the groups of Buhleier 
,143 Denkewalter,144 Newkome,145 and Tomalia.146 Tomalia and co-workers reported 
the formation of polymers with ‘controlled occupation of space in three-dimensions 
as a function of size, shape and disposition of desired organic functionality’. These 
differed from classic monomers and oligomers in their higher degree of symmetry, 
higher branching and a maximized density in reactive end groups. A dendrimer in-
cludes three structural components. An initiator core, an interior layer (made up of 
repeating units radially attached to the core and an exterior) and functionalised end 
groups (attached to the outermost interior layer) (Figure 1.6.). By removing the central 
core, identical dendrons can be obtained. These branched polymer arms are again con-
structed from the above described three structural elements. 
 
Figure 1.6. Schematic representation of a dendron and dendrimer 
The number of dendrons is dependent on the multiplicity of the central core. 
Further away from the core a dendron possesses more and more branch points. Every 
branch points represents one generation. Higher generations are more branched and 
have more end groups. Synthesis of dendrimers is a stepwise process, which can either 
start from the central core outwards, in which case the growth is exponentially,147 or 
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by synthesising dendrons, which are then coupled to a central core.148 Both cases lead 
to a high degree of monodispersity in contrast to classical polymers, where growth is 
statistical, and the end product is polydisperse.149 Like classical polymers, a wide va-
riety of materials can be used as starting materials, even DNA.150 Dendrimers of dif-
ferent generations are commercially available. Polyamidoamine (PAMAM) is com-
monly selected as starting material.147 With a size between 2 and 10 nm dendrimers 
possess the favourable characteristics of nanoparticles. Depending on the number of 
generations the shape of dendrimers can change from small and floppy disks (up to 
generation 4) to spherical, three dimensionally defined and densely packed particles 
(generation 5 and up). The dense packaging can be used to achieve more concentrated 
drug loading. End groups can be changed to obtain hydrophilic or hydrophobic den-
drimers with a hydrophobic or hydrophilic core respectively and to facilitate higher 
binding affinities to target sites.  
1.3.3. Polymers 
Polymeric nanocarriers have been gaining more and more interest in recent 
years, because of their favourable characteristics compared to liposomes and den-
drimers. Liposomes have a few inherent problems, i.e. drug encapsulation is usually 
low and water-soluble drugs have been known to leak out prematurely, as well as a 
poor storage stability.151 Dendrimers are synthetically challenging to produce. For this 
reason, different polymeric structures capable of encapsulation will be discussed in 
the following section. Figure 1.7. gives an overview over the structures under discus-
sion.  
 
Figure 1.7. Schematic representation of a) linear block polymers; b) graft polymers; c) star polymers; 
d) Miktoarm polymers; e) Hyperbranched polymers and f) star-hyperbranched polymers. 
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1.3.3.1. Linear block polymers  
A Block copolymer (Figure 1.7.a.) is according to IUPAC ‘a copolymer that 
is a block polymer. In the constituent macromolecules of a block copolymer, adjacent 
blocks are constitutionally different, i.e. adjacent blocks comprise constitutional units 
derived from different species of monomer or from the same species of monomer but 
with a different composition or sequence distribution of constitutional units.’151 Three 
basic structural types of block copolymers can be defined. The first is the A-B struc-
ture, so called diblock, with A and B being two different repeating units. A block of 
repeating unit A is thereby connected to a block of unit B. The second type is an A-
B-A or A-B-C structure, called triblock. A block of B is enclosed between blocks of 
A on either side or three different block (A, B and C) are connected to form a linear 
block polymer- The third type is a multiblock in the style of (A-B)n, where blocks of 
A and B are repeated to form areas of repeating unit A and B. In comparison to random 
copolymers, block copolymers exhibit well defined structures and their synthesis re-
quires sequential addition of each monomer. Since the two repeating units are differ-
ent in chemical and physical properties, a two-phase morphology on a micro-scale 
level can be observed for block copolymers.152 This gives rise to the spontaneous for-
mation of micelles in certain solvents, where one of the blocks is insoluble. The in-
soluble block forms a core, while the soluble block forms the corona. This behaviour 
can be further favoured by repulsive forces between blocks A and B.153 Linear block 
polymers have been widely studied and manifold applications in cosmetics, stabilisa-
tion of insoluble materials, and drug delivery can be found. Drugs can be incorporated 
in the core chemically (covalent) and/or physically (electrostatic interactions; H-bond-
ing).154-156 The aggregation number, i.e., the number of molecules needed to form a 
stable micelle, is closely relevant to the critical micelle concentration (CMC) i.e. the 
concentration ‘below which virtually no micelles are detected and the limit above 
which virtually all additional surfactant molecules form micelles’.156 For linear block 
copolymers, the aggregation number and CMC are relatively high. Hence, formed 
micelles will easily dissociate in the blood stream due to increased dilution. To pre-
vent this happening cross-linked branches are introduced to enhance micelle stability 
below the CMC,158 which in turn means additional synthetic steps.   
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1.3.3.2. Graft polymers 
Graft polymers consists of a linear backbone from which a large number of 
polymer side arms of a different kind are chemically attached (Figure 1.7.b). In com-
parison to linear block polymers this gives rise to greater possibilities of fine-tuning 
the characteristics e.g. amphiphilicity, by adjusting the lengths of the arms and back-
bone as well as the grafting density.159 In some instances, more stable micelles could 
be obtained in comparison to linear block polymer analogues and the use of graft pol-
ymers for drug encapsulation has been researched.160-164 Graft polymers are often used 
in the formation of hydrogels, highly absorbent polymeric networks, where drugs can 
be incorporated into the network and depending on the constitution of the graft- pol-
ymers, released by pH or other stimuly.165 
1.3.3.3. Star and Miktoarm polymers 
Star polymers are a type of branched polymer where linear ‘arms’ radiate from 
a central branching point or ‘core’ (Figure 1.7.c and d). Star-homo or block polymers 
can be synthesised using the ‘core first’ method where multifunctional initiators prop-
agate the polymerisation of arm A onto the core. Arm B is subsequently either added 
as a pre-existing block or the polymerisation is initiated by the living chain of A. 
However, to form uniform arms all sites need to be equally reactive, have the same 
initiation rate, which must be higher than the propagation rate with steric hindrance 
and repulsions kept at a minimum. The other option is to synthesis star polymers by 
an ‘arm first’ strategy. These can be further subcategorized according to procedure 
used.166 Either the arms are polymerised as already described for linear di- and triblock 
polymers and subsequently added via coupling reactions to a core, i.e. ‘grafted’ onto 
a central core. In this case the core and arms can be synthesised and characterised 
independently before the star is formed.167 The other option is to chain extend linear 
arms with multivinyl crosslinking agents. The ‘arms’ can either be linear homo or 
hetero block polymers, which greatly influences their ability to encapsulate actives 
i.e. homo star polymers seldom form micelles for encapsulation because of their ten-
dency to be either hydrophilic or hydrophobic and they are more often used for the 
formation of hydrogels and subsequent drug encapsulation into gels.168 However, ho-
mostars possessing longer arms and slightly bigger cores, or hetero block polymer 
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stars, may entrap molecules in their corona, forming unimolecular micelles, with a 
hydrophobic core and a hydrophilic corona.169  
Miktoarm polymers (Figure 1.7.d) are a class of star polymers, where at least 
two chemically different arms emit from a common core, and are also sometimes 
called heterostar polymers.170 Miktoarm polymers show smaller aggregation number 
compared to linear polymers, while maintaining the same hydrodynamic radii due to 
the greater difficulty of arms to be accommodated into a micelle.171 Miktoarms are 
able to self-assemble and transform into very interesting structures by adjusting the 
lengths of one or more arms e.g. transformation of a hamburger like structure to a 
worm like structure,170 and are also able to form multicompartment micelles due to 
the possibility of forming structures of three mutually immiscible arms connected via 
a central point.172 
1.3.3.4. Branched/Hyperbranched polymers 
 Branched or Hyperbranched polymers (HBP) are similar in build to den-
drimers, however in contrast to dendrimers these macromolecules have a high disper-
sity and show defects from build in linear segments. Hence, while they are still highly 
branched and possess a large number of end groups, the branching is imperfect (Figure 
1.7.e).173,174 In comparison to dendrimers, hyperbranched polymers are not as syn-
thetical challenging while still maintaining most of the favourable characteristics such 
as solubility and reactivity (Table 1.2.).175 Hyperbanched polymers can be synthesised 
by either single-monomer (SMM) or double-monomer (DMM) methodology, 
whereby either an ABn monomer (SMM) or two momoners directly (DMM) are pol-
ymerised. There are four main sub-categories of SMM; polycondensation of ABn 
Monomer,176 self-condensing vinyl polymerisation (SCVP),177 self-condensing ring-
opening polymerisation (SCROP) 178 and proton-transfer polymerisation (PTP).179 
The synthesis of hetero star block polymers, as mentioned before, is challenging. Hy-
perbranched polymers on the other hand can easily be grown out (graft from) to obtain 
‘star hyperbranched polymers’ (Figure 1.7.f) with a core-shell architecture. Depend-
ing on the monomers used amphiphilic character or an abundance of other features 
can easily be incorporated.180  
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Table 1.2. Comparison between linear, hyperbranched and dendrimeric polymers. Adapted with 
permission from Ref. 175 © 2015 Royal Society of Chemistry 
Polymer Linear Hyperbranched Dendrimer 
Structure 
   
Topology 1D, linear 3D, irregular 3D, regular 
Synthesis One-step, facile One-step, relatively 
facile 
Multi-step, laborious 
Purification Precipitation Precipitation or classi-
fication 
Chromatography 
Scaling-up Already, easy Already, easy Difficult 
Mw Discrepant Discrepant Identical 
PDI >1.1 >1.1 1.0 (<1.05) 
DB 0 0.4–0.6 1.0 
Entanglement strong weak Very weak or no 
Viscosity High Low Very low 
Solubility Low High High 
Functional group At two ends At linear and terminal 
units 
On periphery (termi-
nal units) 
Reactivity Low High High 
Strength High Low Very low 
Hyperbranched polymers possess spatial cavities in comparison to star poly-
mers, whose tightly cross-linked core does not allow for cavities. In comparison to all 
other polymeric structures described before e.g. star polymers, linear block polymers 
or graft polymers, hyperbranched polymers, especially star hyperbranched polymers, 
do not need to self-assemble to stabilise themselves in unfavourable conditions. 
Hence, when used for encapsulation and release in the bloodstream no concerns of 
CMC values arise and no premature disassembly, triggered by outside factors, is pos-
sible. These, as well as the enhanced solubility, and easy manipulation of the many 
end-groups make hyperbranched polymers favourable materials for encapsulation and 
targeted delivery for drugs and genes,181,182 mostly via the formation of core-shell 
particles. Encapsulation and release are directly influenced by the core, which deter-
mines the shape of the hyperbranched polymer, the internal structure which deter-
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mines the internal dimensions and guest-host interactions and the outer-shell that gov-
erns the solubility and accessibility of the core region.183 Core-Shell particles can eas-
ily be obtained by modifying the many end-groups. End-group modifications can be 
divided in four major categories which all give rise to interesting new polymers; End-
capping with short chains or molecules,183 terminal grafting, which affords core-shell 
multi-arm star polymers or hyperstars,184,185 surface growing to fabricate inorganic/or-
ganic-hyperbranched polymer hybrid materials 186,187 and hypergrafting i.e. grafting 
hyperbranched macromolecules to a multifunctional polymeric core to obtain hyper-
grafted polymers.188,189  
1.4. Polymer synthesis 
As has been mentioned before, one major benefit of using polymeric nanocar-
riers is the ability to easily modify every component. Be that either by changing the 
monomers and hence changing the encapsulation ability, size or amphiphilicity, or by 
modifying the outer periphery of a nanocarrier with targeting ligands. This has mainly 
been made possibly by the discovery of a wide range of polymerisation techniques. 
For this reason, the following segment will give a brief overview of frequently used 
polymerisation techniques, which were also used in the following work.  
1.4.1. Free radical (‘conventional’) polymerisation (RP) 
Synthesis by free radical polymerisation accounts for roughly 45 % of all in-
dustrially produced synthetic polymers (~100 mt in 2009).190 In the following seg-
ment, free and controlled radical polymerisation techniques will be described and 
compared as well as considered for their application in drug encapsulation.  
 
Scheme 1.1. Mechanism of free radical polymerisation. 
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Free radical polymerisation, sometimes also called conventional radical 
polymerisation has been known since the 1940s and is one of the most applied 
polymerisation techniques in industry,191 because of a high tolerance for functional 
monomers as well as being synthetically straightforward i.e. tolerant of protic solvents 
and trace impurities of oxygen and monomer stabilisers. Furthermore, reactions can 
be done in aqueous medium (emulsion polymerisation).  
Scheme 1.1. shows the mechanism of RP, which consists of four major steps, 
i.e. initiator dissociation, initiation, propagation and termination. In the first step, a 
radical is generated from a non-radical species. Radical initiators are molecules that 
exhibit a labile bond. Stimuli such as temperature or light lead to the decomposition 
of these molecules and subsequent radical formation. The two most prominent repre-
sentatives of these class of molecules are azoinitiators and peroxides.190 After the gen-
eration of the primary radicals the addition of monomer molecules leads to an initial 
short polymer chain which is called the initiation radical. This step is generally much 
faster than the dissociation of the initiator (ki > kd). This step is followed by the chain 
growths i.e. propagation, with a rate in the order of kp ∼ 102−104 M−1 s−1. Termination 
of the reaction is possible in manifold ways. Generally, it is either possible that radi-
cals can become inactive by radical-radical recombination with an initiator molecule 
i.e. primary radical (self-) termination or growing polymer chains can be terminated 
by atom transfer and atom abstraction reactions i.e. combination, disproportionation 
or chain transfer. However, these manifold termination reactions as well as the fast 
chain growths lead to broad dispersity, low reaction control and the possibilities of 
introducing structural irregularities.190,192,193 The poor reaction control also leads to 
difficulties in the preparation of di- and multiblock polymers.192 The preparation of 
these structures is often only possible if one block is first synthesised by a different 
polymerisation technique and then grown out 194 by RP. However, RP can be used to 
graft polymer chains onto an inorganic surface e.g. silica or titanium, by modifying 
the surface to carry a radical initiator.195,196 To encapsulate hydrophobic actives and 
release them in aqueous medium amphiphilic characteristics need to be incorporated 
into the polymer, which is difficult using RP. However, it is possible to synthesise 
polymer capsules by miniemulsion polymerisation, which can be used to incorporate 
actives 197, 198 or form nanocomposite hydrogels for encapsulation and release or bio-
medical implants.199  
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1.4.2. Reversible-deactivation radical polymerisation (RDP) 
  In RP, the initiator dissociation is slower than the chain growths. Polymers 
formed at the beginning of the reaction are longer then the polymers formed later in 
the reaction (Figure 1.8.a), resulting in broad dispersity (Figure 1.8.b). By using Re-
versible-deactivation radical polymerisation (RDP) methods, previously known as 
controlled/living radical polymerisation (CPR), this can be avoided.200,201 At the same 
time RDP gives rise to the synthesis of many interesting structures e.g. stars or hyper-
branched polymers, which could not be obtained via RP. The basic principal of any 
RDP is an equilibrium between a minimal amount of growing free radicals and a ma-
jority of a dormant species.202 Much research has been done in the development of 
RDPs in the last decades and an in-depth discussion of the different methods is beyond 
the scope of this work. As such the focus is put on atom transfer radical polymerisation 
(ATRP) developed in 1995 by Wang et. al.203 and reversible addition-fragmentation 
chain-transfer polymerisation (RAFT) established in 1998 at the Commonwealth Sci-
entific and Industrial Research Organisation (CSIRO) 204. 
 
Figure 1.8. a) Evolution of molecular weight with monomer conversion for a conventional radical 
polymerisation with constant rate of initiation (dotted line) and a living radical polymerisation (green 
line). Reproduced from Ref. 200 with permission from CSIRO Publishing and b) Typical molecular 
weight distributions for a conventional (black line) and living radical polymerisation (green line). Data 
shown are from GPC analysis of polystyrene prepared by thermal polymerisation of styrene at 110◦C 
for 16 h (Mn 324000, Mw/Mn = 1.74, 72 % conversion) and a similar polymerisation in the presence of 
cumyl dithiobenzoate (0.0029 M) (Mn 14400, Mw/Mn = 1.04, 55 % conversion). Adapted with permis-
sion from Ref. 201 © 2000 Wiley. 
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1.4.2.1. Atom transfer radical polymerisation (ATRP) 
 
Scheme 1.2. Mechanism of ATRP as proposed by Matyjaszewski et. al.  
In ATRP an active species is generated through a reversible redox process 
catalysed by a transition metal on the radical (monomer) and the dormant species 
(Scheme 1.2.). To that end alkyl halides (RX) are used as initiators. For the polymer-
isation of well-defined polymers with narrow size distribution the halide group has to 
selectively and rapidly migrate between the growing chain and the metal complex. 
Initiation needs to be fast and quantitative to avoid the uncontrolled growth of longer 
chains at the start of the reaction. Fast initiation also assures that transfer and termi-
nation reactions are negligible, and the number of growing chains is constant. The 
metal catalyst determines the position of the equilibrium. It has to have two readily 
accessible oxidation states separated by one electron, an affinity for halides and has 
to be able to accommodate an incoming halide in its coordination sphere. A ligand 
(Y) is added to solubilise the metal salt in organic solvent and adjust the redox poten-
tial of the metal centre. The equilibrium constant (Keq = kact/kdeact) determines the 
polymerisation rate. If the constant is too small ATRP will not occur or occur very 
slowly, if however, the constant is too large a large amount of termination reaction 
will occur. To achieve controlled polymerisation the equilibrium has to lay on the side 
of the dormant species to assure that at any given time only a small number of free 
radicals are able to grow and then get ‘capped’ again after a short amount of time by 
the halide to avoid the formation of long polymer chains.  
As with RP, ATRP can be done in bulk, in solution or in emulsion polymeri-
sation, however by using ATRP it is possible to easily synthesise complex polymer 
architectures such as stars, comb polymers or multiblock polymers 202,205,206 as well 
as functionalise the polymer by nucleophilic substitution, radical or electrophilic ad-
dition of the end-chain halide post polymerisation or pre-polymerisation by using a 
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monofunctional ATRP initiator 206,207. ATRP has since been used in a plethora of bi-
omedical applications from direct synthesis of polymer bioconjugates,208,209 polymer 
dug-conjugates,210,211 micelles,211,212 cross-linked nano- and microgels 214,215 and ves-
icles 216,217 to name just a few and an excellent review can be found about the applica-
tion of ATRP in biomedical applications by Siegwarta et. al. 218 
1.4.2.2. Reversible addition−fragmentation chain-transfer polymerisation (RAFT)  
While in ATRP the dormant species is also the source of the radical, a radical 
initiator is needed to start the reaction in RAFT. Hence, the first step of a RAFT 
polymerisation (Scheme 1.3.) is the dissociation of the initiator and subsequent addi-
tion of monomers to the initiator radical.  
 
Scheme 1.3. RAFT mechanism as proposed by the CSIRO group 
The same as in a conventional polymerisation (1). However, shortly after ini-
tiation the propagating radical (Pm•) reacts with a thiocarbonylthio compound 
(RC(=X)AZ with A, X = S), or chain transfer agent (CTA). The instable intermediate 
radical then gives rise via fragmentation to a new radical (R•) (2). This radical is then 
free to react with monomers to form a new propagating radical (Pn•) (3). Chain equi-
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librium is reached by the addition of the propagating radical (Pn•) back onto the thio-
carbonyl compound thereby ‘capping’ its growth and releasing previously dormant 
chains (Pm•) to grow further (4). This equilibrium between active propagating radicals 
(R-Pn/m •) and dormant thiocarbonlythio compound (Z(A=)CX-Pm/n•) affords equal 
opportunity for all chains to grow at equal rates. 
In ATRP controlled polymerisation comes from a reversible activation via 
atom transfer, this equilibrium also determines the rate of polymerisation. In RAFT 
however, deactivation and activation are chain-transfer reactions i.e. radicals are nei-
ther formed nor destroyed. To assure that mostly dormant polymers are present in the 
reaction a higher amount of CTA is present than initiator. After the polymerisation is 
stopped most chains retain the thiocarbonylthio end group and can be obtained as sta-
ble materials, which allows for re-initiation of the polymerisation to afford complex 
polymer architectures.199,203,218 The CTA must fulfil the following criteria to guaran-
tee an efficient polymerisation; it needs to have a reactive C=S double bond (high 
kadd) and a weak S-R bond for rapid fragmentation (high kβ). The R group should 
furthermore be a good leaving group (kβ ≥ k-add) and should efficiently re-initiate 
polymerisation. The addition and fragmentation step are directly influenced by the Z 
and R-group respectively and careful consideration when selecting a CTA has to be 
made in respect to the chosen monomers 200. 
RAFT synthesis, as ATRP, allows for easy pre- and post-polymerisation func-
tionalisation. Pre-functionalisation can be done by modification of either Z or R 
group. Since in RAFT the chain is growing from the R group, functionalities on the R 
group affords α-functionalised polymers, while ω-functionalised polymers are ob-
tained by modifying the Z group. These modifications can range from proteins, to 
ligands for targeted delivery to functional groups such as -N3 or -COOH, which can 
be used to react with sensitive targeting moieties post polymerisation.220 Post-
polymerisation modification is also possible by converting the Z group into a thiol 
which is then readily available to react via thiol-ene chemistry.221 As with ATRP, 
RAFT polymerisation opens the door to the synthesis of manifold complex polymer 
structures 219,222-224 as well as the possibility of a wide variety of biomedical applica-
tions whose discussion is beyond the scope of this work. However, excellent reviews 
can be found in literature.225-227 
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1.5. Solvents and additives used in the formulations 
1.5.1. Solvents 
Although the use of organic solvents in general is unfavourable, for some tech-
niques the use of such solvents is inevitable. For the production of pharmaceutical 
drugs some consideration has to be made before choosing a solvent, i.e., toxicity and 
production method. A guideline on toxicity of organic solvents and their residue limit 
was proposed at the second international conference on harmonization of technical 
requirements for registration of pharmaceuticals for human use (ICH) and subse-
quently published as Guidance for Industry Q3C.228 In this guideline, commonly used 
organic solvents are sorted into three categories. Class 1 solvents are known or 
strongly suspected of human carcinogens and environmental hazards and should be 
avoided. If avoidance is not possible their use needs to be strongly justified and sol-
vent residue needs to be highly restricted. Examples are benzene (residue limit 2 ppm) 
and carbon tetrachloride (residue limit 4 ppm). Class 2 solvents are non-genotoxic 
animal carcinogens, or solvents that can possibly cause irreversible toxicity such as 
neurotoxicity or teratogenicity, as well as solvents with reversible toxicity. The use of 
these solvents should be limited. Residue limits can be calculated as either parts per 
million (ppm) or as a permitted daily exposure (PDE) in gram per day (milligram per 
day), which takes the maximal administered mass of drug per day into account. Ex-
amples for such solvents are chloroform (limit 0.6 mg/day and 60 ppm), methanol 
(limit 30 mg/day and 3000 ppm), acetonitrile (limit 4.1 mg/day or 410 ppm) and cy-
clohexane (limit 38.8 mg/day and 3880 ppm). Class 3 solvents have a low toxic po-
tential and no exposure limit is needed. They generally have PDEs above 50 mg per 
day. Such solvents include acetone, DMSO, and ethanol. Complete classification of 
the most commonly used organic solvents can be found in the Guidance for Industry 
Q3C 228 and in specific reviews.229,230  
Other considerations, as already mentioned, are challenges related to the prep-
aration methods. Many of these have already been described with the corresponding 
techniques, therefore only some general requirements are described here. Techniques 
such as SAS and HGRP require organic solvents to function as solvent to the drugs 
and as anti-solvent to water, another organic solvent or a supercritical fluid, while 
being simultaneously miscible with the antisolvent. Whereas in methods related to 
emulsion and emulsion-freeze-drying, solvents need to be immiscible with water, or 
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at least partially immiscible for the formation of emulsions. If the solvent is removed 
by freeze-drying, the melting points of the selected solvents has to be taken into ac-
count. The solution made from the solvents should have a melting point above the 
lowest temperature in the chamber of the freeze-dryer, although it is still possible to 
freeze dry a small volume frozen solution with a lower melting point with high capac-
ity vacuum. When the melting point is low and the frozen sample melts in the freeze 
dryer, the porous structure and the quality of the nanoparticles can be compromised.  
1.5.2. Additives 
Nanoparticle formation is a rapid process where nucleation is induced by a 
drastic increase of supersaturation or by downsizing microparticles with mechanical 
force. In both cases, particle agglomeration or further particle crystallisation needs to 
be suppressed. Additives, mainly surfactants, are usually added in the processing step 
to address the aggregation problem. Surfactants are amphiphilic molecules consisting 
of a hydrophobic part and a hydrophilic part. Surfactants can be classified according 
to the charge of the hydrophilic part of the molecule as anionic, cationic, zwitterionic, 
or non-ionic. Adsorption of surfactants on surface or surrounding droplets is driven 
by the decrease in free energy at the phase interface. Surfactants can form micelles 
with a hydrophobic core in aqueous medium. The hydrophilic part of the molecule 
interacts strongly with the surrounding water and hence well dispersed.231 An increase 
of surfactant concentration usually leads to a decrease in particle size due to enhanced 
adsorption on the surface, however if the concentration is above the critical micelle 
concentration, the molecules will exist in micelle form and interaction with the drug 
molecules is limited.232 Length and charge of surfactants play another important role 
for stabilization. Longer hydrophobic chains can cover more surface area and the re-
quired amount would be lower. Particles with charged surfactants on the other hand 
show greater electrical repulsion due to the resulting surface charge.233 One major 
concern in using surfactants is the impact that surfactants may have for biomedical 
application and on the environment. Studies show that surfactants can accumulate in 
water and may be toxic to marine life.234,235 Elevated levels of surfactants are also 
known to lead to irritation of the human skin due to changes in the stratum corneum. 
236,237 
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1.5.3. Polymers 
There are two main routes polymers can be used in nanoparticle formulation, 
either as stabilisers or in drug encapsulation which has already been discussed. Some 
polymers can stabilise nanoparticles by adsorption on the surface in the same way as 
surfactants, although in contrast to surfactants polymers can agglomerate in the hy-
drodynamic layer between particles and prevent particle collision and agglomeration 
.238 Depending on the techniques applied, polymers can form scaffolds in the dried 
state, which prolongs the shelf life of nanoparticles.84,103 To address toxicology con-
cerns, recent research has focused on the synthesis of biodegradable polymers and 
polymers made from materials native or similar to the human body, which may also 
increase the cellular uptake. Typical examples of such polymers include poly(lactic 
acid) (PLA),239 poly(lactide-co-glycolide) (PLG) 240 and chitosan.241  
1.6. Applications 
Table 1.3 shows a selection of approved nanodrug products on the market and 
the administrations achieved by drug nanoformulations.245-271 Most of these nanomed-
icines are either produced by top-down processes or encapsulation. The only industri-
ally applied bottom-up technique is spray drying, since it is possible to mix additives 
in the feed solution and achieve encapsulation in one-step. All the drugs produced by 
spray drying listed in Table 1.3. have utilised polymers. Encapsulation in liposomes 
and drug delivery via emulsions are well established methods especially in cancer and 
HIV treatment. Dendrimers are not as well established, which may in part be due to 
the difficulty in synthesising such polymers and also the possible toxicity. To the best 
of our knowledge, the first dendrimer-nanomedicine containing the dendrimer 
SPL7013, an antiviral agent, is VivaGelTM by Starpharma. The drug may be applied 
for topical use to prevent infection with HIV and other sexual transmitted diseases. At 
this time, it is still in Phase III testing.242 The similar limited use has been noticed for 
block copolymer micelles. Genexol®-PM by Samyang Biopharmaceuticals, a poly-
meric micelle formulation of paclitaxel, is currently undergoing Phase II and III tests. 
Other cancer drugs, SP1049C (a doxorubicin polymer micelle conjugate) and NC-
6004 (a cisplatin micelle conjugate) have also been tested.244,245 
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Table 1.3. Selected marketed nanodrugs. 
Name 
Active Ingre-
dient 
Dosage 
form 
Application Method Company 
Pletal Cilostazol oral 
peripheral vas-
cular disease 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Otsuka Pharma-
ceutical Co.245  
Rapamune® Sirolimus oral 
Immunosup-
pressant 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Pfizer 246 
Emend® Aprepitant oral 
Suppresses nau-
sea and vomiting 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Merck 247 
Megace® ES 
Megestrol ac-
etate 
oral Breast cancer 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Par Pharmaceuti-
cals Inc. 248,249 
Tricor® Fenofibrate oral 
Reductionof 
cholesterol lev-
els 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Abbott Laborato-
ries 250 
Avinza® 
Morphine Sul-
phate 
oral 
Severe pain 
treatment 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
King 
Pharmaceuticals 
251 
Focalin® 
Dexme-
thylphenidate 
hydrochloride 
oral 
Attention deficit 
hyperactivity 
disorder 
(ADHD) 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Novartis 252 
Ritalin LA® 
Methylpheni-
date hydro-
chloride 
oral 
Attention deficit 
hyperactivity 
disorder 
(ADHD) 
Wet pearl/ball 
milling (Nano-
CrystalTM) 
Novartis 253 
Triglide® Fenofibrate oral 
Reduction of 
cholesterol lev-
els 
High pressure 
homogenization 
(IDD-P 
Skyepharma) 
Sciele Pharma 
Inc.254 
Abraxane® 
Albumin-
bound 
paclitaxel 
i.v. 
Cancer treat-
ment 
High pressure 
homogenization 
 
Abraxis BioSci-
ence 255 
 
Sporanox® Itraconazole oral Antifungal agent Spray drying 
Janssen  
Pharmaceutica256 
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Prograf® Tacrolimus oral 
Immunosup-
pressant 
Spray drying Atellas 257 
Cesamet® Nabilone oral 
Suppresses nau-
sea and vomiting 
Spray drying 
Meda 
Pharmaceuticals 
258 
Intelence® Etravirine oral HIV treatment Spray drying 
Janssen  
Pharmaceutica259 
Diprivan® Propofol i.v. Anaesthetic Microemulsion Fresenius Kabi260 
Neoral® Cyclosporine oral 
Immunosup-
pressant 
SMEDDS Novartis261 
Norvir® Ritonavir oral HIV treatment SMEDDS 
Abbott Laborato-
ries262 
Fortovase® Saquinavir oral HIV treatment SMEDDS Roche263 
Restasis® 
Cyclosporine 
A 
Oph-
thalmic 
Dry eye syn-
drome 
Lipid emulsion Allergan264 
Durezol® Difluprednate 
Oph-
thalmic 
Eye inflamma-
tion 
Lipid emulsion 
Alcon Pharma-
ceuticals265 
Doxil® Doxorubicin i.v. 
Treatment of 
Kaposi’s sar-
coma 
PEGylated 
liposomes 
Janssen  
Pharmaceuti-
caN.V. 266,267  
Myocet® Doxorubicin i.v. Breast cancer liposomes 
Enzon 
Pharmaceuti-
cals268 
DepoCyt® Cytarabine i.v. 
Leukaemia and 
non-Hodgkin 
lymphoma 
liposomes 
Pacira 
pharmaceuti-
cals269 
DaunoXome® 
Daunorubicin 
citrate 
i.v. Leukaemia liposomes Galen270 
LMX®‐4 Lidocaine topical Local anesthetic liposomes 
Ferndale  
Laboratories 
Epaxal 
Inactivated 
hepatitis A vi-
rus 
paren-
teral 
Hepatitis A vac-
cine 
liposomes Crucell271 
 
1.7. Summary and perspective 
Nanomedicine has shown to be an answer to many problems in pharmaceutical 
applications, particularly in addressing the poor water-soluble problem. A wide range 
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of techniques, including top-down method, bottom-up method, or various encapsula-
tion approaches, have been developed to make drug nanoparticles. Reducing the drug 
particles to nanoscale can enhance dissolution rates and increase water solubility. Fur-
thermore, the decrease in size and functionalisation of the particle surface can facili-
tate the sustainable, targeted, and responsive drug delivery and release. Due to the 
tendency of drug nanoparticles aggregation, the preparation methods have been im-
proved to produce stable aqueous nanoparticle dispersions or prevent nanoparticles 
aggregation by efficient use of stabilisers or dry porous scaffolds.  
Because of the easy control in fabrication process, top-down approaches such 
as wet-milling and high-pressure homogenization have been mostly used by industry 
for nanoformulated drugs on the market. Spray drying is also a technique that has been 
employed industrially. However, it is generally very difficult to produce small, uni-
form, and non-aggregated nanoparticles by the top-down methods. There are also lim-
its for soft compounds or temperature-sensitive drug compounds to be processed by 
milling or homogenization. Various bottom-up processes have been developed and 
investigated to address different aspects of drug nanoformulations, for example, spray 
drying, sonoprecipitation, use of supercritical fluids, emulsions, cryogenic methods, 
and different encapsulation techniques. The results are highly promising. However, 
the cost of production, quality control in different production batches, and meeting 
the regulation requirements, have to be considered carefully before adopting these 
techniques industrially for marketing nanodrug formulations.  
For poorly water-soluble drugs with different properties, a suitable preparation 
technique should be selected to match the compound property and the requirement for 
the targeted application. In terms of producing drug nanoparticles, the challenge is 
how to produce drug nanoparticles with controlled sizes, narrow particle size, and 
control the shape of the nanoparticles. When the nanoformulations have been made 
for potential treatment, a reasonably long shelf life with non-aggregated nanoparticles 
is required, which can be normally met by use of surfactants and/stabiliser. However, 
in terms of treatment, a high ratio of drug to stabiliser is required for therapeutic effi-
cacy, not to mention the potential toxicity or side effects of the stabilisers. When it 
comes to in vivo test or clinical use, the surface of the drug nanoparticles should be 
properly functionalised, binding with multiple modalities (e.g., imaging modality), to 
allow sufficient circulation time in bloodstream, to deliver to the targeted sites, and to 
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release the drug payload on demand by triggers. Imaging techniques could be em-
ployed to tract where the drug nanoparticles are and to better understand the treatment 
outcome and hence to help develop more efficient drug formulations. Overall, 
nanoformulations for poorly water-soluble drugs are highly promising and fast grow-
ing pharmaceutical sector. Great efforts are required from researchers and industries 
to develop and optimize different nanoformulation techniques to achieve the best pos-
sible results in healthcare.  
1.8. Project aims and plans 
The following thesis will focus on the use of branched/hyperbranched poly-
mers to obtain drug nanoparticles by two different bottom-up techniques as well as 
the direct use as drug nanocarriers. The polymers used in Chapter 2 and 3 will be 
synthesised via free radical polymerisation, while the polymers used in Chapter 4 and 
5 will be synthesised by RDP techniques (ATRP and RAFT). Thereby making the 
direct comparison between branched systems obtained by ‘controlled’ and ‘uncon-
trolled’ polymerisation techniques possible.  
In Chapter 2, 3 and 4 emulsion-freeze drying, and a simple solvent evaporation 
technique will be employed to afford drug nanoparticles and drug nanosupensions of 
water insoluble drugs. These two bottom-up techniques were chosen for their mild 
conditions and hence broad applicability for sensitive actives. The (hyper) branched 
polymers were designed to be amphiphilic to avoid any further use of additives. Drug 
nanoparticles obtained by emulsion-freeze drying will furthermore be tested for their 
enhanced antimicrobial activity. Drug nanoparticles formed by solvent evaporation 
will be tested for enhanced dissolution. Chapter 4 will focus on the use of temperature 
responsive polymer nanoparticles for the formation of drug nanosuspensions via sol-
vent evaporation and the changed behaviour facilitated by changing the hydrophilic 
arms from linear to branched PEG will be investigated. 
In Chapter 5 pH responsive, hyperbranched polymers will be designed and 
synthesised by RAFT as a platform for encapsulation and release of water insoluble 
actives. Besides passive targeting the polymers will be surface modified for active 
targeting and tested for the possibility of using the polymers for the formation of hy-
drogels.  
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The focus will be on hyperbranched polymers because of their excellent solu-
bility in most media, easy synthesis and no need to self-assemble as well as the result-
ing longer blood-circulation. The overall aim will be to investigate the possibility to 
develop different multifunctional, stable platforms for drug delivery that are easy to 
synthesis, cost-efficient, highly reproducible and have a long shelf live. 
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Chapter 2 
 
Formulation of drug nanoparticles 
via emulsion-freeze-drying 
 
This Chapter is based on the publications 
U. Wais, A. W. Jackson, Y. Zuo, Y. Xiang, T. He and H. Zhang, "Drug 
nanoparticles by emulsion-freeze-drying via the employment of 
branched block copolymer nanoparticles." J. Control. Release, 2016, 
222, 141-150. 
and 
U. Wais, M. M. Nawrath, A. W. Jackson and H. Zhang, 
“Triclosan nanoparticles via emulsion-freeze-drying for enhanced anti-
microbial activity” submitted to Colloid and Polymer Science 
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2.1. Introduction   
The formulation of nanoparticles by bottom-up techniques is nowadays well 
established and applied in industry e.g. solvent-antisolvent precipitation (SAS),1-3 
high gravity reactive precipitation (HGRP),4,5 supercritical fluid precipitation 6-9 and 
spray drying.10-12 However, most bottom-up techniques suffer from poor particle sta-
bilisation and undesirable Ostwald-Ripening. An established way to prevent this is to 
use stabilising agents i.e. surfactants, that carry the risk of being potentially harmful 
to the body and toxic to the environment.13,14 As an alternative to surfactants, am-
phiphilic polymers can be used to stabilise particles. These polymers can, due to mod-
ern polymerisation techniques, be synthesised with high structural precision and be 
composed of biocompatible monomers like PLA, PLG or chitosan.15-17 Polymers, in 
contrast to surfactants, who form a charged layer around the particles i.e. ionic stabi-
lisation, prevent collision and agglomeration by steric stabilisation 18 and can also be 
used to form scaffolds to stabilise nanoparticles when dried, which leads to prolonged 
shelf life.19,20 
Our group previously reported the use of emulsion freeze-drying to form or-
ganic or drug nanoparticles in situ in water-soluble porous polymer.20 Emulsions were 
successfully stabilised by polymers and surfactants. The polymer scaffold obtained 
after freeze-drying prevents the nanoparticles from aggregating in the solid state, en-
suring a long storage time. The nanoparticles could readily be released by re-suspend-
ing the polymer scaffold in water to produce aqueous nanoparticle dispersion.20,21 
Both polymer (e.g., poly(vinyl alcohol)) and surfactant (e.g., sodium dodecyl sul-
phate) were required to form the emulsions, produce the porous scaffold, and stabilise 
the nanoparticles in aqueous suspensions. It was furthermore possible to a generate 
porous polymer scaffold by freeze drying and then employ a solvent evaporation ap-
proach to form organic/drug nanoparticles directly in the porous polymeric scaf-
fold.19,22 Aqueous nanoparticles dispersion could be prepared similarly. In both ap-
proaches, the use of both polymer and surfactant was important in forming stable 
aqueous nanoparticle dispersions. This, however, can result in low loading of drug 
compounds in the formulations. A formulation that utilises a biocompatible polymer 
acting both as scaffold and surfactant would be advantageous in improving drug load-
ing and reducing the formulation complexity. 
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Scheme 2.1. Schematic representation of the emulsion freeze-drying process using branched diblock 
copolymers.  
This Chapter describes the formation of hydrophobic drug nanoparticles via 
emulsion freeze-drying (Scheme 2.1.). The emulsions were initially formed using dif-
ferent amphiphilic branched polymers of different cores, short PEG arms and two dif-
ferent solvents, cyclohexane and o-xylene. The emulsions were subsequently freeze-
dried to obtain nanoparticles of two different hydrophobic active, Oil Red O (OR), an 
organic dye and indomethacin (IMC). After isolating the best polymer and conditions, 
this method was used to form triclosan nanoparticles, which could readily be re-sus-
pended in aqueous medium and tested on Candida albicans for enhanced microbial 
activity. Afterwards a series using PNIPAm, with varying cross-linkage equivalences 
and longer PEG chains was produced to investigate the influence of cross-linkage on 
emulsion stability and particle size. To that end nanoparticle of IMC and OR using o-
xylene and cyclohexane respectively as oil phase, were formed and evaluated.  
2.2. Experimental 
2.2.1 Chemicals and reagents  
Deionized water was prepared using an AquaMAX-Basic 321 DI water puri-
fication system. Oil Red O (OR) dye content ≥ 75 %, ketoprofen ≥ 98 % (TLC), ibu-
profen ≥ 98 % (HPLC), indomethacin ≥ 99 % (TLC), triclosan, o-xylene ≥ 98 % (GC), 
sodium acetate, N-isopropylacrylamide (NIPAm, 97 %), styrene (S), divinyl benzene 
(DVB), butyl methacrylate (BMA), di(ethylene glycol) dimethacrylate (DEGDMA) 
and dodecanethiol (DDT, 98 %) were purchased from Sigma-Aldrich. Macro-azo 
poly(ethylene glycol) initiator was obtained from Wako Pure Chemical Industries Ltd 
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(Osaka, Japan). Cyclohexane (extra pure), dimethylformamide (DMF, HPLC grade) 
and o-xylene were purchased from Fisher scientific and VWR international respec-
tively. All other solvents were reagent grade and purchased from Sigma-Aldrich. All 
chemicals were used as received.  
2.2.2. Characterisation 
The emulsions were imaged on an Olympus CX41 microscope with Plan mag-
nifying lenses. CellSens entry imaging software by Olympus was used for size meas-
urements. 1H NMR spectra were recorded on Bruker 400 Ultra Shield spectrometer. 
GPC was conducted on a Viscotek TDAmax consisting of a GPCmax integrated sol-
vent and sample delivery module, a TDA 302 Triple Detector Array, and OmniSEC 
software. 2 x PLgel 5 µm Mixed-C (200-2,000,000) columns were applied in sequence 
for separation. DMF was used as the eluent at 0.8 mL/min with column and detector 
temperature at 50 °C, molecular weight values were determined against poly(styrene) 
standards. Particle size was measured by dynamic laser scattering (DLS) analysis on 
a Malvern Zetasizer Nanoseries at 25 °C from Malvern Instruments. Cryo-Transmis-
sion Electron Microscopy (Cryo-TEM). Cryo-TEM to investigate size of the obtained 
nanoparticles was carried out using a vitrification robot (FEI Vitrobot MARK IV). All 
samples were prepared at room temperature and 100 % humidity with blotting time 
of 2 and blot force of 1. The samples (5 µL) were applied onto a grid (Quantifoil, 
R2/2, Holey carbon film, freshly glow-discharged prior to use at 20mA for 30 sec. 
without dilution. Excess sample was blotted away with filter paper to leave a thin film 
on the grid before being vitrified in liquid ethane. Cryo TEM measurements were 
performed on FEI Titan Krios equipped with automated sample loader and Field 
Emission Gun (FEG) operating at 300 kV. Images were recorded with Falcon II cam-
era (4X4) with magnification of 29000 and pixel size of 2.873. Scanning electron mi-
croscope (SEM) images were obtained using a Hitachi S-4800 SEM. The samples 
were coated with gold prior to imaging on an Emitech K550X Automated Sputter 
Coater. The freeze-dried samples were cut into thin slices and carefully mounted to 
the SEM stud using double adhesive carbon tape. For aqueous nanoparticles suspen-
sion, a drop of the suspension was deposited on a clean SEM stud and the solvent was 
left to evaporate before coating with gold. The cyro-transmission electron microscopic 
(cryo-TEM) analysis was performed on Tecnai G2 Spirit - T12 with 120 kV 
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acceleration made by FEI, Hillsboro, USA. Powder x-ray diffraction (PXRD) data 
was collected on a PanalayticalX’Pert Pro Multi-Purpose Diffractometer in high-
throughput transmission geometry. Cu Kα Radiation was used with Λ=1.541 Å and a 
divergence slit of 0.76 mm. Samples were pressed in a well of an aluminium plate and 
scanned at 40 kV and 40 mA over 5-50 ° 2ϑ with a scan time of 60 min and a step size 
of 0.0131°. 
2.2.3. Synthesis of branched poly(ethylene glycol)-b-Poly(N-isopropylacrylamide) ( 
PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45) (1)  
Typically, the radical macro-initiator poly(ethylene glycol) dimer (4 kDa, 2 g, 
0.5 mmol, 1 eq), N-isopropylacrylamide (3.4 g, 30 mmol, 30 eq per PEG chain), eth-
ylene diacrylamide (67 mg, 0.4 mmol, 0.4 eq per PEG chain) and dodecanethiol (40.5 
mg, 0.2 mmol, 0.2 eq per PEG chain) were transferred into a schlenk tube fitted with 
a magnetic stirrer bar and N,N-dimethylformamide (DMF,20 mL) added. The reaction 
mixture was degassed by three freeze-pump thaw cycles and the vessel was backfilled 
with N2. The reaction mixture was then placed in an oil bath at 70 °C and the polymer-
isation was quenched by rapid cooling after 16 h. The reaction mixture was dissolved 
in a minimal amount of tetrahydrofuran (THF) and added dropwise to a large excess 
of ice-cold diethyl ether. The precipitation was repeated once more before the desired 
branched copolymer was obtained as a white solid (2.7 g, theoretical Mw = 10900 
g/mol). Yield = 50 %. 1H-NMR were measured in CDCl3 (400 MHz): 1.19 ppm (s, 
3H, HN-CH3), 1.21 – 1.60 ppm (m, 2H, PEG-CH2), 1.66 – 2.13 ppm (m, 1H, PEG-
CH2-CH-C=O), 3.64 ppm (s, 4H, PEG), 4.03 ppm (s, 1H, -NH).  
2.2.4. Synthesis of branched poly(ethylene glycol)-b-poly(butyl methacrylate) 
(PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45) (2) 
Typically, the radical macro-initiator poly(ethylene glycol) dimer (4 kDa, 2 g, 
0.5 mmol, 1 eq), n-Butyl methacrylate (4.2 g, 30 mmol, 30 eq per PEG chain), Dieth-
ylene Glycol Dimethacrylate (96 mg, 0.4 mmol, 0.4 eq per PEG chain) and dodecan-
ethiol (40.5 mg, 0.2 mmol, 0.2 eq per PEG chain) were transferred into a schlenk tube 
fitted with a magnetic stirrer bar and N,N-dimethylformamide (DMF, 20 mL) added. 
The reaction mixture was degassed by three freeze-pump thaw cycles and the vessel 
was backfilled with N2. The reaction mixture was then placed in an oil bath at 70 °C 
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and the polymerisation was quenched by rapid cooling after 16 h. The reaction mix-
ture was dissolved in a minimal amount of tetrahydrofuran (THF) and added dropwise 
to a large excess of ice-cold petroleum ether (60/80). The precipitation was repeated 
once more before the desired branched copolymer was obtained as a white solid (3.9 
g, theoretical Mw = 11270 g/mol). Yield = 70 %. 
1H-NMR were measured in CDCl3 
(400 MHz): 0.83 ppm (s, 3H, O=C-C-CH3), 0.91 ppm (s, 3H, O=C-CH2-CH2-CH2-
CH3), 1.36 ppm (d, 2H, O=C-CH2-CH2-CH2-CH3), 1.57 ppm (d, 2H, O=C-CH2-CH2-
CH2-CH3), 1.78 ppm (m, 2H, PEG-CH2-CH3), 3.61 ppm (s, 4H, PEG), 3.90 ppm (d, 
2H, O=C-CH2-CH2-CH2-CH3).  
2.2.5. Synthesis of branched poly(ethylene glycol)-b-poly(styrene) (PEG45-b-(PS46-
co-DVB0.6)-b-PEG45) (3)  
Typically, the radical macro-initiator poly(ethylene glycol) dimer (4 kDa, 2 g, 
0.5 mmol, 1 eq), Styrene (3.1 g, 30 mmol, 30 eq per PEG chain), divinylbenzene (52 
mg, 0.4 mmol, 0.4 eq per PEG chain) and dodecanethiol (40.5 mg, 0.2 mmol, 0.2 eq 
per PEG chain) were transferred into a schlenk tube fitted with a magnetic stirrer bar 
and N,N-dimethylformamide (DMF,20 mL) added. The reaction mixture was de-
gassed by three freeze-pump thaw cycles and the vessel was backfilled with N2. The 
reaction mixture was then placed in an oil bath at 70 °C and the polymerisation was 
quenched by rapid cooling after 16 h. The reaction mixture was dissolved in a minimal 
amount of tetrahydrofuran (THF) and added dropwise to a large excess of ice-cold 
diethyl ether. The precipitation was repeated once more before the desired branched 
copolymer was obtained as a white solid (1.9 g, theoretical Mw = 8870 g/mol). Yield 
= 45 %. 1H-NMR were measured in CDCl3 (400 MHz): 1.21 – 1.60 ppm (m, 2H, PEG-
CH2), 1.66 – 2.13 ppm (m, 1H, PEG-CH2-CH-C=O), 3.64 ppm (s, 4H, PEG), 6.57 
ppm (m, 2H, Ar), 7.04 ppm (m, 3H, Ar).  
2.2.6. Formation of polymer nanoparticle dispersions 
Corresponding nanoparticles aqueous suspension can be prepared by a simple 
solvent-removal process. Typically, 10 mg of branched block copolymer was dis-
solved in 5 mL of acetone, followed by addition of 5 mL of water and stirred for 0.5 
h at room temperature. Acetone was removed by evaporation at room temperature, 
and final transparent nanoparticles aqueous suspension was obtained. 
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Triclosan particle size measurements were performed on nanoparticles suspensions in 
YPD medium with concentrations of 0.5 mg/ml. Measurements were performed after 
vigorously shaking the solution for 30 seconds by hand to disperse the material. The 
suspensions were put in a +4 °C fridge for 15 minutes to settle any formed foam and 
larger particles. 
2.2.7. Synthesis of branched poly(ethylene glycol)-b-Poly(N-isopropylacrylamide) 
(PEG135-b-(PNIPAm50-co-EDA2n)-b-PEG135) (4-6) and the corresponding nanoparti-
cle dispersions. 
Typically, the radical macro-initiator poly(ethylene glycol) dimer (12 kDa, 1.2 
g, 0.1 mmol, 1 eq), N-isopropylacrylamide (0.56 g, 5 mmol, 25 eq per PEG chain), 
ethylene diacrylamide (10.1 mg, 0.06 mmol, 0.3 eq per PEG chain) and dodecanethiol 
(10.1 mg, 0.05 mmol, 0.25 eq per PEG chain) were transferred into a small schlenk 
tube fitted with a magnetic stirrer bar and N,N’-dimethylformamide (DMF,7 mL) 
added. The reaction mixture was degassed and the vessel was backfilled with N2. The 
reaction mixture was then placed in an oil bath at 70 °C and the polymerisation was 
quenched by rapid cooling after 16 h. The reaction mixture was dissolved in a minimal 
amount of tetrahydrofuran (THF) and added dropwise to a large excess of ice-cold 
diethyl ether. The precipitation was repeated once more before the desired branched 
copolymer was obtained as a white solid (0.94 g). The molar ratio of ethylene di-
acrylamide per PEG chain was varied as n = 0.3 (4), 0.6 (5), and 0.9 (6) eq per PEG 
change for the PEG-PNIPAM branched block copolymers, while the equivalents per 
PEG chain of N-isopropylacrylamide and dodecanethiol were kept at 25 and 0.25 re-
spectively. Corresponding nanoparticles aqueous suspension can be prepared by a 
simple solvent-removal process. Typically, 10 mg of branched block copolymer was 
dissolved in 5 mL of acetone, followed by addition of 5 mL of water and stirred for 
0.5 h at room temperature. Acetone was removed by evaporation at room temperature, 
and final transparent nanoparticles aqueous suspension was obtained. 
2.2.8. Formulation of nanoparticles by emulsion-freeze-drying approach 
Typically, stock solutions of 0.5 wt % Oil Red O (indomethacin, ibuprofen, 
ketoprofen and triclosan) in cyclohexane (o-xylene) and 2 wt % branched block co-
polymers 1-6 in deionized water were prepared. To that end polymers were dissolved 
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in acetone and water was added dropwise. Acetone was then evaporated off at room 
temperature under constant stirring. Although pharmaceutical Class 2 solvents, cyclo-
hexane and o-xylene were chosen because of the good solubility for Oil red O (triclo-
san) and indomethacin respectively as well as their tendency to form stable emulsions. 
A high melting point of 6 °C and -24 °C respectively and high vapour pressure make 
them furthermore ideal for the freeze-drying process. A study 23 measuring solvent 
residues after lyophilisation showed that after freeze drying solvents with similar va-
pour pressures had solvent residues well within the limit as defined by the Interna-
tional Council for Harmonization of Technical Requirements for Pharmaceuticals for 
Human Use (ICH).24 Under vigorous stirring with an overhead stirrer the cyclohexane 
solution was added dropwise over a period of 2 minutes to the aqueous polymer solu-
tion of PEG45-PNIPAM30 and PEG45-BMA30 at room temperature. PEG45-Sty30 could 
not be dissolved in high concentration in water and was therefore added directly into 
o-xylene with indomethacin. Emulsions with the volume ratios of aqueous phase to 
organic phase (W/O) of 1:4 and 1:1 were prepared. After stirring for 2 minutes with 
an overhead stirrer at 1000 rpm, the emulsions were homogenised for another 2 
minutes using a Power Gen 1000 homogenizer by Fischer Scientific on setting 3. The 
emulsion was rapidly frozen in liquid nitrogen and placed in a CoolSafe freeze dryer 
by Scanvac at a condensing temperature of -90 °C and lyophilised for two days to 
produce dry porous polymer containing organic nanoparticles. After which the water 
to oil ratio was chosen that produced the most stable emulsion for polymers 1-3.  
2.2.9. Determination of the nanoparticles yields in the formulations 
5 mg of freeze dried material was dispersed in 10 mL deionized water and 
centrifuged at 3000 rpm for 3 minutes and another minute at 3600 rpm with an Ep-
pendorf Centrifuge 5415 D. This was to precipitate micronsized particles by centri-
fuging while nanosized particles stay in the supernatant. The precipitant was re-dis-
solved in ethanol. The concentrations of Oil Red O (OR) or other drug compounds 
were determined by UV/Vis absorption on a µQuant spectrometer by Northstar Sci-
entific. Ethanol was added to the aqueous supernatant and water was then added to 
the ethanol solution of precipitation to achieve a 1:1 v/v ethanol/water mixture. The 
measured absorption was compared to a standard curve of OR (or indomethacin) in 
the 1:1 v/v ethanol/water medium. Yield of ketoprofen and ibuprofen was measured 
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on a 1200 series HPLC (because of no UV absorbance on the UV-Vis spectrum) from 
Agilent, comprising a vacuum degasser, quaternary pump, ALS auto-sampler, heated 
column compartment and UV-Vis detector. A 300 mm by 4.6 mm phase symmetry 
silica column with a particle diameter of 5 µm and a pore size of 120 Å was used. A 
flow rate of 1 ml/min was set. The mobile phase was a mixture of hexane and isopro-
pyl alcohol with 70 % hexane for ketoprofen and 90 % hexane for ibuprofen. All tests 
were carried out at 20 °C. All signals were UV detected at 254 nm. Data analysis was 
performed using Agilent Chemstation software, version B.02.01 (Agilent Technolo-
gies, USA).  
Nanoparticle yield was calculated as follows. Microparticles and aggregates 
were removed by centrifugation. The yield of suspended drug/dye in water was cal-
culated as described below: 
𝒀𝒊𝒆𝒍𝒅 =
𝒎𝑵𝑷
𝒎𝑻
×  𝟏𝟎𝟎 =
𝒎𝑺
𝒎𝑺 + 𝒎𝑷
× 𝟏𝟎𝟎    (𝟏. 𝟏. ) 
Where mNP is the mass of drug/ dye suspended in water and mT is the total 
initial mass of drug/ dye. mS is the mass of drug/ dye in the suspension after centrifu-
gation and mP is the mass of precipitated drug/ dye after centrifugation. To determine 
the mass in suspension, 1.5 ml sample was added to 1.5 ml ethanol and measured by 
UV/Vis. The centrifugation precipitant was re-dissolved in 3 mL ethanol. 1,5 ml of 
this solution was then added to 1.5 ml DI water and measured by UV/Vis. Quantities 
of drug/ dye were determined against calibration curves of known concentrations in 
ethanol. 
2.2.10. Antimicrobial activity of triclosan nanoparticles  
The efficacy of the nanoparticles was tested on opportunistic fungal patho-
gen Candida albicans in formulation with the broad-spectrum antimicrobial agent 
Triclosan. Growth kinetics of C. albicans exposed to different dilutions of stock solu-
tions of 2 mg/ml of PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 stabilised triclosan 
nanoparticles, triclosan and 10 mg/ml of PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45. 
Cell growth was monitored by optical density at 600 nm (OD600) over a period of 5 h 
incubation at 37°C, 150 rpm. C. albicans was first grown aerobically at 37°C, 200 
rpm in a 100 mL- Erlenmeyer flask with 40 mL YEPD (10 g/L Yeast Extract (Fisher 
BioReagents), 20 g/L Bacteriological Peptone (Oxoid), 20 g/L Dextrose (Sigma-
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Aldrich) media overnight. Overnight culture was inoculated into fresh YEPD media 
in NUNC 96-well plates containing dilutions of polymer stabilised triclosan nanopar-
ticles, triclosan and PEG45-PNIPAM30 respectively with a final volume of 200 µL per 
well. OD600 measurements were taken in triplicate using a Varioskan™ Flash spectral 
scanning multimode reader (Thermo Scientific, Singapore).   
2.3.  Results and discussion  
2.3.1.  Synthesis of PEGylated hyperbranched block copolymers 
 
Scheme 2.2. Schematic representation of the synthesis of a) PEG45-b-(PNIPAm60-co-EDAm0.8)-b-
PEG45 (1); b) PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 (2); c) PEG45-b-(PS46-co-DVB0.6)-b-
PEG45 (3) and d) PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 with varying cross-linked equivalences  
Branched diblock copolymers were synthesised using a macro-initiator PEG 
azo-dimer with a molecular weight of 4000 g/mol and three core-forming monomers 
N-isopropylacrylamide, n-butyl methacrylate and styrene. To form lightly branched 
copolymers these were copolymerised with the cross-linkers ethylene diacrylamide 
(EDAm) (synthesised by Dr A. Jackson in ICES), diethylene glycol methacrylate 
(DEGDMA) and divinyl benzene (DVB), respectively (1-3). Next, branched block 
copolymers of a PEG macro-azo initiator with a molecular weight of 12000 g/mol and 
PNIPAm with cross-linkage equivalences of 0.3, 0.6 and 0.9 (4-6) were synthesised. 
Scheme 2.1 shows a schematic representation of the synthesis of polymer 1-6.  
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Table 2.1. shows the synthetic parameters used in the synthesis of polymers 1-
6. For polymers 1-3 a (hydrophobic to hydrophilic) ratio of 0.66:1 units was chosen 
to obtain lightly cross-linked, amphiphilic polymer nanoparticles. All polymers were 
synthesised using the same parameters. The obtained polymers were characterised us-
ing 1H-NMR (Figure 2.2.), DLS (Table 2.1. and Figure 2.1. d-f) and GPC (Figure 
2.1.a-c and Table 2.2). Gel permeation chromatography (GPC) analysis of branched 
macromolecules does not yield accurate molecular weights when compared to linear 
calibration standards. However, GPC analysis (Figure 2.1.) confirmed the successful 
consumption of the PEG azo-dimer and the high dispersity values obtained are typical 
of branched macromolecules. Aqueous nanosuspensions for DLS were prepared by 
dissolving polymer 1-3 in acetone and adding water dropwise. Acetone was evapo-
rated off under constant stirring and the obtained suspension were used to measure 
particle size. Sizes obtained by DLS in aqueous medium of 33, 64 and 38 nm for 
polymers 1-3 respectively, showed that unimolecular branched block copolymers 
were obtained and not linear block copolymers.  
 
Figure 2.1 Characterisation of branched diblock copolymers PEG45-b-(PNIPAm60-co-EDAm0.8)-b-
PEG45 (1), PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 (2) and  PEG45-b-(PS46-co-DVB0.6)-b-PEG45 
(3) via gel permeation chromatography in THF (a-c) and dynamic light scattering (d-f) in H2O.  
Table 2.2. GPC data of polymers 1-3 
Branched copolymer Conv. Mna (kDa) Mwa PDIa (Mw/Mn) 
 % kDa - 
1 99 8,400 16,200 1.93 
2 83 8,000 22,300 2.79 
3 77 3,900 20,000 5.26 
a Determined by GPC in THF. b Determined by DLS analysis in H2O (0.1 wt %). 
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Figure 2.2. 1H-NMR in CDCl3 of of a) PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1); b) PEG45-b-
(PBMA50-co-DEGDMA0.7)-b-PEG45 (2) and c) PEG45-b-(PS46-co-DVB0.6)-b-PEG45 (3). 
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Figure 2.2 shows the 1H-NMR measured in CDCl3 after purification by pre-
cipitation of the polymer into petroleum ether (60/80) three times. The peak at 3.61 
ppm can be assigned to the ethylene group of PEG. These signals were integrated and 
compared to the signals of the core forming monomers to obtain the degree of 
polymerisation. In figure 2.2.a the signals at 3.9 ppm (s, 1H, -NCH) and 1.04 (s, 6H, 
-NCH3) were chosen because they are specific to PNIPAm. Integration shows that a 
conversion of 99 % was reached and PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 was 
obtained. In Figure 2.2.b nBMA signals at 1.36 ppm (d, 2H, -CH2CH3), 1.57 (d, 2H, 
-CH2CH2CH2-) and 3.91 ppm (d, 2H, -COCH2CH2-) were chosen. Integration showed 
that the conversion was 83 % and that PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 
was obtained. Figure 2.2.c shows the NMR spectra of PEG45-b-(PS46-co-DVB0.6)-b-
PEG45. The integration of signals at 6.58 ppm (m, 2H, Ar, -CH) and 7.07 ppm (m, 3H, 
Ar, -CH) show that the conversion was 77 %. The trend in conversion from NIPAm 
> nBMA > Styrene is due to the different reactivity’s of the chosen monomers.25  
The ability to form nanoparticles by emulsion freeze-drying and stabilisation 
was further investigated in dependency of cross-linkage. To that end, branched copol-
ymer of PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 with varying cross-linkages of 
n = 0.3, 0.6 and 0.9 (4-6) were synthesised by Dr A. Jackson in ICES, Singapore. A 
longer PEG chain of a molecular weight of 12000 g/mol was chosen, because a longer 
PEG chain was believed to lead to an increased ability to form emulsions with higher 
oil phases. DLS data (Table 2.1.) shows that the obtained polymers 4-6 were branched 
block copolymers of 70, 81 and 96 nm. The increased sizes reflect the use of the longer 
PEG chains. With increasing cross-linker equivalences the particle size increased. 
More cross-link equivalences could lead to the incorporation of more linear polymer 
chains into a unimolecular branched polymer, which would increase the size. 
2.3.2. Hydrophobic dye and drug nanoparticles by emulsion freeze-drying effect of 
core forming monomer  
Polymers 1, 2 and 3 were used to form emulsions with two organic solutions 
of indomethacin in o-xylene and oil red in cyclohexane, which were subsequently 
lyophilised to generate nanoparticles, which could be re-suspended to form nanosus-
pensions. The nanoparticles were investigated using DLS to obtain size data. UV/Vis 
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was used to calculate nanoparticle yield. The best conditions, i.e. polymer, o/w ratio 
and oil phase solvent were identified and used for further tests. 
2.3.2.1. Emulsion freeze-drying of Indomethacin 
Emulsions were formed with aqueous dispersions of polymers 1 and 2. To that 
end 2 wt % aqueous stock solutions of 1 and 2 were obtained by dissolving the poly-
mers in acetone and evaporating into water to assure that well dispersed polymer 
nanosupensions were obtained. These were emulsified using a homogenizer with a 
0.5 wt % indomethacin solution in o-xylene in a ratio of o/w 4:1 (80 % oil phase). 
Polymer 3 could not be dissolved in water in such high concentrations and was sub-
sequently added to o-xylene directly with the indomethacin and homogenised with 
pure water in the same ratio. Figure 2.3. shows microscope pictures of the obtained 
emulsions. Figure 2.3. a, c, and e show emulsions formed from 1, 2 and 3 respectively 
with 80 % oil phase. None of the emulsions were stable for longer than a few minutes 
and separation could be observed under the microscope. Although, emulsions formed 
from polymer 1 were slightly more stable than their counterparts. We ascribed this to 
be a result of the high oil content. Consequently, emulsions were formed with 50 % 
oil phase (o/w 1:1) (Figure 2.3. b, d and f). This led to the formation of stable emul-
sions for 1 with uniform droplet sizes between 10 and 20 µm (Figure 2.3.b). Emul-
sions formed with 3 were also slightly more stable with less oil phase, however a 
broad distribution of droplet sizes could be found ranging from as small as 5 µm to 
almost 100 µm (Figure 2.3. f). Emulsion formed from polymer 2 on the other hand, 
could not be stabilised even with a lesser oil content (Figure 2.3. d). The reason for 
that might be that o-xylene is a poor theta solvent for the BMA core and as such the 
ability to stabilise even lower oil phase emulsions is diminished. All emulsions were 
rapidly frozen in liquid nitrogen and lyophilised. All obtained emulsions were oil-in-
water emulsions. 
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Figure 2.3. Emulsions formed from stock solutions of 0.5 wt % indomethacin in o-xylene and 2 wt % 
stock solutions of a) Polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) with 80 % oil phase; b) 
Polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) with 50 % oil phase; c) Polymer PEG45-b-
(PBMA50-co-DEGDMA0.7)-b-PEG45 (2) with 80 % oil phase; d) Polymer PEG45-b-(PBMA50-co-
DEGDMA0.7)-b-PEG45 (2) with 50 % oil phase; e) Polymer ) PEG45-b-(PS46-co-DVB0.6)-b-PEG45 (3) 
with 80 % oil phase; and f) Polymer ) PEG45-b-(PS46-co-DVB0.6)-b-PEG45 (3) with 50 % oil phase.  
Figure 2.4. shows SEM pictures of the polymer 1 scaffold obtained after emul-
sion freeze-drying emulsions of 80 % and 50 % oil phase. All other samples contain-
ing polymer 2 and 3 had collapsed after two days i.e. the sample shrunk and lost its 
porosity. Due to that reason, no images were taken. In Figure 2.4. a clear difference 
between the scaffold formed from an emulsion of 80 % oil (Figure 2.4.a) and 50 % 
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oil (Figure 2.4.b) can be observed. While the scaffold of 50 % oil phase shows clear 
emulsion templating i.e. emulsion droplets can still be observed as spheres, the scaf-
fold from 80 % more closely resembles a reef, a possible result of the more unstable 
emulsion.  
 
Figure 2.4. SEM pictures of a) IMC nanoparticles stabilised by a polymer PEG45-b-(PNIPAm60-co-
EDAm0.8)-b-PEG45 (1) Matrix after emulsion freeze-drying of an o-xylene/water emulsion with 80 % 
oil phase and b) indomethacin nanoparticles stabilised by a polymer PEG45-b-(PNIPAm60-co-
EDAm0.8)-b-PEG45 (1) Matrix after emulsion freeze-drying of an o-xylene/water emulsion with 50 % 
oil phase. Magnified 1000 times (left) and 5000 times (right).  
The obtained polymer scaffolds containing indomethacin nanoparticles were 
re-suspended in DI water, however no stable nanosuspension for DLS measurements 
could be obtained. Therefore, Yeast Extract-Peptone-Dextrose (YEPD) medium was 
used, because it had been shown before that in growths medium PEGylated particles 
did not agglomerate.26 Table 2.3. shows the obtained DLS data as well as the nano-
particles yields.  
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Table 2.3. DLS data in YEPD medium and nanoparticles yield from indomethacin nanoparticles ob-
tained by forming emulsions of water/o-xylene stabilised by polymer PEG45-b-(PNIPAm60-co-
EDAm0.8)-b-PEG45 (1) 
Oil phase Polymer 
Dh 
Z-Average 
PDI 
Dh 
Int. % 
Yield 
%  nm - nm % 
80 1 749 ± 297 0.8 
1209 ± 297 
208 ± 40 
59 
50 1 657 ± 297 0.9 
910 ± 154 
131 ± 52 
74 
No DLS data of samples using polymers 2 and 3 could be obtained because 
not enough could be re-dispersed in water or medium after the scaffold had collapsed. 
Nanoparticles formed from higher oil phase emulsions produced bigger particles, then 
when less oil was used e.g. 749 nm compared to 657 nm. This, as well as the lower 
yield of 54 % was ascribed again to a more unstable emulsion. Figure 2.5. shows the 
samples re-dispersed in water. None of the samples could be completely re-dispersed 
to obtain a nanoparticle yield of 100%.  
 
Figure 2.5. Nanosuspensions of indomethacin (IMC) nanoparticles obtained by emulsion freeze-dry-
ing after re-suspension in DI water stabilized by PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1), 
PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 (2) and PEG45-b-(PS46-co-DVB0.6)-b-PEG45 (3)  
 
2.3.2.2. Emulsion freeze-drying of Oil Red O 
Cyclohexane is a good solvent for freeze-drying and emulsion formation. For 
that reason, it was investigated if changing the oil phase solvent to cyclohexane would 
improve the nanoparticles formation. Stock solutions of polymer 1 and 2 were created 
as has been described before and emulsified with a 0.5 wt % oil red/cyclohexane 
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solution. No stock solution of 3 could be obtained because the polymer could not be 
dissolved in cyclohexane or water.  
Figure 2.6. shows the microscope pictures of emulsions formed after homog-
enisation. In the case of 1 it was observed that emulsions formed with 80 % oil (Figure 
2.6. a) were not stable while emulsions formed with 50 % oil were stable (Figure 2.6. 
b) with oil droplet sizes between 20 and 50 µm. When stock solutions of 2 were emul-
sified with cyclohexane stable emulsions with small droplets could be obtained re-
gardless of oil content (Figure 2.6. c and d). All obtained emulsions were oil-in-water 
emulsions. 
 
Figure 2.6. Emulsions formed from stock solutions of 0.5 wt % oil red in cyclohexane and 2 wt % 
stock solutions of a) Polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and 80 % oil; b) Polymer 
PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and 50 % oil; c) Polymer PEG45-b-(PBMA50-co-
DEGDMA0.7)-b-PEG45 (2) and 80 % oil and d) Polymer PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 
(2) and 50 % oil.  
After lyophilisation red powders were obtained and imaged using SEM. Fig-
ure 2.7. shows the results. All samples, except for polymer 2 emulsified with 50 % oil 
phase, produced stable scaffolds. This might be a result of the increased hydrophobi-
city of nBMA which led to higher oil phase emulsions being more stable. While the 
 73 
 
emulsion templating in scaffolds produced from 1 and 50 % oil phase is clearly dis-
cernible (Figure 2.6. b), scaffolds using higher oil content i.e. 80 % formed from 1 
and 2 exhibited fibre like structures (Figure 2.6. a and b).  
 
Figure 2.7. SEM pictures of oil red nanoparticles stabilised by a polymer scaffold after emulsion 
freeze-drying of a) Polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and 80 % oil; b) Polymer 
PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and 50 % oil and c) Polymer PEG45-b-(PBMA50-co-
DEGDMA0.7)-b-PEG45 (2) and 80 % oil. 1000 times magnified (left) and 10000 times magnified (right).  
The three samples were subsequently re-suspended in water (Figure 2.8.). 
Nanosuspensions of emulsions with 50 % oil phase could be formed in the case of 
polymer 1, while 80 % oil phase failed. Polymer 2 with 80 % oil could form nanosus-
pensions of OR. Scaffolds which had collapsed already, were not re-suspended 
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because it had been shown before (Figure 2.5.) that these would not be able to form 
suspensions. As had already been done for indomethacin, DLS data and yield were 
measured in YEPD medium. Table 2.4. shows the data obtained.  
 
Figure 2.8. Nanosuspensions of oil red nanoparticles obtained by emulsion freeze-drying OR with 
polymers PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and PEG45-b-(PBMA50-co-DEGDMA0.7)-b-
PEG45 (2).  
All OR nanoparticle formed via emulsion freeze-drying showed large sizes of 
1366 and 859 nm as well as high PDIs of 0.5 and 0.6. However, using polymer 1 led 
to a high yield of 99 % nanoparticles in solution.  
Table 2.4. DLS data in YEPD medium and nanoparticles yield of OR nanoparticles obtained by form-
ing emulsions of water/cyclohexane stabilised by PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) and 
PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 (2). 
Oil phase Polymer 
Dh 
Z-Average 
PDI 
Dh 
Int. % 
Yield 
%  nm - nm % 
80 2 1366 ± 48 0.5 
2089 ± 1094 
506 ± 191 
70 
50 1 859 ± 36 0.6 
1043 ± 225 
375 ± 208 
99 
Table 2.5. gives a summarized overview of all conditions used in the screening 
process, as well as nanoparticle yield, PDI and DLS size data. Due to the favourable 
emulsion, scaffold and nanoparticle stability as well as nanoparticle yield and DLS 
size data, polymer 1 and cyclohexane/water with 50 % oil phase (entry 4) were utilised 
to prepare triclosan nanoparticles. 
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2.3.3. Activity of triclosan nanoparticles against Candida albicans 
After having investigated the best possible parameters to form nanoparticles 
by emulsion freeze-drying using branched block copolymers we used the following 
parameters, 50 % cyclohexane and polymer 1, to form triclosan nanoparticles. Figure 
2.9. show emulsions formed from a 2 wt % aqueous polymer 1 solution and a 0.5 wt 
% triclosan cyclohexane solution (Figure 2.9. a) and a control emulsion of 2 wt % 
aqueous polymer 1 solution and cyclohexane without triclosan (Figure 2.9. b). 
 
Figure 2.9. Microscope imagines of emulsions of cyclohexane/water in a ratio of 1:1 with a) 2 wt % 
aqueous polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) solution + 0.5 wt % triclosan and b) 
2 wt % aqueous polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) solution. 
Stable oil in water emulsions with small and uniform droplets of between 20 
to 30 µm could be obtained (Figure 2.9. a). The control emulsion also formed stable 
o/w emulsion and showed, in average, smaller droplet sizes of around 10 µm, which 
is likely a result of the changed viscosity of cyclohexane without the dissolved triclo-
san (Figure 2.9. b).  
After freeze-drying white powders were obtained that could be readily re-dis-
solved in water to form nanosuspensions with no discernible precipitant. The dried 
powders also exhibited storage stability over several months. SEM pictures of the ob-
tained powder showed emulsion templated scaffolds for both emulsions (Figure 2.10). 
Upon closer inspection, spherical protrusions of around 200 to 300 nm could be ob-
served for the scaffold containing triclosan (Figure 2.10.a). These could be the triclo-
san nanoparticles however, the low contrast between organic compounds makes it 
difficult to make this assertion with full certainty. DLS data in YPED medium gave 
the size of triclosan nanoparticles as 280 ± 12 nm (Z-Average), 260 ± 15 nm (Intensity 
%) and 148 ± 9 nm (Number %) with a low PDI of 0. 36 (Figure 2.11.b). Comparison 
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with the freeze-dried material obtained of emulsions formed with only polymer 1 
showed significant less, as well as smaller spherical protrusions, which were presum-
ably formed by rapid freezing (Figure 2.10.b). 
 
Figure 2.10. SEM imagines of polymer scaffolds after emulsion freeze-drying of emulsions of cyclo-
hexane/water in a ratio of 1:1 with a) 2 wt % polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1)  
+ 0.5 wt % triclosan and b) 2 wt % polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1). 
Cryo-TEM of triclosan nanoparticles suspended in YEPD Medium (Figure 
2.11.a) was measured to obtain a more accurate picture of the size and shape. The 
obtained pictures show spherical particles between 150 and 300 nanometre, confirm-
ing the DLS data. Studies have shown previously that the cell uptake of spherical 
shaped nanoparticles compared to rod-shaped particles of the same size increased by 
up to 500 %. This was attributed to an increase in membrane wrapping time needed 
for non-spherical particles.27 Hence, the triclosan nanoparticles obtained from emul-
sion freeze-drying exhibit a favourable shape for cell uptake.  
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Figure 2.11. a) Cryo-TEM images of triclosan nanoparticles in YEPD medium obtained by emulsion 
freeze-drying and b) DLS data of triclosan nanoparticles in YEPD medium obtained by emulsion 
freeze-drying.  
Nanoparticles of triclosan were used to test their antimicrobial activity against 
Candida albicans. C. albicans was chosen as a model organism because it is well 
adapted to laboratory testing and because it is the leading cause for Invasive candidi-
asis (IC), accounting for 40 % of all IC cases. IC is a leading cause of nosocomial 
blood stream infections in hospitals in the USA with a high mortality rate of 40 %.28,29 
Triclosan was chosen because of its very low water solubility of only about 10 
µg/ml.30 Triclosan as received and triclosan nanoparticles formed by emulsion freeze-
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drying stabilised by polymer 1 were added to C. albicans in concentrations of 6 to 1 
µg/ml in steps of 1 µg/ml and incubated till optical density of 1 was reached. Optical 
density at 600 nm was measured every half hour by our collaborator M. Nawrath in 
Industrial biology in ICES. The nanoparticles could be re-dispersed directly into DI 
water to form a stock solution of 2 mg/ml. For comparison, a triclosan stock solution 
of 2 mg/ml and polymer stock solution of 10 mg/ml were made. Triclosan as received 
could not be dissolved directly into water in such high concentrations and had to be 
dissolved in methanol and then added to medium. Figure 2.12. shows the growth 
curves of Candida albicans incubated with the highest and lowest concentrations of 
triclosan as received, triclosan nanoparticles and polymer 1.  
 
Figure 2.12. Growths curves of Candida albicans after the addition of triclosan (blue) methanolic 
solutions in YEPD medium, triclosan nanoparticles and polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-
b-PEG45 (1) (red) re-suspended in YEPD medium and polymer PEG45-b-(PNIPAm60-co-EDAm0.8)-b-
PEG45 (1)  re-suspended in YEPD medium (green) as well as Candida albicans without any additives 
(black).  
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The black curve in Figure 2.12. shows the growth of C. albicans without any 
additives over a period of 5 hours. For direct comparison, the green curve shows the 
growths of cells after the addition of polymer 1. No inhibition could be observed, 
proving that there is no influence of polymer on the growths inhibition of C. albicans. 
The inhibition of C. albicans with triclosan as received (blue) was highly dependent 
on the concentration used. As such, low concentrations of 1 µg/ml had almost no ef-
fect on the cells, while 6 µg/ml significantly slowed down the cell growths. Using 
triclosan nanoparticles (red) showed that even at low concentrations the growths was 
stunted almost as much as when the highest concentration of triclosan as received was 
used. Previous studies of triclosan nanosuspensions tested on E.coli and S. Aureus had 
already shown that nanosizing greatly improved the activity of triclosan by up to 10 
times and up to 8 times against Corynebacterium.23,31 However, no studies on C. al-
bicans had been done up to this point. Differences in activity enhancement between 
these organisms are likely a result of the difference in cell wall composition and as 
such a direct comparison is not possible.  
Figure 2.13 shows the obtained data of growths curves for triclosan as received 
(Figure 2.13.a) and triclosan nanoparticle (Figure 2.13.b) concentrations of 1, 2, 3, 4, 
5 and 6 µg/ml. For triclosan as received, the inhibitory activity significantly depends 
on the concentration, while triclosan nanoparticles seem to inhibit growths in almost 
the same manner independent of concentration. To illustrate this better, the OD600, i.e. 
the optical density measured at 600 nm, after 5 h incubation was plotted against the 
concentration (Figure 2.13.c). It could clearly be observed that triclosan as received 
showed a decrease in growths with increasing concentration as was expected. How-
ever, when triclosan nanoparticles were used, it was observed that the OD600 after 5 h 
was only slightly higher for the lowest concentration compared to the highest i.e. 0.57 
to 0.48.  
This can be explained by the higher dissolution rate as well as higher availa-
bility of nanosized particles. Higher dissolution rate according to the Noyes-Whitney 
equation is a direct consequence of an increased surface area brought on by a de-
creased size,32-34 which has been proven repeatedly for different water insoluble ac-
tives.35,36 Studies with gold and silver nanoparticles have shown that nanoparticles, 
because of their decreased size, can be taken up by cells via endocytosis. One study 
found that nanoparticles anchored onto the cell walls, where they were able to form 
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pits where more nanoparticles could agglomerate and taken into the cell by endocyto-
sis.37-40 Both effects favour the cell intake and as such even at small concentration 
enough active. i.e. triclosan, can reach the cells to stop the population from growing 
compared to non-processed triclosan. Therefore, lower amounts of drugs are sufficient 
to reach the same therapeutic efficacy. 
 
Figure 2.13. Growths curves of Candida albicans after the addition of different concentrations of a) 
triclosan; b) triclosan nanoparticles and c) OD600 after 5h of C. albicans incubated with triclosan and 
triclosan nanoparticles against concentration.  
2.3.4.  Hydrophobic dye and drug nanoparticles by emulsion freeze-drying in de-
pendence of cross-linking  
The influence of cross-linking density of the polymers on nanoparticle size 
and emulsion stabilisation was investigated as well. To that end, a series of PEG135-
b-(PNIPAm50-co-EDAm2n)-b-PEG135 with cross-linker equivalences of n = 0.3, 0.6 
and 0.9 (4-6) was synthesised by Dr A. Jackson in ICES. A PEG-dimer with a higher 
molecular weight of 12000 g/mol was chosen, because it was theorised that a higher 
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Mw would lead to emulsions with better stability and the ability to obtain emulsions 
with higher percentage oil, which would in turn mean higher loading. The synthesis 
has been discussed in 2.3.1 and will, for that reason, not be discussed here. As had 
already been done before, cyclohexane/oil red and o-xylene/indomethacin solutions 
were used to form emulsions and subsequently nanoparticle.  
2.3.4.1 Emulsions freeze drying of Oil Red O 
Emulsions of 2 wt % aqueous polymer stock solutions and 0.5 wt % oil red 
(OR) in cyclohexane were formed. Oil phase percentages were chosen as 66 % (o/w 
= 2/1), 75 % (o/w = 3/1) and 80 % (o/w = 4/1). It was observed that emulsions formed 
by polymer 4 were stable over all percentages of oil, while emulsions of polymer 5 
became more unstable when less oil was used i.e. 66 % oil phase failed to form a 
stable emulsion. The trend continued with polymer 6 where only 80 % oil phase emul-
sions were stable enough to be lyophilised. This may be a result of higher cross-link-
ing producing particles with tighter cores and more polymer chains, which in turn 
leads to more PEG arms on the surface of the particle. These particles are then in-
creasingly more hydrophilic and the wettability by water is higher,22 up to the point 
where adsorption at the oil/water interface is not possible anymore. Increasing the 
percentage of oil could have forced the adsorption.  
Figure 2.14. shows SEM pictures of OR nanoparticles and the polymer scaf-
folds obtained after emulsion freeze-drying of emulsions stabilised by polymer 5 and 
6 with 80 % oil phase content. Figure 2.14. a and b show the emulsion templated 
scaffolds of polymer 5 and 6 of emulsion formed with 80 % oil respectively. Both 
scaffolds show the structure associated with an emulsion. Scaffolds formed from 5 
however show slightly smaller spheres i.e. droplets pre-lyophilisation, than scaffolds 
of polymer 6. This corresponds well with the observation that increased cross-linkage 
led to destabilisation of the emulsions. Figure 2.14. b and d show SEM images of 
nanoparticles obtained after re-dispersion of OR nanoparticles stabilised in the poly-
mer scaffolds in water. Nanoparticles of around 200 to 300 nm were obtained.  
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Figure 2.14. SEM pictures of a) Scaffold of an 80 % oil phase emulsions after emulsion freeze-drying 
of 2 wt % polymer PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 (5) + 0.5 wt % oil red; b) Nanoparti-
cles of oil red after resuspension of a; c) Scaffold of a 80 % oil phase emulsions after emulsion freeze-
drying of 2 wt % polymer PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) + 0.5 wt % oil red and d) 
Nanoparticles of oil red after resuspension of c.  
The obtained powders could readily be re-suspended in water to form nano-
suspensions. Figure 2.15.c shows the obtained nanosuspensions as well as OR dis-
solved in cyclohexane (Figure 2.15.a) and unprocessed, undissolved OR in water (Fig-
ure 2.15.b) for comparison.  
 
Figure 2.15. a) Oil Red O dissolved in cyclohexane; b) Oil Red O as received dissolved in water and 
c) Oil Red O nanoparticles produced by emulsion freeze-drying in water.  
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Nanosuspensions were measured by DLS and UV/Vis to acquire size and na-
noparticle yield. The results are shown in Table 2.6. Data obtained indicated that with 
decreasing oil phase the nanoparticle yield increased e.g. from 45 to 50 % yield when 
the oil phase percentage decreased from 80 % to 66 % for polymer 4, while the PDI 
decreased e.g. 0.42 to 0.35 going from 80 % to 66 %. No discernible particle size trend 
could be observed, indicating that by using emulsion freeze-drying with branched pol-
ymers, consistently small particles could be obtained almost independent of cross-
linkage. The plotted DLS data in Figure 2.16. confirms this observation.  
Table 2.6. Overview of size and yield of OR nanoparticles prepared by emulsion freeze drying stabi-
lised by PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4); PEG135-b-(PNIPAm50-co-EDAm1.2)-b-
PEG135 (5) and PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) 
Cross 
linkage 
Oil Phase 
[ %] 
Dh 
Z-Average 
[nm] 
Dh 
Int. % 
[nm] 
PDI 
Yield 
[ %] 
 % nm - % 
0.3 (4) 80 395 438 0.42 45 
0.3 (4) 75 340 980, 274 0.39 37 
0.3 (4) 66 423 760,231 0.35 50 
0.6 (5) 80 506 606, 115 0.29 54 
0.6 (5) 75 298 376 0.22 67 
0.6 (5) 66 not stable not stable not stable not stable 
0.9 (6) 80 348 456 0.33 36 
0.9 (6) 75 not stable not stable not stable not stable 
0.9 (6) 66 not stable not stable not stable not stable 
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Figure 2.16. DLS data of oil red nanoparticles re-suspended in water of a) freeze-drying an 80 % 
emulsion stabilised by PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4); PEG135-b-(PNIPAm50-co-
EDAm1.2)-b-PEG135 (5) and PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) and b) emulsions of var-
ying oil percentages stabilised by PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4).  
The emulsion freeze-drying approach also ensures long storage stability. To 
verify this, nanosuspensions were formed immediately after freeze-drying and after 8 
and 9 months storage at room temperature. Figure 2.17. shows the plotted DLS data.  
 
Figure 2.17. DLS data of oil red nanoparticles after resuspension in water stabilised by polymer 
PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) from a) 80 % oil phase emulsion after being stored 
and re-suspended after 9 months and directly after freeze-drying and b) 66 % oil phase emulsion after 
being stored and re-suspended after 8 months and directly after freeze-drying. 
Figure 2.17. shows that after 8 and 9 months the OR nanoparticles were 
slightly bigger than immediately after freeze-drying, hence some agglomeration 
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probably occurred. However, the size increase is quite small, showing that the poly-
mer scaffold is excellent in stabilising nanoparticles against agglomeration.  
2.3.4.2 Emulsions freeze drying of Indomethacin 
Indomethacin was chosen as a model drug as had been done before in 2.3.2.1. 
Emulsions were formed by homogenizing 2 wt % aqueous solutions of 4-6 and 0.5 wt 
% indomethacin in o-xylene. In contrast to using cyclohexane as oil phase solvent, 
emulsions formed from o-xylene could be formed for all oil phase percentages and all 
cross-linkages.  
Figure 2.18. shows microscope pictures of emulsions containing 75 % oil of 
polymer 5 and 6 respectively (Figure 2.17. a and b) and an emulsion formed using 6 
and 80 % oil. All formed emulsions were oil in water emulsions. The average droplet 
size spanned between 3 µm and 20 µm with the average size being around 5 µm for 
all emulsions formed for polymers 5 and 6 using the same oil percentage. This seemed 
to indicate that the droplet size was independent of cross-linking when o-xylene was 
used as oil phase. However, when the oil percentage was decreased, the droplet size 
decreased slightly which should lead to smaller nanoparticles.  
 
Figure 2.18. Optical microscopic images of the emulsions formed by dispersing IMC/o-xylene solution 
in aqueous polymer solution. a) PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 (5) with 75 % oil phase; 
b) PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) with 75 % oil phase and c) PEG135-b-(PNIPAm50-
co-EDAm1.8)-b-PEG135 (6) with 66 % oil phase 
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After freeze-drying the emulsions, SEM pictures were taken of all three vari-
ations of the cross-linked branched polymer scaffolds with 80 % oil phase (Figure 
2.19.). Those were chosen because they produced the highest nanoparticle yield, 
which will be discussed further on. All scaffolds clearly show emulsion templating. 
The scaffolds of polymers 4 and 5 both showed similar sized vesicles templated by 
the oil droplets (Figure 2.19. a and b). Unfortunately, no high magnification SEM 
pictures of the scaffold of polymer 6 (Figure 2.19.c) could be obtained and as such the 
vesicle sizes could not be observed well enough to make any assertions about the size 
of the droplet templated spheres.  
 
Figure 2.19. SEM pictures of scaffolds formed by emulsion freeze-drying of emulsions of 80 % oil 
phase and 0.5 wt % indomethacin using a) 2 wt % polymer PEG135-b-(PNIPAm50-co-EDAm0.6)-b-
PEG135 (4);; b) 2 wt % polymer PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 (5)  and c) 2 wt % poly-
mer PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6). 
The scaffolds could readily be re-suspended in water to form nanosuspensions of in-
domethacin. Table 2.7 shows the DLS data measured and the nanoparticles yield. All 
sizes were between 550 and 480 nm and no discernible size trend could be observed. 
However, the nanoparticle yield tended to decrease with less oil phase and lower 
cross-linkages of 0.3 eq (4) and 0.6 eq. (5) While the yield increased slightly for higher 
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oil phases when 0.9 eq. (6) cross-linkages were used and small PDIs of around 0.3 
and under could be obtained for all samples.  
To give a better insight into size changes in dependence of cross-linkage and 
oil phase content the size data was plotted in Figure 2.20. Data was plotted for the 
same oil phase percentage with varying cross-linkage (Figure 2.20 a, b and c) and for 
constant cross-linkage and varying the oil phase (Figure 2.20. d, e and f). The plotted 
data shows that while no significant difference between sizes overall could be ob-
served, polymer 5 produced multiple peaks in the DLS i.e. two main particle size 
populations. This is also reflected in the higher PDIs as seen in Table 2.7.  
Table 2.7. Overview of size and yield of indomethacin nanoparticles prepared by emulsion freeze dry-
ing stabilised by PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4); PEG135-b-(PNIPAm50-co-
EDAm1.2)-b-PEG135 (5) and PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6).  
Cross 
linkage 
Oil Phase 
[ %] 
Dh 
Z-Average 
[nm] 
Dh 
Int. % 
[nm] 
PDI 
Yield 
[ %] 
 % nm - % 
0.3 (4) 80 480 472 0.22 40 
0.3 (4) 75 475 486 0.18 23 
0.3 (4) 66 484 396, 192 0.36 28 
0.6 (5) 80 551 408 0.35 46 
0.6 (5) 75 476 492, 148 0.51 38 
0.6 (5) 66 552 713, 219 0.43 40 
0.9 (6) 80 454 472, 93 0.33 53 
0.9 (6) 75 507 545, 163 0.33 43 
0.9 (6) 66 470 484, 112 0.38 64 
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Figure 2.20. DLS data of indomethacin nanosuspensions formed by emulsion freeze drying emulsion 
formed with a) 80 % oil phase with different cross-linkages; b) 75 % oil phase with different cross-
linkages; c) 66 % oil phase with different cross-linkages; d) 2 wt % of polymer PEG135-b-(PNIPAm50-
co-EDAm0.6)-b-PEG135 (4) with different oil phase percentages e) 2 wt % of polymer PEG135-b-
(PNIPAm50-co-EDAm1.2)-b-PEG135 (5) with different oil phase percentages; and f) 2 wt % of polymer 
PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) with different oil phase percentages.  
Generally, amorphous drugs exhibit higher solubility and dissolution rate, 
which is favourable for clinical applications.41 The crystallinity of indoemthacin na-
noparticles was therefore examined by PXRD. Figure 2.21 shows the measured data 
of as received indomethacin (Figure 2.21 a), nanoparticles of indomethacin formed 
after emulsion freeze-drying in the presence of 4-6 (Figure 2.21 b, d and f), pure pol-
ymer 6 and centrifugated nanosuspensions to obtain pure nanoparticles with the least 
amount of polymer (Figure 2.21 e). 
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Figure 2.21. PXRD data of a) crystalline indomethacin; b) indomethacin nanoparticles in polymer 
PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) scaffold; c) polymer PEG135-b-(PNIPAm50-co-
EDAm1.8)-b-PEG135 (6); d) indomethacin nanoparticles in polymer PEG135-b-(PNIPAm50-co-
EDAm1.2)-b-PEG135 (5) scaffold; e) Nanoparticles of indomethacin after centrifugation of indometha-
cin nanosuspension and f) indomethacin nanoparticles in polymer PEG135-b-(PNIPAm50-co-EDAm1.8)-
b-PEG135 (6) scaffold.  
Sharp peaks could clearly be seen for crystalline indomethacin (Figure 2.21 
a), while in the PXRDs of nanoparticles stabilised by polymer scaffolds of 4,5, and 6 
(Figure 2.21 b, d and f) only three peaks could be found on top of an amorphous ‘halo’ 
 91 
 
between 15° to 30°. These peaks could not be assigned to indomethacin. For this rea-
son, polymer 6 alone was measured (Figure 2.21 c) and the same signals could be 
detected, which are probably a result of semicrystalinity. Polymers typically form 
amorphous structures, however semicrystalline structures which exhibit amorphous 
and crystalline regions are known for polymers as well. Semicrystallinity accounts for 
the sharp peaks in the PXRD, as well as the broad underlying peak, the so called 
‘halo’, from 15° to 30°. In order to identify the phase of indomethacin particles more 
clearly, the indomethacin nanoparticles were separated from the polymer by centri-
fuging at 13,000 rpm for 5 min. A control experiment with aqueous polymer solution 
at this speed showed no precipitation of the polymer. Figure 2.21 c shows the similar 
PXRD pattern as Figure 2.21 b, d and f (non-centrifuged), but with the peak intensity 
significantly decreased. This led us to the conclusion that these peaks were more likely 
the artefacts of polymer adsorbed to indomethacin particles and precipitated together. 
This indicated that amorphous indomethacin nanoparticles were produced by this ap-
proach. 
Long term storage stability was measured by re-suspending the powders after 
8 months of storage at room temperature and measuring DLS. Figure 2.22 shows these 
results.  
 
Figure 2.22. DLS data of indomethacin nanoparticles after resuspension in water stabilised by PEG135-
b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) from a) 80 % oil phase emulsion after 8 months and directly 
after resuspension and b) 66 % oil phase emulsion after 8 months and directly after resuspension. 
Figure 2.22 clearly shows that sizes of indomethacin nanoparticles formed by 
emulsion freeze-drying stabilised in a polymer scaffold of 4 did not significantly 
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change over 8 months. In case of emulsions form 80 % oil the sizes did not change at 
all. Showing that the polymers used are excellent in stabilising against agglomeration.  
2.3.4.3. Emulsions freeze drying of ketoprofen and ibuprofen 
In order to demonstrate the versatility of the emulsion-freeze drying approach, 
two more drugs, ketoprofen and ibuprofen were processed using the same procedure. 
Since the highest yield for indomethacin was achieved using polymer 6 and 66 % o-
xylene, these conditions were also used for ketoprofen and ibuprofen.  
 
Figure 2.23. Optical microscopic images of the emulsions formed by a) polymer PEG135-b-
(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) with 66 % oil phase and 0.5 wt % ibuprofen; b) polymer 
PEG135-b-(PNIPAm50-co-EDAm1.8)-b-PEG135 (6) with 66 % oil phase and 0.5 wt % ketoprofen and c) 
DLS size data of ketoprofen and ibuprofen nanoparticles after resuspension in water after emulsion 
freeze-drying. 
It was possible to form stable emulsions with droplet sizes between 5 to 25 μm 
(Figure 2.23. a and b) with ketoprofen being slightly smaller and more uniform. After 
freeze-drying, porous white powders were obtained for both ketoprofen and 
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ibuprofen, which were dissolved in water to produce a clear suspension without any 
precipitates observed. This indicates that a 100 % yield of nanoparticles for ketoprofen 
and ibuprofen was achieved by the emulsion-freeze-drying approach. DLS measure-
ments were performed without any pre-treatment of the nanosuspensions. The DLS 
profiles by intensity (Figure 2.23 c) gave the peak size 198 nm for ibuprofen and 211 
nm for ketoprofen. The particle size distribution (PDI) was calculated to be 1.32 for 
ketoprofen and 1.15 for ibuprofen.  
2.4.  Conclusions  
Initially branched diblock copolymers composed of low Mw PEG (2000 kDa) 
arms and hydrophobic cores of PNIPAm, nBMA and styrene were synthesised by 
conventional radical polymerisation in a one-pot synthesis. These monomers were 
chosen because of their different hydrophobicity and solubility in organic solvents. 
Initially emulsions were formed using o-xylene with 0.5 wt % indomethacin and 2 wt 
% aqueous polymer solutions in ratios of 4:1 (80 % oil) and 1:1 (50 % oil), which 
were lyophilised to obtain indomethacin nanoparticles stabilised by a branched poly-
mer scaffold. The obtained dry powders were re-dispersed in medium to form nano-
suspensions and analysed for size and stability in dependence of branched polymer 
used. It was observed that only the use of PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 
(1) produced stable emulsions and nanoparticles. This was attributed to o-xylene be-
ing a bad θ-solvent for PEG45-b-(PBMA50-co-DEGDMA0.7)-b-PEG45 (2), while 
PEG45-b-(PS46-co-DVB0.6)-b-PEG45 (3) was too hydrophobic to be re-dispersed at all. 
Changing the oil phase to cyclohexane and using the same weight percentages, nano-
particles of Oil Red O stabilised by 1 as well as 2 could be obtained. Because of the 
increased amphiphilic character of 2 in comparison to 1 only emulsions of o/w ratios 
of 4:1 (80 %) could produce nanoparticles when 2 was used, while 1 formed more 
stable emulsions with o/w ratios of 1:1 (50 %).  
Because of the high nanoparticle yield and relatively small particle sizes pol-
ymer 1 and cyclohexane were chosen to form triclosan nanoparticles by emulsion 
freeze-drying which could readily be dissolved in water to form nanosuspensions. 
These triclosan nanoparticles showed sizes of below 300 nm. Triclosan nanoparticles 
were then tested for enhanced antimicrobial activity against C. albicans. In compari-
son to as received triclosan it was possible using triclosan nanoparticles formed by 
emulsion freeze-drying to disperse the highly hydrophobic triclosan directly into 
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water without the need for methanol as a co-solvent. The antimicrobial activity of 
aqueous nanosuspensions of triclosan compared to non-processed triclosan was found 
to be 6 times higher.  This would be highly advantageous in a medical setting because  
less active needs to be administered to achieve the same results. This shows not just 
that nanoparticles stabilised in a branched diblock copolymer scaffold formed by 
emulsion freeze-drying are excellent in addressing the problem of water insolubility 
of drugs but are also a promising solution to the problem of emerging resistance in 
many bacterial and fungi strains due to over medication.42-44 Simultaneously the de-
creased dosage would be greatly cost beneficial to our health care systems as well 
reduce the strain wide spread over use of antimicrobial agents have put on our envi-
ronment.45  
Next, the influence of cross-linking on emulsion stability and nanoparticle for-
mation and size was studied. PEG-PNIPAm was chosen as core forming monomer for 
further studies. Three different equivalences of cross-linking were chosen as well as 
a longer PEG chain (Mw 6000 kDa), to facilitate the possibility to stabilise higher oil 
phase ratios and as such achieve higher drug loading. All three branched diblock co-
polymers (0.3, 0.6 and 0.9 eq. cross-linking (4-6)) were tested for their ability to form 
emulsions and nanoparticles with cyclohexane (oil red) and o-xylene (indomethacin) 
in ratios of 4:1 (80 %); 3:1 (75 %) and 2:1 (66 %). It was possible to consistently 
obtain drug nanoparticles with sizes of around 500 nm and smaller as well as narrow 
PDIs. The small PDIs were attributed to be the result of the uniform droplet sizes 
obtained while forming the emulsion i.e. similar droplets contain similar amounts of 
drug available to form nanoparticles, hence narrow PDIs. Furthermore, high particle 
yields using both o-xylene and cyclohexane when using lighter cross-linked branched 
copolymers were achieved, with high cross-linkage only producing stable emulsions 
in specific environments.  
In summary, it was possible to synthesise and optimise a non-toxic, am-
phiphilic branched block copolymer to form stable emulsions that could be used to 
form nanoparticles via an emulsion freeze-drying approach by varying the core mon-
omers used and the cross-linkage. The so obtained dry powders could be readily re-
dispersed into water to form nanosuspensions. Dry formulations were stable against 
agglomeration over months.  
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Considering the enhanced bioavailability, easy preparation, consistent nano-
particles sizes and high yields, as well as the prolonged stability against agglomera-
tion, the emulsion freeze-drying process presents itself as a favourable alternative to 
conventional bottom-up techniques like spray-drying, which is often used in the phar-
maceutical industry. The spray-drying process presents a few major limitations like 
the difficulties in working with thermolabile substances, due to the high risk of de-
composition or change in property, as well as the poor thermal efficiency of the pro-
cess which leads to a low cost-efficiency and the need for addition of stabilisers.46,47 
Emulsion freeze-drying with branched block polymers would be a way to circumvent 
these issues.  
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Chapter 3 
 
Formation of hyperbranched pol-
ymer stabilised drug nanoparticles 
via solvent evaporation 
 
This Chapter is based on the publication 
U. Wais, A. W. Jackson, T. He and H. Zhang, “Formation of hydropho-
bic drug nanoparticles via ambient solvent evaporation facilitated by 
branched diblock copolymers.”, Int. J. Pharm., 2017, 533, 245-253. 
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3.1. Introduction 
Chapter 2 focused on the use of different PEGylated branched diblock copol-
ymers to form nanoparticles and to stabilise them against agglomeration via emul-
sion freeze-drying. In this Chapter, these polymers were used to form nanoparticles 
by a simple solvent evaporation approach.  
Bottom-up methods often employ small molecule surfactants as stabilisers for 
drug nanoparticles, unfortunately, agglomeration is still a significant issue unless the 
solvent is removed quickly.1,2 This key drawback introduces scalability issues with 
most bottom-up processes.  
Thermodynamic crystallisation methods generally utilise mild conditions and 
are energy and cost efficient. Therefore, they may be ideal for industrial production. 
However, crystallisation methods are commonly used to obtain large single crystals, 
and it is desirable to obtain drug nanoparticles which are much smaller and amor-
phous for improved solubility.3 Solvent mediated crystallisation studies with car-
bamazepine and different amino acids showed that the addition of certain surfactants 
(e.g. sodium lauryl sulphate, sodium taurochlorate) could prolong or even inhibit the 
transformation or growth of certain polymorphic forms.4-6 One study demonstrated 
that polymer additives were able to delay nucleation on the basis of hydrogen-bond 
formation with the active ingredient.7 It was also observed that the application of 
polymers could prevent the formation of crystalline materials via arrest of the amor-
phous particles, after either evaporation by spin-coating, spray drying 8, 9 or solvent 
casting, whereby polymeric films with incorporated drugs are produced. However, 
higher amounts of drug loading led to the recrystallisation of hydrophobic drug in 
solution. 10  
Despite these inhibitory characteristics, drug particles produced by solvent 
evaporation are commonly in the micron range.10-13 Consequently, the development 
of thermodynamic crystallisation for drug nanoparticles facilitated by surfactants or 
polymers could be highly beneficial. The main goal in this area is to develop a route 
to nano-sized drug nanoparticles which requires mild conditions and a simple/ cost-
effective process. Herein, we describe the formation of hydrophobic drug nanoparti-
cles via a simple ambient solvent evaporation approach. This process employs the 
more benign organic solvent ethanol and simple open-air evaporation at room tem-
perature. The yields of hydrophobic Ketoprofen drug nanoparticles in the region of 
100 
 
Dh ≈ 200 nm can reach 96 % while the stability of the nanoparticles in solution 
reaches up to 9 months.  
3.2. Experimental 
3.2.1. Materials 
Deionized water was prepared using an AquaMAX-Basic 321 DI water puri-
fication system. Ibuprofen ≥ 98 % (HPLC), indomethacin ≥ 99 % (TLC), Keto-
profen ≥ 98 % (TLC), Oil Red O (OR) dye content ≥ 75 %, anthracene (97 %), mac-
ro-initiator poly(ethylene glycol) dimer (12 kDa), and 1-dodecanethiol (DDT) were 
purchased from Sigma-Aldrich and used as received. Tetrahydrofuran (THF) from 
Aldrich was purified by refluxing with sodium overnight under nitrogen to remove 
water, then distilled prior to use. All other solvents were purchased from Sigma-
Aldrich and used as received.  
3.2.2. Characterisation  
Particle size and Zeta-potential were measured by dynamic laser scattering 
(DLS) analysis on a Malvern Zetasizer Nanoseries at 25 °C from Malvern Instru-
ments. The measurements were performed on aqueous nanoparticles suspensions 
with a concentration of ~ 0.2 mg/mL. Microparticles or aggregates were removed by 
centrifugation with an Eppendorf Centrifuge 5415 D at 3000 rpm for 3 minutes and 
one minute at 3600 rpm to ensure that larger particles precipitate. Cryo-
Transmission Electron Microscopy (Cryo-TEM) was used to investigate the habit of 
the obtained nanoparticles and was carried out using a vitrification robot (FEI Vitro-
bot MARK IV). All samples were prepared at room temperature and 100 % humidi-
ty with blotting time of 2 and blot force of 1. The samples (5 µL) were applied onto 
a grid (Quantifoil, R2/2, Holey carbon film, freshly glow-discharged prior to use at 
20mA for 30 sec. without dilution. Excess sample was blotted away with filter paper 
to leave a thin film on the grid before being vitrified in liquid ethane. Cryo TEM 
measurements were performed on FEI Titan Krios equipped with automated sample 
loader and Field Emission Gun (FEG) operating at 300 kV. Images were recorded 
with Falcon II camera (4X4) with magnification of 29000 and pixel size of 2.873. 
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3.2.3. Nanoparticle formulation by solvent evaporation  
The branched block copolymer PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 
(4-6) and drug were added to a glass vial containing 6 ml of solvent (dichlor-
methane, acetone or ethanol) in mass ratios of 1:1, 2:1 and 3:1. The total polymer + 
drug concentrations were 2 mg/ml. For example, for the ratio of PEG-b-
PNIPAm:drug at 3:1, 9 mg of PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 (4-6) 
and 3 mg of drug were dissolved in 6 ml of the selected solvent under vigorous stir-
ring. Polymer to ketoprofen ratios of 1:1 to 10:1 were tested by dissolving 5 mg 0.6 
cross-linked PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 (4-6) and 5 mg to 0.5 mg 
ketoprofen in 6 ml ethanol. If the materials did not dissolve quickly the mixture was 
gently heated to 55 °C. After an initial screening for the most suitable solvent, the 
solution was either left to evaporate without stirring at room temperature, 50 °C and 
80 °C or was rotary evaporated under reduced pressure at 30 °C and 50 °C. The 
endpoint of evaporation was verified visually, i.e. the sample was deemed finished 
when no solvent could be seen anymore.    
3.2.4. Determination of nanoparticle yield  
Evaporated samples were dispersed into distilled water. Microparticles and 
aggregates were precipitated by centrifugation for 3 minutes at 3000 rpm and a fur-
ther minute at 3600 rpm on an Eppendorf Centrifuge 5415 D. Particle Yield was 
calculated as described below. 
𝒀𝒊𝒆𝒍𝒅 =
𝒎𝑵𝑷
𝒎𝑻
×  𝟏𝟎𝟎 =
𝒎𝑺
𝒎𝑺 + 𝒎𝑷
× 𝟏𝟎𝟎      (𝟑. 𝟏) 
Where mNP is the mass of nanoparticles, mT the total mass of added drug 
compound, mS the mass of particles in the suspension after centrifuging, and mP the 
mass of precipitated particles after centrifuging. Nanoparticle mass was measured 
using UV/Vis. To measure the nanoparticle mass in the nanosuspension, 100 µL 
sample were added to 2900 µL ethanol and measured on a UV 2700 UV/Vis from 
Shimadzu. Precipitant was re-dissolved in 3 mL ethanol. 60 µL of this stock solution 
was then added to 2940 µL ethanol and measured. The raw data was analysed using 
the software UV Probe 2.52.  
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3.2.5. Determination of dissolution rate 
Dissolution rates were tested using a Flow-Through USP IV Dissolution Ap-
paratus by Erweka. 2.0 mg of ketoprofen as received and 8.0 mg ketoprofen: PEG-
b-PNIPAm 0.33: 1 (2.0 mg Ketoprofen + 6.0 mg PEG-b-PNIPAm) were added to 
glass beads and filled into the flow through cells. Membrane filters of 0.2 µm pore 
sizes were inserted before and after the glass beads. A flow rate of 4.15 % was cho-
sen and the temperature was set to 37 °C. The set-up was set to close loop and 200 
mL DI water was continuously passed through the flow cell. The beaker containing 
the medium was kept at 37 °C and stirred at 100 rpm. At specific time intervals 2.4 
ml samples were withdrawn and 0.6 ml ethanol was added to ensure that all the Ke-
toprofen was completely dissolved for analysis. UV/Vis was employed to determine 
concentration. 
3.3. Results and Discussion 
The synthesis of PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 (4-6) with n = 
0.3, 0.6 and 0.9 was described and discussed in Chapter 2 and will therefore not be 
discussed again. After preliminary evaluation of hydrophobic drug (Ketoprofen and 
Oil Red O) encapsulation by solvent evaporation, the branched copolymer with 0.3 
and 0.6 cross-linking ratio showed best results in terms of nanoparticle size and sta-
bility. Presumably, a cross-linking molar ratio of 0.9 eq (6) relative to each PEG 
chain results in more tightly cross-linked branched diblock copolymers which is not 
favourable for good polymer to drug/ dye interactions during solvent evaporation. 
Therefore, polymers 4 and 5 were selected for a more systematic and detailed evalu-
ation. PEG45-b-(PNIPAm60-co-EDAm0.8)-b-PEG45 (1) had also been tested for en-
capsulation, but low nanoparticle yields led to the abandonment of this polymer for 
solvent evaporation.  
3.3.1. Solvent screening 
Dichloromethane (DCM) a non-polar solvent, acetone a polar aprotic solvent 
and ethanol a polar protic solvent were initially tested for formulation of organic 
nanoparticles by solvent evaporation (simply leaving the solutions in open vial in a 
fume cupboard) at ambient temperatures. These solvents were chosen for their varie-
ty in vapour pressure, polarity and for their low toxicity (ICH class 2 or 3).14 Oil Red 
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O (OR), an organic dye, was used as a model hydrophobic compound for the screen-
ing process in a mass ratio of 1:1 with polymers 4 and 5. The use of oil red led to 
easy recognition of successful nanoparticle formation by visual observation and the 
facile determination of nanoparticle yield by UV/Vis.  
Table 3.1. Yield, size and PDI of oil red nanoparticles measured by DLS, prepared from oil red and 
PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) and PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 
(5) (1:1) with different organic solvents. 
Table 3.1 shows the results for the evaporation of oil red and 4 (5) from dif-
ferent solvents at room temperature (around 25 oC). It was observed that the nano-
particle yield for the evaporation from acetone was under 30 % for both polymers. 
Thus, acetone was ruled out for further study due to low nanoparticle yield, although 
small particle sizes of around 200 nm could be achieved for polymer 4. DCM and 
ethanol both gave a good nanoparticle yield of 76 % and 88 % for 4 and 12 % and 1 
% for polymer 5 respectively. Particles obtained from evaporating ethanol were less 
than half the size of particles obtained by evaporating DCM (145 nm vs. 339 nm) in 
the case of 4. For 5 the use of dichloromethane as a solvent lead to smaller sizes 
(220 nm) and higher particle yield. However still not as high, as was achieved using 
4. The slightly higher yield, smaller polydispersity index (PDI) of 0.27 (values 
greater than 0.7 would indicate a very broad particle size distribution and that the 
DLS technique is not suitable) and its lower toxicity led to the selection of ethanol 
as a solvent for further experiments. Although the results for 5 and Oil Red O were 
poor with each solvent it was still decided to continue with both 4 and 5 in ethanol, 
to see if this trend continued with different hydrophobic actives 
Cross-linkage Solvent Z-Average PDI Yield 
  nm - % 
0.3 (4) DCM 339 ± 8 0.41 76 
0.3 (4) Acetone 220 ± 2 0.26 27 
0.3 (4) Ethanol 145 ± 0 0.27 88 
0.6 (5) DCM 220 ± 2 0.26 12 
0.6 (5) Acetone 359 ± 18 0.07 1 
0.6 (5) Ethanol 315 ± 23 0.33 1 
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3.3.2 Organic compounds and poorly water-soluble drugs 
Subsequently the versatility of the solvent evaporation approach was investi-
gated to form nanoparticles of three different hydrophobic actives (including two 
hydrophobic drugs).  
Table 3.2 shows sizes, nanoparticle yield and PDI of 3 different hydrophobic 
compounds, which were evaporated from ethanol to form nanoparticles. Although 
using polymer 5 initially showed low particle yield and higher sizes when Oil Red O 
was evaporated from ethanol (Table 3.1.) the same procedure using ketoprofen (in-
domethacin) showed promising results with a particle size of 209 nm and 30 % drug 
loading (218 nm and 15 %), as well as narrower PDIs compared to 4. The lower 
yield obtained when Oil Red O was used with higher cross-linking (5 compared to 
4) could be a consequence of the larger size and higher hydrophobicity of Oil Red O 
compared to drug molecules like ketoprofen or indomethacin. It was hypothesised 
that good interactions between the hydrophobic active and polymer are required dur-
ing solvent evaporation to allow diffusion into the branched core and increased 
Table 3.2. Size, yield, Zeta potential and PDI of oil red and poorly water-soluble drugs evaporated 
in the presence of PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) and PEG135-b-(PNIPAm50-co-
EDAm1.2)-b-PEG135 (5) from ethanol.  
cross-
linking [eq] 
drug/ dye 
drug/ dye: polymer 
mass ratio 
Dh  
Z-Average 
PDI Yield 
   nm - % 
0.3 Oil Red O 1: 1 146 ± 0 0.26 75 
0.3 Indomethacin 1: 1 374 ± 2 0.38 35 
0.3 Ketoprofen 1: 1 203 ± 5 0.32 80 
0.3 Ketoprofen 0.33: 1 208 ± 5 0.22 96 
0.6 Oil Red O 1: 1 315 ± 23 0.33 1 
0.6 Indomethacin 1: 1 218 ± 1 0.24 15 
0.6 Ketoprofen 1: 1 209 ± 2 0.25 30 
0.6 Ketoprofen 0.33: 1 209 ± 2 0.23 88 
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cross-linking density could hinder these interactions when larger and more hydro-
phobic actives are employed. The same effect could be observed using anthracene (a 
highly hydrophobic fluorescent dye) and ritonavir (an antiretroviral drug) with pol-
ymer 4. Although the space in the core should be larger, due to lower cross-linking, 
no quality DLS data could be obtained. This was attributed to the increased hydro-
phobicity of ritonavir and anthracene as well as the higher spatial demand in the case 
of ritonavir. However, for a mass ratio of 1:1 of drug to polymer, nanoparticle under 
400 nm could be formed for both polymers for all the drugs used. The relevant DLS 
profiles are shown in Figure 3.1., which also shows the afore mentioned comparison 
of cross-linkage and nanoparticle size using Oil Red O as well as indomethacin as 
model compounds (Figure 3.1.c and d).  
Figure 3.1. DLS profiles of different drugs and drug to polymer ratios evaporated from ethanol solu-
tions at room temperature in the presence of a) PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4); b) 
PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 (5); c) Oil Red O with varied cross-linkage and d) 
Indomethacin with varied cross-linkages.  
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Figure 3.1. a and b show DLS data for all actives evaporated from ethanol in 
the presence of 4 and 5 respectively. It could be observed that in the case of lower 
cross-linking the obtained nanoparticle size varied from compound to compound e.g. 
oil red 146 nm and indomethacin 374 nm. Higher cross-linkage, although showing 
slightly lower drug encapsulation, gave almost the same nanoparticle sizes for all 
tested compounds and showed a general lower PDI (Table 3.2).  
Interestingly the obtained ketoprofen nanoparticles with sizes of about 200 
nm did not vary significantly independently of cross-linkage of the polymer or drug 
to polymer ratios. However, the PDIs and nanoparticle yields did. PDI seemed to 
increase with increasing drug content, more so for lower cross-linkage e.g. 0.22 to 
0.32 for 4 compared to 0.23 to 0.25 for 5. The percentage of drug in suspension in-
creased with decreasing drug content, as expected. In the case of 5 a decrease of 58 
% nanoparticle yield could be observed when the drug to polymer ratio was changed 
from 0.33:1 to 1:1, while at the same decrease in the presence of 4 only lead to a 
decrease of 16 %. This was because the initial nanoparticle yield was already quiet 
high at 80 % for a drug to polymer ratio of 1:1. As polymer 5 showed a greater de-
pendence on the drug: polymer ratio this system was chosen for a more detailed in-
vestigation into the influence of drug to polymer ratio on nanoparticle size and yield 
of suspended drug. 
 
Figure 3.2. Nanosuspensions of Oil Red O and ketoprofen in the presence of a) PEG135-b-
(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) (0.3 cross-linking); b) PEG135-b-(PNIPAm50-co-EDAm1.2)-b-
PEG135 (5) (0.6 cross-linking) and c) control experiments using ketoprofen.  
Photographs of the obtained nano-suspensions of ketoprofen and Oil Red O 
using polymer 4 and 5 displayed in Figure 3.2. a and b. Control experiments using 
ketoprofen without any polymeric material present are shown in Figure 3.2.c. Two 
control experiments were performed to confirm the necessity of branched diblock 
copolymer during solvent evaporation. To start with, ketoprofen was directly added 
to water, the mixture stirred and left overnight, this resulted in a fine powder at the 
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water/ air interface. Secondly, ketoprofen was dissolved in ethanol, the solvent 
evaporated then water added, this afforded insoluble large crystals of ketoprofen at 
the water/ air interface. 
3.3.3 Influence of drug to polymer ratio on particle size and nanoparticle yield  
To determine the optimum drug to polymer ratio with respect to highest na-
noparticle yield and influence on nanoparticle size polymer 5 and ketoprofen were 
evaporated from ethanol with varying drug to polymer ratios ranging from 0.2: 1 to 
1: 1 (drug: polymer). For each experiment, the ethanol volume was kept constant to 
ensure the same evaporation rate. The premise was that this investigation might also 
elucidate the mechanism of drug nanoparticle formation. Table 3.3. shows the yield 
of suspended drug in water and resulting drug nanoparticle size and PDI. Figure 
3.3.a displays the relationship between the yield of suspended ketoprofen with vary-
ing drug: polymer ratios from 0.2: 1 (17 wt % ketoprofen) to 1: 1 (50 wt % keto-
profen) and Figure 3.3. b displays the relationship between the drug nanoparticle 
sizes after suspension in water with varying drug: polymer ratios.  
Table 3.3. Yield of suspended drug, hydrodynamic diameter (Dh) and PDI of drug nanoparticles 
prepared by evaporated from ethanol in the presence of polymer PEG135-b-(PNIPAm50-co-EDAm1.2)-
b-PEG135 (5) branched diblock copolymer and subsequent re-dispersion in water with varying mass 
of ketoprofen. 
Ketoprofen: poly-
mer mass ratio 
ketoprofen 
Z-Average  
Dh  
PDI Nanoparticle yield 
 wt% nm - % 
0.2: 1 17 211 ± 10 0.22 92 ±3 
0.3: 1 23 210 ± 9 0.25 92 ±3 
0.4: 1 29 222 ± 14 0.27 89 ±6 
0.5: 1 33 205 ± 23 0.26 81 ±13 
0.6: 1 28 277 ± 22 0.38 81 ±15 
0.7: 1 41 259 ± 7 0.21 81 ±10 
0.8: 1 44 263 ± 38 0.23 80 ±13 
0.9: 1 47 239 ± 32 0.22 78 ±7 
1: 1 50 273 ± 15 0.26 55 ±10 
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Figure 3.3. Plotted DLS data of a. initial total wt % of ketoprofen (relative to polymer) v yield of 
suspended drug in solution and b. initial total wt % of ketoprofen (relative to polymer) v drug nano-
particle size. 
The yield of ketoprofen suspended clearly shows a dependence on the initial 
ratio of drug: polymer, and a point at which this ratio is optimal. Between 17 – 29 wt 
% of ketoprofen the yield of suspended drug is very high (92 – 89 %), when the wt 
% of ketoprofen reaches 33-48 wt % a slight decrease in drug yield to 80 % could be 
observed. The yield dropped significantly when the the wt % reaches ≥50. An ap-
proximate trend has been noticed that the yield deviations increase roughly with the 
increase of ketoprofen percentage. A similar trend was also observed for the size of 
the drug nanoparticles. This result would suggest that there is a minimum “cut-off” 
of polymer 5 required to successfully stabilise the ketoprofen drug nanoparticles 
during solvent evaporation and to disperse the resulting nanoparticles in water. It 
would appear that 70 – 85 wt % of branched diblock copolymer is required to facili-
tate the formation and dispersion of ketoprofen nanoparticles when the cross-linking 
density is 0.6 eq. Figure 3.3. b shows very consistent drug nanoparticle sizes (Dh = 
200 – 220 nm) when the wt % of ketoprofen is 17 – 33 wt % (the range in which 
there is enough polymer to facilitate the process). However, when the initial wt % of 
ketoprofen increases significant variation in the size of drug nanoparticles (Dh = 200 
– 300 nm) could be seen which could suggest that when the initial amount of poly-
mer is lower (relative to the hydrophobic drug) the stabilization process is much 
more random and uncontrolled. 
3.3.4 Cryo-TEM and PXRD characterisation of ketoprofen nanoparticles 
Cryo-TEM analysis (Figure 3.4.) of ketoprofen drug nanoparticles prepared 
with polymer 4 with a drug: polymer ratio of 0.33: 1 was performed. This sample 
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was selected for Cryo-TEM analysis due to high yields of suspended drug after 
aqueous dispersion. Spherical particles of between 200-350 nm were observed. 
These sizes corresponded well to previous data obtained by DLS.  
 
Figure 3.4. Cryo-TEM images of ketoprofen drug nanoparticles facilitated by the evaporation of 
ethanol in the presence of PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) at a drug: polymer ratio 
of 0.33: 1. 
Amorphous drug particle show better dissolution behaviour then their crys-
talline counterpart 27. As such PXRD data was measured of the obtained nanoparti-
cles to determine if the obtained nanoparticles are amorphous or crystalline. Figure 
3.5. shows the obtained data.  
   
Figure 3.5. PXRD data of a) Ketoprofen nanoparticles stabilised by PEG135-b-(PNIPAm50-co-
EDAm0.6)-b-PEG135 (4) (ratio 0.33:1); b) Ketoprofen nanoparticles stabilised by PEG135-b-
(PNIPAm50-co-EDAm1.2)-b-PEG135 (5) (ratio 1:1); c) Ketoprofen evaporated without polymer pre-
sent, d) Ketoprofen nanoparticles stabilised by PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 (5) 
(ratio 0.2:1), e) Ketoprofen nanoparticles stabilised by PEG135-b-(PNIPAm50-co-EDAm1.2)-b-PEG135 
(5) (ratio 0.9:1) and f) pure polymer.  
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After ethanol evaporation the solid material obtained showed amorphous 
character independent of polymer employed. This amorphous character was evident 
with drug: polymer ratios of 1: 1 (Figure 3.5. b) and 0.33: 1 (Figure 3.5. a) by the 
lack of diffraction peaks on the PXRD patterns. When the evaporation is performed 
without any polymer present the solid Ketoprofen obtained display crystalline char-
acter (Figure 3.5.c). The lack of diffraction patterns by PXRD measurement usually 
results from the low percentage of crystalline materials in a matrix or the low crys-
tallinity of the materials. Due to the high content of ketoprofen in the measured 
samples, it can be reasonable concluded that ketoprofen nanoparticles showed an 
amorphous character. Polarised light microscope (PLM) may be additionally used to 
qualitatively identify the crystalline phase-based birefringence, by dispersing the 
samples in paraffin oil and subsequent imaging.15,16 However, as PLM is mainly 
effective for micron particles,17 it may be difficult to obtain convincing images. This 
data confirms that the application of branched diblock copolymers during solvent 
evaporation prevents the undesirable formation of crystalline ketoprofen.  
From the obtained dynamic light scattering, Cryo-TEM and powder x-ray 
diffraction data the following mechanism (Scheme 3.1.) is proposed for the for-
mation of drug nanoparticles. Initially, PEG-b-PNIPAm is fully solvated in ethanol 
and the drug compounds is dissolved at the molecular level. As the ethanol slowly 
evaporates the drug molecules diffuse into the branched diblock copolymer cores 
due to increasing drug concentration in solution, which prevents significant drug 
crystallisation. After ethanol evaporation the drug molecules are intimately distrib-
uted among the polymeric material, presumably small amounts of drug crystals or 
agglomerates will be present (during this stage cross-linking density plays a key role 
on the possible diffusion of drug molecules into branched diblock copolymers). Af-
ter dispersion in water the solid material is broken up and spherical amorphous drug 
nanoparticles are formed. 
Scheme 3.1. Formation of drug nanoparticles facilitated by branched diblock copolymers via solvent 
evaporation. 
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3.3.5. Dissolution rates of ketoprofen nanoparticles 
According to the Noyes-Whitney equation a decrease in size and subsequent 
increase in surface area is the reason why drug nanoparticles show an increase in 
dissolution rate compared to non-processed drugs.18 Dissolution rates were meas-
ured for ketoprofen (control experiment) and drug nanoparticles of ketoprofen: 4 
(0.33: 1). The measurements were done using a USP IV flow through apparatus, to 
assure that the nanoparticles were not able to leave the sample cell and only dis-
solved ketoprofen was measured. As small amounts of ketoprofen were measured to 
remain under sink conditions a closed loop set-up was chosen to minimise the meas-
urement errors. Figure 3.7. shows the dissolution rates measured in the first 60 mins 
(crucial time scale in drug solubilisation).  
 
Figure 3.6. Dissolution rate of ketoprofen and ketoprofen: PEG135-b-(PNIPAm50-co-EDAm0.6)-b-
PEG135 (4) (0.33: 1) nanoparticles in H2O.  
The percentage of ketoprofen that could be dissolved unfortunately did not 
reach a 100 % within this time limit. This was attributed to a significant amount of 
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the material (ketoprofen (control) as well as ketoprofen drug nanoparticles) being 
‘stuck’ to the cell wall as well as to the glass beads. The glass beads were needed to 
ensure laminar flow and keep turbulences to a minimum. Furthermore, it has been 
shown for the USP IV that at a low velocity the experimental dissolution is inhibit-
ed,19 however low velocity flow rates more closely resemble the situation that may 
be encountered in the intestines where inhomogeneous fluid ‘pockets’ of almost stat-
ic flow rates can be found.20 The commonly available devices measuring dissolution 
are usually for larger amounts of sample and larger sample sizes i.e. micron-range. 
Characterisation of dissolution rate of drug nanoparticles has been a significant chal-
lenge.21 For example, our own efforts by using the light scattering approach21 did not 
produce meaningful data. Although not completely convincing (because of the low 
percentage dissolved) the data obtained (Figure 3.6.) shows that ketoprofen drug 
nanoparticles of ketoprofen: 4 show a significant increase in dissolution compared to 
non-processed ketoprofen (control). The ketoprofen present in the drug nanoparti-
cles was dissolved at a level of 22 % after 15 mins while at the same time only 8 % 
of ketoprofen could be dissolved from the control experiment. 
3.3.6. Influence of temperature and pressure during evaporation 
Table 3.4. The size and PDI of ketoprofen nanoparticles prepared by ketoprofen and polymer 
PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) (0.33:1) evaporated from ethanol at different tem-
peratures by open air evaporation and rotary evaporation. The data listed are for the as-prepared 
sample (t = 0 months) and stored in desiccator for 3 months. All the samples were freshly dissolved 
in water prior to DLS analysis. (r.t. means room temperature at 20 °C).  
  t = 0 months t = 3 months 
sample Method T 
Z-Average 
Dh 
PDI 
Z-Average 
Dh 
PDI 
  °C nm - nm - 
1 Evaporation r.t. 208 ± 5 0.22  210 ± 4 0.22 
2 Evaporation 50 193 ± 2 0.21  303 ± 10 0.37 
3 Evaporation 80 213 ± 2 0.12 249 ± 3 0.21 
4 Rotary evaporated 30 288 ± 4 0.27 219 ± 1 0.19  
5 Rotary evaporated 50 204 ± 2 0.08 280 ± 4 0.35  
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The influence of variations in evaporation conditions on the resulting keto-
profen nanoparticles in the presence of 4 formed with a drug: polymer ratio of 0.33: 
1 was further investigated. This branched diblock copolymer and drug: polymer ra-
tio was selected due to its high yield of suspended drug after dispersion in water. 
The influence of evaporation temperatures (room temperature, 50 °C and 80 °C) and 
pressure (air evaporation and rotary evaporation at 30 °C or 50 °C) were studied. All 
of the obtained solid samples after solvent evaporation could be suspended com-
pletely in water to produce stable drug nanoparticle suspensions without any precipi-
tates. A total of five samples (1 – 5) were prepared under various conditions, each 
sample was dispersed in water directly after solvent evaporation (time = 0 months). 
The dynamic light scattering profiles are displayed in Figure 3.7. a. To investigate 
stability during storage each sample was stored as a dry solid for three months be-
fore dispersion in water (time = 3 months), the dynamic light scattering data ob-
tained is summarized in Table 3.4. Samples 1 – 3 displayed drug nanoparticles with 
similar sizes (Dh ≈ 200 nm) after immediate dispersion (time = 0 months). This sug-
gests that atmospheric evaporation is not significantly affected by temperature. After 
3 months storage in solid form Samples 2 (50° C) and 3 (80° C) showed a minor 
increase in nanoparticle size and PDI after dispersion in water. Sample 1 (room tem-
perature) showed a very consistent size and PDI after dispersion in water after 3 
months of storage in solid form. These results clearly indicate that increasing the 
temperature during atmospheric evaporation does not impede nor improve the evap-
oration process. Samples 4 and 5 also displayed very promising nanoparticle sizes 
and PDIs. After dry storage for 3 months the drug nanoparticles readily dispersed in 
water without any significant increase in size. These results suggest that the obtained 
drug nanoparticles are suitably stabilised against aggregation by PEG-b-PNIPAm 
branched diblock copolymers. To further investigate the long-term storage potential, 
in solution, Sample 1 Ketoprofen nanoparticles dispersed in water after 0 days were 
left in water at room temperature and analysed by dynamic light scattering after 3 
months (Dh = 204 ± 4 nm, PDI = 0.20) and 9 months (Dh = 225 ± 1 nm, PDI = 0.35) 
(Figure 3.7.b). No aggregation could be observed after 9 months, demonstrating the 
long-term stability of drug nanoparticles not only in solid state but also in aqueous 
suspension.  
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Figure 3.7. DLS profiles of ketoprofen nanoparticles in water prepared by evaporation of ketoprofen: 
polymer PEG135-b-(PNIPAm50-co-EDAm0.6)-b-PEG135 (4) 0.33:1 from ethanol. a) evaporated at dif-
ferent temperatures and pressures and b) Evaporated from room temperature (sample 1) and stored in 
solution or dry for 3 and 9 months.  
 
3.4. Conclusion 
In Chapter 2 it was observed that branched diblock copolymers of PEG-b-
PNIPAm with longer PEG arms (Mw 6000 kDa) and lower cross-linkage (0.3 and 
0.6 eq.) could stabilise nanoparticles slightly better than PEG-b-PNIPAm with 
shorter PEG (Mw 2000 kDa) and higher cross-linkage. Due to this they were subse-
quently used in this Chapter to form drug nanoparticles via a simple solvent evapo-
ration technique. Initially different solvents were screened for their ability to facili-
tate the formation of drug/polymer nanoparticles. Favourable nanoparticles sizes and 
low PDI were obtained by evaporating ethanol. Due to the low toxicity and the non-
hazardous pharmaceutical classification, ethanol was chosen for all further experi-
ments. Hydrophobic actives (IMC, OR and ketoprofen) were screened to investigate 
the broadness of application of this approach. The screening process showed that all 
actives screened could be nanosized to particles of ~ 200 nm and higher yields could 
be achieved when less cross-linked branched polymers were used. This effect tended 
to be even more pronounced when the steric demand of the active increased e.g. Oil 
Red O. The best results were achieved using ketoprofen and ethanol (small particle 
sizes and high yields) regardless of branched block copolymers. However, decreas-
ing the polymer to drug ratio and increasing the cross-linking, led to dramatically 
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reduced nanoparticles yields. To study the optimal loading ratio, i.e. least amount of 
polymer needed, ketoprofen and polymer 4 (0.6 cross-linked PEG-PNIPAm) were 
added in mass ratios of 0.1:1 to 1:1 to a constant amount of ethanol (to assure the 
same evaporation rate). DLS data obtained indicated no significant size changes 
across all ratios tested. UV/Vis data showed the optimal drug:polymer ratio (highest 
yield) to be 0.3:1. DLS, UV/Vis, Cryo-TEM and PXRD data was used to discern 
shape, sizes and the amorphous character of the drug nanoparticles. A mechanism 
for the formation of drug/polymer complexes could be proposed based on the meas-
ured data. Branched polymers are thought to arrest the crystal growth by ‘anchoring’ 
their hydrophobic core onto a growing crystal phase. The so formed film forms 
spherical particles spontaneously to stabilise the particles when water is added. Size 
and shape in the herein described evaporation technique is very much depended on 
evaporation rate of the solvent. Hence, we investigated the influence of changing the 
kinetics by temperature and pressure i.e. faster evaporation due to higher tempera-
tures and lower pressure. No notable changes in size or size distribution was ob-
served. Enhanced dissolution could be found for ketoprofen nanoparticles compared 
to non-processed ketoprofen.  
In summary, it was possible to form nanoparticles of hydrophobic actives in 
high yields of up to 96 % with particles sizes around 200 nm by using branched 
block copolymers of PEG135-b-(PNIPAm50-co-EDAm2n)-b-PEG135 (n = 0.3 and 0.6) 
and a simple solvent evaporation technique. Due to the use of ethanol this technique 
uses only non-toxic materials and solvents and is highly cost efficient as well as en-
ergy efficient. The process could further be accelerated by increasing the tempera-
ture and reducing the pressure without significant changes to the particle sizes, PDIs 
or yields of the produced nanoparticles. The obtained dry films as well as re-
dispersed nanosuspensions showed good storage stability over 3 months (dry) and 
up to 9 months (sol.) with no discernible size change. As such the herein presented 
method would be a cost-efficient and environmentally friendly alternative to con-
ventional techniques used in the production of nanodrugs, such as media milling or 
spray drying.  
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Chapter 4 
 
Solubilisation of hydrophobic 
drugs facilitated by thermorespon-
sive hyperbranched polymers 
 
This Chapter is based on the publication 
J.-H. Liu, U. Wais, Y.-M. Zuo, Y. Xiang, Y.-H. Wang, A. W. Jackson, 
T. He and H. Zhang, “Unimolecular branched block copolymer nanopar-
ticles in methanol for the preparation of poorly water-soluble drug nano-
particles” J. Mater. Chem. B, 2017, 5, 423-427. 
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4.1. Introduction 
Chapter 2 focused on the use of branched polymers to form a stabilising scaf-
fold against agglomeration around drug nanoparticles, obtained via emulsions freeze-
drying. Chapter 3 focused on using the same branched polymers to obtain drug nano-
particles by a simple solvent evaporation method. All polymers used were synthesised 
by conventional radical polymerisation and from linear PEG and were solids. Both 
techniques provided dry material, which could be re-dispersed in water to form nano-
suspensions.  
In this Chapter, branched polymers with non-linear PEG arms were synthe-
sised to directly form nanosuspensions of hydrophobic actives without obtaining dried 
nanoparticles first. Considering that most biomedical and environmental application 
require aqueous formulations of water insoluble active, nanosuspensions could be a 
suitable solution and obtaining nanosuspensions directly with high yields would be 
beneficiary. The branched polymer poly(oligo(ethylene glycol) methyl ether methacry-
late)-b-poly((butyl methacrylate)-co-(ethylene glycol dimethylacrylate)) (p(OEGMA-b-
p(nBMA-co-EGDMA)) was synthesised in two different OEGMA:nBMA ratios of 36:60 
(DP 36/60) and 36:40 (DP 36/40) with equal ratio of cross-linkage (0.9). The polymerisa-
tion technique was changed to ATRP, a living polymerisation technique, from conven-
tional radical polymerisation and hence branched PEG, i.e. OEGMA, was used to obtain 
hydrophilic arms. By changing the polymerisation technique, it was assured that random 
chain growth is inhibited and as such a better control over the resulting architecture could 
be achieved.1  
BMA was chosen as the core forming monomer due to its temperature sensitive 
behaviour. BMA exhibits upper critical solution temperature (UCST) behaviour in meth-
anol. Although the UCST is not as well studied as the better-known phenomena of lower 
critical solution temperature (LCST) examples, especially in organic solvents or water/sol-
vents mixtures, are known.2-5 Quite a few of these examples are, unfortunately, often toxic. 
However, some non-hazardous examples have been shown which would be favourable for 
pharmacologic applications. An especially interesting focus lays hereby on polymers ex-
hibiting UCST in water miscible solvents like methanol.5  
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Figure 4.1. p(BMA) at different temperatures in MeOH; at 25 °C before heating (right); heated to 55 
°C (middle) and cooled down to 25 °C again (left).  
Polymers showing UCST behaviour become soluble above a specific temperature, 
in comparison to LCST where a polymer becomes insoluble above a specific temperature.6 
Although OEGMA itself also shows a UCST in methanol, it is at -10 °C and as such out-
side of the temperature range interesting for this study.7 Figure 4.1. shows the temperature 
dependent transition of pBMA from insoluble to soluble back to insoluble. At 25 °C the 
linear PBMA strands are insoluble and stabilise by agglomeration. Heating to 55 °C leads 
to the linear PBMA strands becoming soluble and unimolecular polymer strands can be 
found in solution. PBMA turns insoluble again by cooling back down to 25 °C and ag-
glomeration of the linear polymers can be observed.  
1H-NMR measurements of linear pBMA blocks in deuterated methanol at 25 
°C and 60 °C show the reversible precipitation and solvation of the polymer (Figure 
4.2. A). At 25 °C (Figure 4.2. A; spectrum ii and iii) no BMA signals can be detected. 
Heating to 60 °C (Figure 4.2. A; spectrum i) led to the solubilisation of linear block 
pBMA and NMR signals can be recorded. The shift of the H2O signal at 25 °C is a 
direct consequence of polymer/water interactions due to solubilisation. The inlaid pic-
ture (Figure 4.2.B) shows that at 60 °C a clear methanolic polymer solution (i) can be 
obtained (linear block pBMA unimolecular dissolved), while at 25 °C pBMA precip-
itates out of solution as a white solid (ii and iii).8 
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Figure 4.2. Studies of p(nBuMA) solubility in MeOH-d4. (A) 1H NMR spectra of (i) p(nBMA) heated 
to 60 °C, (ii) p(nBMA) after heating and cooling to 25 °C, (iii) p(nBMA) at 25 °C before heating; (B) 
photographs of p(nBMA) within the NMR tube at different temperatures – (i) 60 °C, (ii) after cooling 
to 25 °C, and (iii) at 25 °C prior to heating. Adapted with permission from Ref. 8 © 2014 Royal Society 
of Chemistry 
In a branched copolymer like p(OEGMA-b-p(nBMA-co-EGDMA), OEGMA 
forms a hydrophilic shell at ambient temperature around the hydrophobic core of pBMA. 
When the solution is heated above the UCST the core becomes soluble. Micelles formed 
from such a diblock polymer would fall apart in this case. 9,10 However, branching leads to 
the retention of the core-shell structure. Heating and cooling through the UCST subse-
quently results in structural changes, i.e. collapse or shrinkage of one component, and size 
change due to agglomeration.11 This behaviour could be used to form unimolecular poly-
mer nanoparticle solutions in water by directly evaporating from the methanolic solution 
instead of the standard two-step, time consuming procedure of dialysing against water.12,13 
122 
 
In this Chapter, a thermoresponsive branched diblock copolymers of p(OEGMA)-
b-(pBMA-co-pEGDMA) was synthesised by ATRP in two different ratios of hydrophilic 
to hydrophobic block. The thermoresponsive behaviour in methanol was used to incorpo-
rate hydrophobic actives i.e. ketoprofen and Oil Red (OR) and form drug nanoparticles in 
suspension.   
4.2. Experimental 
4.2.1. Chemicals and reagents  
Deionized water was prepared using an AquaMAX-Basic 321 DI water puri-
fication system. Anthracene reagent grade, 97 %, ketoprofen ≥ 98 % (TLC) and Oil 
Red O (OR) dye content ≥ 75 % were purchased from Sigma-Aldrich and used as 
received. All other solvents were purchased from Sigma-Aldrich and used as received.  
4.2.2. Characterization 
The 1H NMR spectra were recorded using a Brucker Avance III HD spectrom-
eter at 500.13 MHz. Samples were analysed at 25 °C and 60 °C in MeOD. Particle 
sizes were measured by dynamic laser scattering (DLS) analysis on a Malvern 
Zetasizer Nanoseries at 25 °C from Malvern Instruments. Aqueous polymer solutions 
were obtained by dissolving branched diblock copolymers with a concentration of ~ 
0.5 mg/ml in acetone under constant stirring. Water was added, and acetone was evap-
orated off in the fume cupboard. The obtained solution was directly used to measure 
DLS data. The measurements of aqueous drug nanosuspensions were performed with 
a concentration of ~ 0.2 mg/ml. Microparticles or aggregates were removed by cen-
trifugation with an Eppendorf Centrifuge 5415 D at 3000 rpm for 3 minutes and one 
minute at 3600 rpm to ensure that larger particles precipitate.  
4.2.3. Synthesis of branched diblock copolymer p(OEGMA)-b-p(nBMA-co-EGDMA) 
(DP 36/40 and DP 36/60) by ATRP 
Typically, synthesis of p(OEGMA)36-b-p(nBMA37-co-EGDMA0.9) could be 
described as follows: into a Schlenk flask (50 ml) OEGMA (2.04 g, 6.8 mmol, 40 eq.), 
CuBr (24.5 mg, 0.17 mmol, 1 eq.), 2,2-bipyridine (bpy) (53.1 mg, 0.34 mmol, 2 eq.) 
and anisole (0.3 ml, for internal 1H-NMR standard) were added to an isopropanol/wa-
ter mixture (92.5:7.5 v/v, 4.2 ml) and degassed for an hour and a sample was taken 
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for NMR analyses, after which ethyl α-bromoisobutyrate (EBriB) (33.2 mg, 0.17 
mmol, 1 eq.) were added using a microsyringe, and stirred under N2 atmosphere at 
ambient temperature. In a second 50 ml Schlenk flask, CuCl (16.9 mg, 0.17 mmol, 1 
eq.), bpy (53.1 mg, 0.34 mmol, 2 eq.), nBMA (0.965 g, 6.8 mmol, 40 eq.) and 
EGDMA (29.2 mg, 0.15 mmol, 0.9 eq.) were added to 5.8 ml of the same isopropa-
nol/water mixture and degassed for an hour. After the conversion of OEGMA had 
reached 96 %, the mixture was added into the first flask rapidly using a syringe and 
taking care not to admit any air. A sample was taken immediately for NMR analysis. 
The reaction was carried out at ambient temperature under N2. After the conversion 
had reached 94 % the reaction was stopped by adding THF to the mixture and expos-
ing it to air. The mixture was passed through an Al2O3 column to remove the copper 
species. The branched diblock copolymer was obtained after precipitation three times 
into hexane and dried under vacuum. 
4.2.4. Nanoparticle formulation by solvent evaporation  
40 mg of POEGMA-b-nBMA (DP 36/60 and DP 36/40) and 40 mg drug (ke-
toprofen, anthracene and OR) were stirred in 5 ml methanol for 20 min at room tem-
perature (20 °C). The samples were then heated to 56 ̊C and stirred at 5000 rpm for 
further 20 min. After cooling to room temperature, 5 ml deionized water was added. 
It was noticed that the solution with POEGMA-b-nBMA (DP 36/40) turned opaque 
while the solution with POEGMA-b-nBMA (DP 36/60) was still clear. Another pro-
cedure was to directly process the methanol solution at room temperature. Methanol 
was evaporated off at room temperature in the fume cupboard. The endpoint of the 
evaporation was determined by visual examination. After evaporation of methanol, 
the samples with added water produced aqueous suspensions, which were analysed 
directly. The dry samples formed from methanol solution after evaporation were dis-
solved in 5 ml water to form suspensions for measurement. 
4.2.5. Determination of Nanoparticle yield  
After solvent evaporation the solid samples obtained were dispersed into wa-
ter. Microparticles and aggregates were removed by centrifugation. The yield of sus-
pended drug/dye in water was calculated as described below: 
𝐘𝐢𝐞𝐥𝐝 =
𝐦𝐍𝐏
𝐦𝐓
×  𝟏𝟎𝟎 =
𝐦𝐒
𝐦𝐒 + 𝐦𝐏
× 𝟏𝟎𝟎      (𝟒. 𝟏. ) 
124 
 
 
Where mNP is the mass of drug/ dye suspended in water and mT is the total 
initial mass of drug/ dye. mS is the mass of drug/ dye in the suspension after centrifu-
gation and mP is the mass of precipitated drug/ dye after centrifugation. The centrifu-
gation precipitant was re-dissolved in 3 mL ethanol and measured by UV/Vis. All 
samples were analysed in 1 to 1 (v/v) solutions of water/ethanol. Quantities of drug/ 
dye were determined against calibration curves of known concentrations in etha-
nol/water 1:1. 
4.3.  Results and discussion  
4.3.1 Synthesis of temperature sensitive branched diblock copolymers  
An amphiphilic A-B branched block copolymer was synthesised at ambient 
temperatures by a one-pot Cu(I)Br/2,2-bypiridine (bpy) catalysed, ATRP polymerisa-
tion in an isopropanol (IPA)/H2O mixture using ethyl α-bromoisobutyrate (EBriB) 
initiator. Although pBMA is considered to be highly hydrophobic, the polar isopro-
panol is a good theta solvent for the polymer.14 However, while isopropanol is a good 
solvent for BMA and p(BMA) and leads to the polymers acting like an ideal chain, 
p(OEGMA) is insoluble at room temperature in isopropanol, because of its UCST. 
The UCST for p(OEGMA) monopolymer chains of around the same molecular weight 
as were synthesised in the first step has been shown to be around 22 °C. However, at 
higher concentrations of the polymer the UCST increased dramatically. Adding water 
as a co-solvent led to dramatic decreases of the UCST in isopropanol, i.e. without 
water a UCST of 35.6 °C was measured for a linear monopolymer of 23000 g/mol, 
while in the presence of 4 vol % water the UCST decreased to -10 °C. This was at-
tributed to the strong hydrogen bonding of water with p(OEGMA). Hence, the use of 
a isopropanol /water mixture was not just used to solubilise inorganic salts but also to 
ensure that p(OEGMA) was soluble at mild conditions and readily available for the 
second step of the polymerisation. The addition of hydrophobic polymers to the 
p(OEGMA) chain was found to be another factor that decreased the UCST. However, 
this was tested for the case of linear polymers and not branched polymers, where the 
hydrophobic cores might be more protected and as such have less influence.15  
In the first step OEGMA (MW = 300 g/mol) was polymerised to afford a linear 
block of p(OEGMA). A relatively low degree of polymerisation (DP) of 40 was aimed 
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for. The reaction was monitored by 1H-NMR. To that end an internal standard of ani-
sole was added before the reaction was started and an NMR spectrum was recorded. 
Figure 4.3. and Figure 4.4. show the 1H-NMR spectra measured for DP 36/40 through-
out the reaction. 
 
Figure 4.3. 1H-NMR of the first-step of the one-pot synthesis of DP 36/40 
Vinyl signals at 6.08 ppm (s, 1H, -C=CHH) and 5.31 ppm (s, 1H, -C=CHH) 
were integrated to 100 (%) the anisole signal at 6.86 ppm (s, 3H, -C-OCH3) was inte-
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grated subsequently and the obtained value was then used to check the reaction con-
version. After 5 hours only 4 % of unreacted monomer remained (Figure 4.3.) and a 
mixture of nBMA and EGDMA was added. This allowed for the propagation of the 
hydrophobic block p(BMA) while simultaneously branching to other growing chains 
is occurring. The reaction conversion was followed as had been done in the first step. 
The reaction was stopped when 93 % conversion was reached (Figure 4.4.). The pol-
ymer was purified by precipitation into hexane. 
 
Figure 4.4. 1H-NMR of the first-step of the one-pot synthesis of DP 36/40 
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Figure 4.5. shows the 1H-NMR in CDCl3 of DP 36/40 after purification as an 
example. Integration of the CH3 signal of OEGMA at 3.39 ppm (s, 3H, -CH2)3-4-O-
CH3) to 108 (3H x 36 repeating units) gave 86 H atoms for the signal of nBMA at 
1.41 ppm (3H, -CH2-CH2-CH3), which would mean that only 28 repeating units were 
added of nBMA. This unexpectedly low number might be a consequence of the cross-
linking. Due to cross-linking some methyl groups of nBMA might be ‘hidden’ inside 
the core and as such some hydrogens might not be visible in the spectra. Hence, the 
degree of polymerisation was calculated using the NMR spectra recorded during the 
polymerisation
Figure 4.5. 1H-NMR measured in CDCl3 of DP 36/40 after purification. 
The synthesis of DP 36/60 was followed in the same fashion. A solution of 
nBMA and EGDMA was added after a conversion of 90 % was reached. Table 4.1. 
shows the parameters used in both syntheses as well as the sizes obtained by measur-
ing DLS in water. To assure that unimolecular nanoparticles were measured and not 
agglomerates, the polymers were dissolved in acetone and water was added dropwise. 
After acetone was evaporated off, DLS was measured in water. The measured sizes 
of 32 and 29 nm indicate the successful formation of branched polymers.  
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Table 4.1. Synthetic parameters for the synthesis of the branched diblock copolymers DP 36/40 and 
DP 36/60 as well as DLS size data. 
Branched 
Block  
Copolymer 
OEGMA nBMA EGDMA Yield  size (Dh) 
 eq. % nm 
DP 36/40 40 40 0.9 60 32 
DP 36/60 40 60 0.9 56 29 
4.3.2.  Characterisation  
To compare the synthesised polymers, our collaborator Dr Tao He, synthesised 
the branched copolymer p(OEGMA)36-b-(pBMA20-co-pEGDMA0.9) (DP 36/20) and the 
corresponding diblock p(OEGMA36-b-BMA54) (DB DP 36/54).  
 
Figure 4.6. DLS data of p(OEGMA36)-b-(nBMA-co-EGDMA0.9) branched A-B block copolymer nanopar-
ticles and the corresponding linear analogue after heating the solution through the UCST in methanol. (A) 
DLS data; blue dashed line DP 36/60; black dashed line DP 36/40; green dashed line DP 36/20 and red line 
DB DP 36/54. And corresponding TEM images (B) linear DB DP 36/54; (C) branched DP 36/60; (D) 
branched DP 36/40; (E) branched DP 36/20 and (F) branched nanoparticles of DP 36/60 after heating through 
the UCST and dialysing into water (data recorded by Dr Tao He).  
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DLS data and TEM was measured in methanol and water at ambient temperatures 
to investigate if the method of thermal annealing is a viable alternative to dialysis. To that 
end the polymers were heated through the UCST and then cooled down to room tempera-
ture. Figure. 4.6. shows the obtained DLS data and TEM images.  
In methanol, the Z-Average decreased from 37 nm to 33 nm to 25 nm with 
decreasing nBMA lengths (DP 36/60 > DP 36/40 > DP36/20) (Figure 4.6. A). The 
corresponding diblock DB DP 36/54 showed sizes under 10 nm. This was assumed to 
be a single diblock copolymers solvated by p(OEGMA). This data showed that 
branched copolymers were obtained. The corresponding TEM images showed spher-
ical nanoparticles with slightly larger sizes of 48 nm, 40 nm and 28 nm for DP 36/60, 
DP 36/40 and DP 36/20 respectively (Figure 4.6. C-E). The analogue diblock polymer 
DB DP 54/60 formed an irregular film and no single nanoparticles could be detected 
(Figure 4.5. B). To demonstrate that the approach of heating through the UCSTs af-
fords unimolecular, well dispersed nanoparticles, the same as dialysis against water, 
nanoparticles of DP 36/60 were transferred from methanol to water by dialysis. The 
obtained TEM images (Figure 4.6.F) shows an average size of 45 nm and DLS Z-
Average of 32 nm. The similar sizes indicate that the method of thermal annealing can 
be used as an alternative way to form nanoparticles more efficiently.  
The stages of thermal annealing in methanol are shown in scheme 4.1. Dry 
polymer (i) is dissolved in methanol by heating through the UCST, whereby uni-
molecular polymer nanoparticles are obtained (ii). After cooling down to room tem-
perature in methanol the nBMA core contracts but the polymer nanoparticles do not 
agglomerate (iii) addition of water and subsequent evaporation of MeOH at room tem-
perature affords the same unimolecular nanoparticles (iv).  
 
Scheme 4.1. Schematic representation of the thermal annealing process. i) dry polymer; ii) unimolec-
ular branched polymer dissolved by heating through the UCST; iii) branched polymer at ambient Tem-
perature in methanol and iv) branched polymer unimolecular dissolved in water.  
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The thermoresponsive behaviour was subsequetnly utilised to form drug 
nanoparticle. DP 36/40 and DP 36/60 were chosen for drug nanoparticle formation 
because of their bigger sizes and subsequent bigger core sizes. It was theorised that 
bigger core spaces would be able to stabilise hydrophobic nanoparticles better in aque-
ous solution. 
4.3.3. Solvent evaporation at ambient temperature 
A simple solvent evaporation procedure as that had been used in Chapter 3 
was also applied to pOEGMA-b-p(nBMA-co-EGDMA) branched copolymers. The 
DLS data after resuspension in water is shown in Table 4.2.  
Table 4.2. DLS data of of different hydrophobic actives evaporated from methanol and then re-dis-
persed into water. Drug:Polymer ratios were kept at 1:1. 
Polymer Drug Z-Average Number % PDI 
  nm - 
DP 40/60 Oil Red O 362 ± 4 52 ± 11 0.36 
DP 40/60 Ketoprofen -* -* -* 
DP 36/40 Oil Red O 212 ± 3 -# 0.93 
DP 36/40 Ketoprofen 80 ± 2 34 ± 5 0.38 
* no measurement possible due to sample agglomerating; # high polydispersity and/or cumulant fit error 
high, no number % measurement possible  
Independent of hydrophobic active used, no satisfactory results could be ob-
tained. No nanoparticles were obtained for ketoprofen when DP 40/60 was used, 
while the small size of around 80 nm of ketoprofen nanoparticles formed by DP 40/40 
hints at encapsulation of the active instead of the formation of drug nanoparticles. 
Both polymers used were able to form oil red nanoparticles. However, poor measure-
ments as well as relatively high PDIs led us to believe that the formed nanoparticles 
were not stable in water. It was assumed that due to the change from linear PEG to 
non-linear PEG (OEGMA), which led to a physical change from a powder (PEG135-
b-(PNISOPROPANOLm25-co-EDAm2n)-b-PEG135) to a resin like morphology, the 
polymer could not be dissolved into water directly after methanol was evaporated. 
Hence drug nanoparticles could not be sufficiently stabilised and resuspended after 
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complete solvent evaporation. It was subsequently decided to evaporate into water to 
form drug nanosuspensions directly. 
4.3.4.  Solvent evaporation directly into water 
When linear and block copolymers have been used before to produce drug 
nanosuspensions, the loading is usually done by solvent displacement or precipita-
tion.16 It is often difficult to load drugs into micelles in high yields and to obtain par-
ticles which are the right size to utilise the enhanced permeability and retention (EPR) 
effect. Herein, nanosuspensions of three hydrophobic actives, oil red, ketoprofen and 
anthracene were formed using DP 36/40 and DP 36/60 directly without redispersing 
a dry formulation. The evaporation yielded milky suspensions. The obtained DLS data 
and nanoparticle yield is presented in Table 4.3. 
Table 4.3. DLS data of different hydrophobic actives evaporated from methanol into water. Drug: 
Polymer ratios were kept at 1:1. 
Polymer Drug Z-Average Number % PDI Yield 
  nm - % 
DP 36/60 Ketoprofen 198 ± 3 170 ± 9 0.03 100 
DP 36/60 Oil Red O 109 ± 41 -# 0.17 34 
DP 36/60 Anthracene 611 ± 8 459 ± 52 0.17 33 
DP 36/40 Ketoprofen 214 ± 3 208 ± 3 0.02 100 
DP 36/40 Oil Red O 66 ± 1 31 ± 2 0.15 17 
DP 36/40 Anthracene 495 ± 6 399 ± 26 0.19 39 
# high polydispersity and/or distribution fit error high, no number % measurement possible  
Using DP 36/60 afforded Ketoprofen particles of around 200 nm and no pre-
cipitant could be observed. Nanoparticles of anthracene, a highly hydrophobic dye 
could also be formed with sizes of around 600 nm and a nanoparticle yield of 33 %. 
DLS data could not be obtained in sufficiently good enough quality of oil red particles 
to confidently make a judgement about the particle size. When DP 36/40 was used the 
DLS data obtained for oil red showed very small particles of around 66 nm. Consid-
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ering the size of polymer nanoparticles measured without oil red (32 nm), nanoparti-
cles might not have been formed, but rather branched particles with encapsulated oil 
red in their core comparable to a micelle. This would also explain the low particle 
yield. However, when anthracene or ketoprofen were used particles of 208 and 495 
nm respectively could be obtained and in the case of ketoprofen a nanoparticle yield 
of 100 % was achieved. In all cases high loading was observed, considering that the 
initial concentration in water was 8 mg/ml. For anthracene a nanosuspension with 
concentrations of 3 mg/ml in water were obtained. Compared to the water solubility 
found in literature of 0.0013 mg/ml 17 this translates to an increase of 2000 %. Nano-
particle suspensions of ketoprofen could be obtained with a concentration of 8 mg/ml 
compared to unprocessed ketoprofen solutions of 0.05 mg/ml.18 The DLS data for 
ketoprofen and oil red (DP 36/40) is shown in Figure 4.5.  
   
Figure 4.7. DLS data of a) ketoprofen nanosuspension using DP 36/60 and DP 36/40 and b) oil red 
nanosuspension using DP 36/40 as stabilisers. 
The branched diblock copolymers used in this work were synthesised by 
ATRP via the ‘arm’ first method. As such the longer the core forming chain can grow, 
the higher the statistical change that other polymer chains can be ‘grabbed’. Hence 
intramolecular cross-linking increases, which in turn leads to the branched polymer 
being more spherical and ordered. It can be theorised that because the core region in 
DP 36/40 is shorter it is also less protected/ordered and can interact better with drug 
molecules. DP 36/60 on the other hand is slightly more ordered and as such the core 
is more protected by OEGMA arms and cannot interact as well with drug molecules. 
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This could be an explanation why, overall, using DP 36/40 led to slightly better results 
with lower nanoparticle sizes and smaller PDIs.  
 
Scheme 4.2. Schematic representation of drug nanosuspension formation during and after methanol 
evaporation in the presence of a) unimolecular polymer nanoparticles and b) agglomerated polymer 
nanoparticles.  
Nanosuspensions were formed by adding hydrophobic actives and polymers 
in a mass ratio of 1:1 to methanol and heating through the UCST to obtain a solution 
of well dispersed, unimolecular polymer nanoparticles and hydrophobic active. Water 
was added, and methanol was evaporated off at ambient temperatures. The addition 
of water should additionally lead to a decrease of the UCST temperature19 and an 
increase in p(OEGMA) solubility, thus favouring the retainment of unimolecular pol-
ymer nanoparticles even at room temperature. The evaporation of methanol leads to 
the interaction of hydrophobic actives with the hydrophobic core of the branched pol-
ymer nanoparticles to protect against the increasingly hydrophilic environment. These 
particles then stabilise by agglomerating, i.e. the hydrophilic OEGMA arms cover the 
surface of a hydrophobic drug/pBMA complex. If the polymer nanoparticles would 
not be well dispersed as unimolecular nanoparticles as was achieved by using the ther-
mal annealing process, but exist in solution as agglomerates, the interaction between 
drug and core would be complicated (Scheme 4.2.)  
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4.4.  Conclusions 
In this Chapter, branched diblock copolymer made from non-linear PEG arms 
and a thermoresponsive core of nBMA were synthesised via ATRP and used to di-
rectly form solutions of polymer nanoparticles by thermal annealing of a methanolic 
solution. The same polymer was then used to directly form nanosuspensions with very 
high drug content of up to 8 mg/ml and a nanoparticle yield of 100 %. While we 
focused in Chapter 3 on the stabilisation and growth inhibition ability of branched 
polymers in dependence on core cross-linkage, this Chapter focused on structural 
properties and core composition in relation to the ability to form nanoparticles. This 
was mainly possible because in comparison to the materials used in Chapter 3, which 
were synthesised by conventional radical polymerisation, the synthesis by ATRP af-
forded branched polymers of higher order due to better reaction control. Cryo-TEM 
images and DLS data confirmed, in comparison to an analogue diblock polymer, the 
successful synthesis of cross-linked branched polymer nanoparticles. The straightfor-
ward one-pot synthesis using isopropanol/water mixture at ambient temperatures 
would be favourable for industrial application. The thermal annealing behaviour could 
successfully be used to obtain methanolic solutions of unimolecular polymer nano-
particles without the need for a lengthy dialysis process. OEGMA as well as BMA 
exhibit thermo-responsive behaviour. OEGMA is known to have an LCST, while 
BMA exhibits UCST, both of which are of great interest to the pharmaceutical indus-
try. The LCST and UCST are both greatly influenced by the type and lengths of the 
co-polymers as well as the lengths of the thermoresponsive block.15,20,21  
After the initial characterisation, two polymers DP 36/40 and DP 36/60 were 
chosen for comparison of core composition dependent drug nanoparticle formation. 
To this end the UCST behaviour in methanol was initially used to obtain dried nano-
particles of ketoprofen and Oil Red O. This approach failed since the obtained mate-
rials could not be re-dispersed in water in a satisfactory manner. Consequently, drug 
nanosuspension were formed directly by dissolving the water insoluble drug and 
branched polymer in methanol, heating through the UCST to obtain unimolecular 
branched polymer nanoparticles and dissolved drug, followed by the addition of water 
and evaporation of methanol at ambient temperatures. With this approach nanosus-
pensions of ketoprofen, OR and anthracene in high yields were successfully obtained. 
Ketoprofen nanosuspensions with concentrations of 8 mg/ml with a drug to polymer 
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ratio of 1:1 mass ratio could be achieved, while for anthracene the nanosuspension 
concentration using the same ratios were at 3 mg/ml, which corresponds to 50 wt % 
and 25 wt % respectively. Both concentrations were unusual high compared what can 
normally be found in literature for diblock micelles e.g. 20-25 wt %.22-24 Comparison 
of drug nanoparticle sizes and yields allowed to make conclusions about the stabilisa-
tion ability of the branched polymers in dependency of core composition and as such 
structural order. We observed that what we believed to be higher ordered structures 
i.e. more closely resembling dendrimers (DP 36/60) were less able to ‘anchor’ onto a 
crystal surface due to decreased hydrophobic interactions.  
In summary we were able to successfully obtain nanosuspensions of highly 
water insoluble drugs with high yields, narrow PDIs and small particles sizes.  
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Chapter 5 
 
Solubilisation of hydrophobic 
drugs facilitated by pH-responsive 
hyperbranched polymers 
 
This Chapter is based on the publication 
U. Wais, H. Zhang and A. W. Jackson. “Star polymers possessing pH-
responsive hyperbranched cores via RAFT polymerisation” under prep-
aration 
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5.1. Introduction 
Chapter 4 focused on the utilisation of ATRP to form branched amphiphilic 
polymers with a temperature responsive core. ATRP was chosen to impart good con-
trol over the resulting architecture than could be previously obtained using conven-
tional free radical polymerisation as reported in Chapter 2 and 3.  
Hyperbranched polymers (HBPs) are an interesting class of polymer architec-
tures that have, in recent years, gained significant attention for biomedical application, 
due to their similarities to dendrimers. However, while dendrimers require a multistep 
synthesis and a laborious purification process, HBPs are synthetically easier to obtain 
while still maintaining many of the characteristics of dendrimers.1 HBPs show en-
hanced solubility in a wide range of solvents due to lower chain entanglement, low 
melt and solution viscosity and a reduced hydrodynamic radius. Furthermore, they 
possess a large amount of chain ends for modification.2 
 
Figure 5.1. Schematic representation of a star hyperbranched polymer and its different regions e.g. 
core, arms and surface.  
One of the most commonly used synthetic route to obtain HBPs is self-con-
densing vinyl polymerisation (SCVP). The combination of SCVP with reversible-de-
activation radical polymerisation (RDRP) techniques such as ATRP and RAFT af-
fords better control of branch lengths and variable functionalities 2 as well as the pos-
sibility for chain-extension of a second block to form star hyperbranched polymers 
(SHBP).3,4 However, the combination of SCVP and RDRP requires the synthesis of 
an inimer to act as an initiator/monomer, which can be expensive and difficult to scale-
up.5 O’Brien et. al. 6 used conventional radical polymerisation in the presence of a 
vinyl monomer and a divinyl cross-linker to obtain hyperbranched polymers. Perrier 
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et. al. 7,8 extended this method by combining it with RAFT, which enables a straight 
forward, finely tunable and cost-effective route to form hyperbranched polymer that 
can easily be chain-extended to afford star polymers. The use of RAFT polymerisation 
makes it possible to tailor each part of a SHBP, i.e. core, arms and surface (Figure 
5.1.) individually to suit specific needs, such as targeting or stimuli responsiveness.   
The clinical application of polymers as drug nanocarriers and bioimaging tools 
is often hampered by the non-specific nature of polymers, instability in the blood 
stream, possible toxic decomposition products and short retention time.9,10 The non-
specific targeting can be addressed by modifying the polymer nanoparticle with small 
molecules which can act as antagonists for proteins on the surface of certain cells. 
Most polymers such as star-polymers, linear block polymers or bottle-brush polymers 
need to self-assemble to be able to encapsulate actives. However, these self-assembled 
structures fall apart and prematurely release their cargo when the concentration falls 
below the critical micelle concentration (CMC), which is often than not when injected 
into the bloodstream. On the other hand, three dimensional structures such as den-
drimers and HBPs can encapsulate actives without self-assembly. This is because their 
branched cores already exhibit cavities which can be employed to encapsulate hosts. 
In addition, their chain ends can easily be used to afford nanocarriers with targeting 
moieties. Compared to their linear analogues increased sensitivity, specificity and cir-
culation time could be observed when HBPs were used.11  
 
Figure 5. 2. Schematic representation of abnormal environment found in malignant tissue and cells 
used for active and passive targeting. 
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It has been shown that HBPs made from temperature sensitive monomers 
showed favourable behaviour for cell-targeting. Above the LCST the particles ag-
glomerated into sub-micron particles and were able to enter the cells, while below the 
LCST, in the branched form, cells were excluded from entering.12 Stimuli responsive 
polymers are especially interesting in cancer treatment, since cancer cells, and the 
malignant surrounding tissue, exhibit an abnormal environment compared to healthy 
tissue 13 (Figure 5.2.). Polymeric nanoparticles also have the additional benefit of be-
ing able to utilise the enhanced permeability and retention (EPR) effect.14 To enhance 
the specificity of drug release at the target side pH or temperature responsive polymers 
are often chosen as carriers to facilitate the encapsulation and release at the pH or 
temperatures of malignant cells.15 Polymers with pH responsiveness are particularly 
interesting because the cationic character of protonated polymers is known to facilitate 
the delivery into cells e.g. non-viral gene delivery.2  Increased specificity can easily 
be afforded by using RAFT polymerisation and modifying the polymers with target-
ing moieties pre- or post-polymerisation.16 
In this Chapter, a series of pH sensitive star hyperbranched polymers of the 
general constitution poly(ethylene glycol) methyl ether methacrylate-b-poly(2-(di-
ethylamino)ethyl methacrylate-co-di(ethylene glycol) dimethacrylate) p(OEGMA)80-
b-p(DEAEMAx-co-DEGDMA2) with x = 25, 50, 100 and 200 as well as a diblock 
polymer p(OEGMA80-b-DEAEMA50) were synthesised via RAFT polymerisation. In 
order to study the influence of core composition on branching and pH sensitive be-
haviour, the hydrophilic arms and cross-linker equivalences were kept constant at 80 
and 2, respectively. The series was then studied for pH responsive behaviour. 
OEGMA is known to exhibit a LCST. Hence, temperature was employed as a second 
stimulus and all polymers were tested for their behaviour at temperatures above and 
below the LCST and at low and high pH values. Subsequently the SHBP with the 
most favourable core-cross-linking was chosen to study pH responsive release of a 
hydrophobic drug, gelation behaviour and the surface modification with a fluorescent 
dye.  
5.2. Experimental 
5.2.1. Materials and Characterization 
4-((((2-Carboxyethyl)thio)carbonothioyl)thio)-4-cyanopentanoic acid 
(BM1433) was purchased from Boron Molecular. Oligoethylene glycol methacrylate 
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monomethyl ether (OEGMA, Mw ≈ 300 g/mol), 2-(diethylamino)ethyl methacrylate 
(DEAEMA) and di(ethylene glycol) dimethacrylate (DEGDMA) were passed through 
a basic alumina column to remove the inhibitor prior to use. 1H NMR spectra were 
recorded on Bruker 400 Ultra Shield spectrometer. Size exclusion chromatography 
(SEC) was conducted on a Waters 717 plus autosampler equipped with a Waters 515 
pump and a Waters 2414 refractive index (RI) detector. Three columns; Styragel 
HR0.5 (0-1,000), Styragel HR3 (500-30,000) and a Styragel HR5E (2,000-4,000,000) 
were applied in sequence for separation. Tetrahydrofuran was used as the eluent at 0.3 
mL/min, molecular weights were determined against poly(styrene) standards. Static 
light scattering analysis was completed on a Viscotek Triple Detector Array (TDA) 
302 equipped with a Refractive Index (RI) detector, Viscometer, Right Angle (90°) 
Light Scattering (RALS) and Low Angle (7°) Light Scattering (LALS). Separation 
was performed using two PLgel 5um Mixed-B columns connected in series. Samples 
were injected at a volume of 100 µL and eluted through the system at flow rate of 1 
mL/min in THF. A temperature of 30 °C was maintained during separation and detec-
tion. Poly(styrene) 210 kDa was used as calibration for absolute molecular weight 
determination by Light Scattering. Deionized water was prepared using an Aqua-
MAX-Basic 321 DI water purification system. Hydrodynamic diameter values were 
determined by dynamic light scattering (DLS) analysis on a Malvern Zetasizer Na-
noseries from Malvern Instruments at 25 °C. The measurements were performed on 
aqueous nanoparticles solutions with concentrations of 3 mg/ml. UV/Vis analysis was 
performed on a Shimadzu UV-2700, Indomethacin concentrations were determined 
against a calibration curve of solutions of known concentration in EtOH. 
5.2.2. Synthesis of DEAEMA Hyperbranched Polymers (HB1-HB4) 
Hyperbranched polymers (HB1-4) were synthesised by the follow procedure. 
All experiments were conducted with constant monomer and solvent concentrations 
and varying amounts of RAFT chain transfer agent, radical initiator and cross-linker 
(Table 5.1). In a typical synthesis (HB1) the RAFT chain transfer agent 4-((((2-car-
boxyethyl)thio)carbonothioyl)thio)-4-cyanopentanoic acid (184 mg, 0.6 mmol, 1 eq), 
di(ethylene glycol) dimethacrylate (238 mg, 1.2 mmol, 2 eq), 2-(diethylamino)ethyl 
methacrylate (2.78 g, 15 mmol, 25 eq) and azobisisobutyronitrile (9.8 mg, 60 µmol, 
0.1 eq) were transferred into a schlenk flask fitted with a magnetic stirrer bar and 
N,N’-dimethylformamide (3.0 g) added. The reaction mixture was degassed via three 
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freeze-pump-thaw cycles and backfilled with N2. The reaction was heated to 70 °C 
and stirred at 500 rpm for 16 h after this time NMR analysis confirmed conversions 
of 90 – 99 %. The reaction was quenched by rapid cooling, and the polymer purified 
by three precipitations from THF into water. The polymer was dissolved into chloro-
form and dried over MgSO4. The purified polymer was isolated as a yellow waxy 
solid. 1H NMR (CDCl3): δ 4.70 (br, C(O)OCH2CH2O), 4.00 (br, C(O)OCH2CH2N), 
3.63 (br, C(O)OCH2CH2O), 2.71 (br, CH2CH2N), 2.58 (br, N(CH2CH3)2), 1.84 (br, 
CH2C(CH3)), 1.04 (br, N(CH2CH3)2), 0.88 (br, CH2C(CH3)). 
5.2.3. Synthesis of OEGMA-b-DEAEMA Star Hyperbranched Polymers (SHB1-4) 
Star hyperbranched polymers (SHB1-4) were synthesised by the follow pro-
cedure. All experiments were conducted with constant concentrations of hyper-
branched polymer precursor, monomer, solvent and radical initiator (Table 5.2). In a 
typical synthesis (SHB1) the hyperbranched polymer precursor (HB1, 0.68 g, 0.125 
mmol, 1 eq), oligo(ethylene glycol) methyl ether methacrylate (3.0 g, 10 mmol, 80 
eq) and azobisisobutyronitrile (2.1 mg, 12.5 µmol, 0.1 eq) were transferred into a 
schlenk flask fitted with a magnetic stirrer bar and N,N’-dimethylformamide (11 g) 
added. The reaction mixture was degassed via three freeze-pump-thaw cycles and 
backfilled with N2. The reaction was heated to 70 °C and stirred at 500 rpm for 16 h 
after this time NMR analysis confirmed conversions of 90 – 99 %. The reaction was 
quenched by rapid cooling, and the polymer purified by three precipitations from THF 
into hexane. The purified polymer was isolated as a yellow oil. 1H NMR (CDCl3): δ 
4.07 (br, C(O)OCH2CH2N and C(O)OCH2CH2O), 3.65 (br, (CH2CH2O)n), 3.54 (br, 
CH2OCH3), 3.37 (br, CH2OCH3), 2.95-2.65 (br, CH2CH2N and N(CH2CH3)2), 1.81 
(br, CH2C(CH3)), 1.14 (br, N(CH2CH3)2), 0.87 (br, CH2C(CH3)). 
5.2.4. Synthesis of DEAEMA Linear Polymer (LP1)  
RAFT chain transfer agent 4-((((2-carboxyethyl)thio)carbonothioyl)thio)-4-
cyanopentanoic acid (92 mg, 0.3 mmol, 1 eq), 2-(diethylamino)ethyl methacrylate 
(2.78 g, 15 mmol, 50 eq) and azobisisobutyronitrile (4.9 mg, 30 µmol, 0.1 eq) were 
transferred into a schlenk flask fitted with a magnetic stirrer bar and N,N’-dimethyl-
formamide (3.0 g) added. The reaction mixture was degassed via three freeze-pump-
thaw cycles and backfilled with N2. The reaction was heated to 70 °C and stirred at 
500 rpm for 16 h after this time NMR analysis confirmed a conversion of 99 %. The 
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reaction was quenched by rapid cooling, and the polymer purified by three precipita-
tions from THF into hexane. The purified polymer was isolated as a yellow waxy 
solid. 1H NMR (CDCl3): δ 4.01 (br, C(O)OCH2CH2N), 2.71 (br, CH2CH2N), 2.59 (br, 
N(CH2CH3)2), 1.84 (br, CH2C(CH3)), 1.05 (br, N(CH2CH3)2), 0.89 (br, CH2C(CH3)). 
5.2.5. Synthesis of OEGMA-b-DEAEMA Linear Diblock Polymer (DB1) 
The linear polymer DEAEMA50 (LP1, 1.16 g, 0.125 mmol, 1 eq), oligo(eth-
ylene glycol) methyl ether methacrylate (3.0 g, 10 mmol, 80 eq) and azobisisobu-
tyronitrile (2.1 mg, 12.5 µmol, 0.1 eq) were transferred into a schlenk flask fitted with 
a magnetic stirrer bar and N,N’-dimethylformamide (11 g) added. The reaction mix-
ture was degassed via three freeze-pump-thaw cycles and backfilled with N2. The re-
action was heated to 70 °C and stirred at 500 rpm for 16 h after this time NMR analysis 
confirmed conversions of 92 %. The reaction was quenched by rapid cooling, and the 
polymer purified by three precipitations from THF into pentane. The purified polymer 
was isolated as a yellow oil. 1H NMR (CDCl3): δ 4.07 (br, C(O)OCH2CH2N and 
C(O)OCH2CH2O), 3.65 (br, (CH2CH2O)n), 3.54 (br, CH2OCH3), 3.37 (br, 
CH2OCH3), 3.15-2.85 (br, CH2CH2N and N(CH2CH3)2), 1.83 (br, CH2C(CH3)), 1.26 
(br, N(CH2CH3)2), 0.93 (br, CH2C(CH3)). 
5.2.6. pH-Responsive Investigation (SHB1-4 and DB1) 
Aqueous solutions of shell hyperbranched polymers (SHB1-4) and the linear 
diblock copolymer (DB1) were prepared by dissolving 30 mg polymer in 2 ml ace-
tone, followed by the addition of 10 ml DI water at pH 5. Acetone was removed by 
evaporation at room temperature under constant stirring at 500 rpm. After acetone 
evaporation, 1M HCl(aq) and 1M NaOH(aq) were used to adjust the pH values from 5 
to 9. Values were determined using a Mettler Toledo S220 pH probe. Measurements 
were performed in triplicate, by cycling between pH 5 and 9.    
5.2.7. Indomethacin solubilisation and pH-Triggered Release   
Typically, 200 mg of shell hyperbranched polymer SHB1-4 (or linear diblock 
copolymer DB1) and 100 mg Indomethacin (IMC) were dissolved in 10 mL EtOH, 
and 10 mL DI water added slowly. EtOH was evaporated at room temperature under 
constant stirring at 500 rpm. The obtained solution was filtered to remove the excess 
IMC, UV-Vis was used to determine the % of IMC in solution. After the ethanol was 
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removed the pH of the obtained IMC/polymer solution was measured at pH 6.5. The 
10 mL aqueous solution obtained was split into two stock solutions, one 5 mL solution 
was maintained at pH 6.5 and the second 5 mL solution adjusted to and maintained at 
pH 5.0. pH adjustments were made using small aliquots of 1M HCl(aq) and 1M 
NaOH(aq). At specific time points small samples were extracted and centrifuged to 
isolate the precipitated IMC from the IMC/polymer solution. 30 μL of the supernatant 
was taken out and dissolved in 2.97 mL EtOH for UV/Vis analysis, against a calibra-
tion curve of known IMC concentrations in EtOH, the remaining solution was replen-
ished with 30 μL H2O at pH 5 or 6.5 and added back to the respective IMC/polymer 
stock solutions. 
5.2.8. Thiol Functionalisation of Star Hyperbranched Polymer via Aminolysis 
The thiol chain end-functional star hyperbranched polymer (SHB2-SH) was 
synthesised by the following procedure. Trithiocarbonate chain end-functionalised 
star hyperbranched polymer (SHB2, 2.31 g, approx. 0.07 mmol of trithiocarbonate 
end-group, 1 eq) was dissolved in THF (10 mL) and transferred to a Schlenk flask 
fitted with a rubber septum. The solution was degassed via three freeze-pump-thaw 
cycles and backfilled with N2. 3-Aminopropanol (0.26 g, 3.50 mmol, 50 eq) was added 
via syringe and the reaction was heated to 45 °C for 2 h. After this time the reaction 
was purified by two precipitations from THF into hexane. The polymer was isolated 
as a clear oil. Aminolysis was confirmed by UV-Vis (3 mg/ mL in THF) of SHB2 
compared with SHB2-SH. The process was performed under identical conditions with 
the linear diblock copolymer (DB1) to afford the thiol end-functionalised DB1-SH.  
5.2.9. Gelation of Thiol Functional End-functionalised Star Hyperbranched Polymer 
SHB2-SH (150 mg) was dissolved in the minimal amount of acetone required. 
H2O (2 mL) was then added followed by H2O (1 mL) containing 10 µl H2O2 (30 % 
w/w). The solution was left open for acetone to evaporate, the resulting polymer con-
centration is 5 wt %. Successful gelation was confirmed by the vial inversion test. The 
experiment was repeated using different polymer concentrations (1 and 10 wt %) and 
control experiments performed with SHB2, DB1 and DB1-SH. 
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5.2.10. Conjugation of Fluorescein via Thiol-ene Click Chemistry 
SHB2-SH (0.2 g, approx. 6.0 µmol of thiol end-group, 1 eq) and N-(5-Fluo-
resceinyl)maleimide (3.0 mg, 7.0 µmol, 1.2 eq) were dissolved in DMF (2 mL), the 
reaction was stirred for 20 h at room temperature in the dark. The polymer was puri-
fied by dialysis against H2O in a 5 mL Float-A-Lyzer (Mw cut-off 8-10 kDa) for 24 h. 
After removal of water via freeze-drying, the desired polymer (SHB2-Dye) was ob-
tained as a red oil. Successful dye conjugation was confirmed by UV-Vis (3 mg/ mL 
in H2O) of SHB2-Dye compared with SHB2 and SHB2-SH. 
5.3.  Results and discussion        
5.3.1.  Synthesis of p(OEGMA)80-b-p(DEAEMAx-co-DEGDMA2)  
A series of star hyperbranched polymers of the general structure pOEGMA80-
b-(DEAEMAx-co-DEGDMA2) with x = 25; 50; 100 and 200 as well as a linear di-
block polymer p(OEGMA80-b-DEAEMA50) were synthesised by RAFT polymerisa-
tion via a ‘core-first’ approach. The polymers were named HB1-4 (hyperbranched 
polymer) and LP1 (linear polymer) before being grown out with OEGMA, after which 
they were denominated as SHB1-4 (star hyperbranched polymer) and DB1 (diblock 
polymer). In case of hyperbranched and star hyperbranched polymers the numbers 1-
4 represent the degree of polymerisation of DEAEMA, i.e. HB1 = (DEAEMA25-co-
DEGDMA2), SHB1 = pOEGMA80-b-(DEAEMA25-co-DEGDMA2), HB2 = (DE-
AEMA50-co-DEGDMA2) and SHB2 = pOEGMA80-b-(DEAEMA50-co-DEGDMA2) 
and so on. In case of the linear and diblock polymer only one polymer of the consti-
tution p(DEAEMA50) (LP1) and p(OEGMA80-b-DEAEMA50) (DB1) were synthe-
sised. Scheme 5.1. shows a schematic presentation of the synthesis. Table 5.1 gives 
an overview of the synthetic parameters used for the hyperbranched cores (HB1-6) 
and linear polymer LP1. Table 5.2. shows the synthetic parameters used for the chain-
extension to form star hyperbranched polymers (SHB1-4) and linear diblock DB1 re-
spectively.  
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Scheme 5.1. Schematic presentation of the synthesis of a) hyperbranched cores HB1-4 and extension 
to star hyperbranched polymers SHB1-4 and b) linear polymer LP1 and extension to diblock polymer 
DB1 by RAFT polymerisation.  
Initially, the pH responsive monomer DEAEMA was polymerised in the pres-
ence of a cross-linker (DEGDMA) and a RAFT chain transfer agent to afford hyper-
branched polymers of DEAEMA-co-DEGDMA. This has been initially reported by 
Perrier et. al. using methyl methacrylate (MMA) and ethylene glycol dimethacrylate 
(EGDMA).7 The copolymerisation of DEAEMA with the a relatively low equivalence 
of cross-linker (DEGDMA) by RAFT led to hyperbranched polymers. Table 5.1. 
shows the synthetic parameters used, as well as DLS data measured in THF, where 
the hyperbranched polymers are uniformly dissolved. Initially the cross-linker to CTA 
ratio was fixed at 2:1 and the monomer ratio was varied to 25, 50, 100 and 200 (HB1-
4). Conversion was measured by 1H-NMR. High conversions of over 90 percent were 
achieved for all polymers. The polymers were purified by precipitation twice into DI 
water.  
After successfully obtaining polymers HB1-4 the cross-linking to CTA equiv-
alence was varied from 2:1 to 3:1, while keeping the ratio of cross-linker:DEAEMA 
at 1:25. However, when the crosslinking:CTA ratio exceeded 2 (HB5 and HB6), the 
reaction gelled. Confirming what had previously been observed in the RAFT polymer-
isation of EGDMA and methyl methacrylate (MMA) by Perrier et. al. 7  
DLS data in THF showed that with increasing monomer units the size of the 
HB polymers increased from 14 nm to 33 nm from HB1 to HB4. Linear polymer LP1 
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only show a size of 5 nm in THF, as expected for a linear polymer. Hence, branching 
was successfully achieved for HB1-HB4.   
Table 5.1. Synthetic parameters for hyperbranched cores and linear block polymer HB1-6 and LP1, 
DLS data in THF, DB = degree of branching and RB = average repeat units per branch (1/DB). 
Name 
[DEAEMA] : [CTA] 
: [DEGDMA] : 
[AIBN] 
Conversion Yield 
Dh in 
THF 
DB RB 
 - % % nm - - 
HB1 25 : 1 : 2 : 0.1 99 73 17 0.135 7.41 
HB2 50 : 1 : 2 : 0.1 99 52 21 0.068 14.71 
HB3 100 : 1 : 2 : 0.1 96 43 24 0.035 28.57 
HB4 200 : 1 : 2 : 0.1 90 27 35 0.019 52.63 
HB5 75 : 1 : 3 : 0.1 gelled - - - - 
HB6 100 : 1 : 4 : 0.1 gelled - - - - 
LP1 50 : 1 : 0 : 0.1 92 30 5 - - 
All experiments were performed in 50 wt % DMF at 70 °C for 20h 
The degree of branching (DB), i.e. the fraction of branching units in each mac-
romolecule, can be determined by analysing the 1H-NMR spectra of HB1-HB4. Fig-
ure 5.3 shows an example of a NMR spectra of HB2 (Figure 5.3.a and b) and SHB2 
(Figure 5.3.c) measured in CDCl3. Equation 5.1 is used to calculate DB by relating 
the number of terminal (T), linear (L) and branching (B) units.22 In RAFT polymeri-
sation the terminal groups are equal with the chain transfer agent’s R-group (R) and 
Z-group (Z). Equation (5.1) can be modified to yield equation (5.2). The Z-group used 
are not visible in 1H-NMR spectroscopy. However, Z-groups and R-groups are ap-
proximately equal and so equation (5.3) can be obtained.5 Linear (non-cross-linked) 
polymers have a DB close to zero, while perfectly branched structures have a DB of 
one.  
𝐷𝐵 =  
𝐵 + 𝑇
𝐵 + 𝑇 + 𝐿
        (𝟓. 𝟏)                                    𝐷𝐵 =  
𝐵 + 𝑅 + 𝑍
𝐵 + 𝑅 + 𝑍 + 𝐿
        (𝟓. 𝟐)      
𝐷𝐵 =  
𝐵 + 2𝑅
𝐵 + 2𝑅 +  𝐿
         (𝟓. 𝟑) 
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When the integrals (Figure 5.3.b) of the terminal R-group protons (R) (-
CH2COOH) at 2.33 ppm, the DEGDMA (B) protons (-CH2CH2O-) at 3.63 ppm and 
the DEAEMA (L) protons (-CH2CH2N-) at 4.00 ppm are inserted into equation 5.3, it 
is possible to obtain the degree of branching for each DEAEMA-co-DEGDMA hy-
perbranched polymer (Table 5.1.) and the average repeat units per branch (RB), which 
is equal to 1/DB. The degree of branching increased from 0.019 (HB4) to 0.135 (HB1) 
as the initial feed ratio of [DEAEMA]:[DEGDMA] increases from 100 to 12.5. The 
ratio of monomer to cross-linker is higher in HB1 (12.5:1) than HB4 (100:1), as such 
the statistically possibility to incorporate a second chain via a cross-linker is higher in 
HB1. Furthermore, shorter linear blocks should be more mobile and have less steric 
hindrance to ‘grab’ another growing polymer chain, favouring higher degrees of 
branching. 
By using RAFT polymerisation, the prepared cores could easily be extended, 
even after prolonged storage at -20 °C, with OEGMA. Star hyperbranched polymers 
comprising of a hydrophobic hyperbranched core of DEAEMA and a linear hydro-
philic exterior of OEGMA were obtained. OEGMA was chosen due to its known bi-
ocompatibility. Table 5.2. shows the synthetic parameters used for the extension of 
HB1-HB4 and LP1 to star hyperbranched and diblock polymer SHB1-SHB4 and 
DB1, the size data measured in THF, as well as the number of arms. 
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Figure 5.3. a) 1H-NMR in CDCl3 of HB2; b) Expansion of 1H NMR (CDCl3) spectra of HB2 used to 
determine degree of branching (DB) and c) 1H-NMR in CDCl3 of SHB2. 
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All reactions reached conversions of over 90 %. Purification was done by pre-
cipitation into cold hexane three times. The size data measured in THF, where both 
blocks are soluble, shows an expected trend of decreasing sizes from SHB1 to SHB4 
with a size dip for SHB3. The size decrease is a direct consequence of a decreasing 
degree of branching from HB1 to HB4. Less chains are incorporated and hence grown 
out. The number of incorporated arms can be calculated as   
𝑛𝑜. 𝑜𝑓 𝑎𝑟𝑚𝑠 =  
𝑀𝑛𝑜𝑓 𝑆𝐻𝐵 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 −  𝑀𝑛𝑜𝑓 𝐻𝐵 𝑝𝑟𝑒𝑐𝑢𝑟𝑠𝑜𝑟
𝑀𝑛
𝑡ℎ𝑒𝑜. 𝑜𝑓 𝑝𝑜𝑙𝑦(𝑂𝐸𝐺𝑀𝐴)
     (𝟓. 𝟒) 
Where the number average molecular weight (Mn) of SHB polymer and HB 
polymer were obtained from static light scattering (SLS) measurements in THF (Table 
5.3.) and the theoretical number average molecular weight of linear segments between 
branching points (Mn
theo.) of poly(OEGMA) was calculated according to the following 
equation  
𝑀𝑛
𝑡ℎ𝑒𝑜. =  80 × 𝑀𝑊 𝑜𝑓 𝑂𝐸𝐺𝑀𝐴 × 𝐶𝑜𝑛𝑣.    (𝟓. 𝟓) 
With the mass average molar mass (Mw) taken from Table 5.3. and the con-
version (Conv.) taken from Table 5.2. As had been observed in the size data in THF, 
the number of arms increased with increasing [DEAEMA]:[DEGDMA] feed ratio 
from 100 to 12.5, from 13.07 (SHB1) to 3.65 (SHB4).  
Table 5.2. Synthetic parameters for star hyperbranched and diblock polymer SHB1-4 and DB1, DLS 
data in THF and number of arms. 
Name 
[OEGMA] : [Macro-RAFT] 
: [AIBN] 
Conversion Yield 
Dh in 
THF 
No. of 
arms 
 - % % nm - 
SHB1 80 : 1 (HB1) : 0.1 95 98 65 13.07 
SHB2 80 : 1 (HB2) : 0.1 96 71 66 9.59 
SHB3 80 : 1 (HB3) : 0.1 96 67 36 4.08 
SHB4 80 : 1 (HB4) : 0.1 96 37 52 3.65 
DB1 80 : 1 (LP1) : 0.1 92 69 21 - 
All experiments were carried out in 24 wt % DMF at 70 °C for 20h 
Gel permeation chromatography (GPC) was recorded of HB1-HB4; SHB1-
SHB4; LP1 and DB1 in THF. The results are presented in Table 5.3. All measured 
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molecular weights were off compared to what had been calculated from 1H-NMR e.g. 
HB1 was calculated to be Mn = 4900 g/mol and measured by GPC to be Mn = 5900 
g/mol. This phenomenon has been described before for HB polymers.1,19 GPC 
measures the hydrodynamic volume of a polymer and compares this to a linear stand-
ard of poly(styrene) of a known molecular weight. HBPs, due to their branched archi-
tecture, form coiled structures and as such the comparison to linear polymers is most 
likely unsuitable as a method. However, the obtained broad dispersity (PDI) values of 
2.24-1.81 and 2.07-1.83 are indicative of cross-linked polymers obtained by copoly-
merisation with divinyls. Absolute Mn values obtained by online static light scattering 
displayed much high values confirming the preparation of cross-linking macromole-
cules. Theoretical Molecular weights for HB1-HB4 and LP1 were calculated using 
equation (5.6) with BM1433 being the chain transfer agent. Theoretical Molecular 
weights for SHB1-SHB4 and DP1 were calculated as 
𝑀𝑊
𝑡ℎ𝑒𝑜𝑟. = (
[𝐷𝐸𝐴𝐸𝑀𝐴]
[𝐵𝑀1433]
× 𝑀𝑊 𝑜𝑓 𝐷𝐸𝐴𝐸𝑀𝐴 × 𝐶𝑜𝑛𝑣. ) + 𝑀𝑊 𝑜𝑓 𝐵𝑀1433   (𝟓. 𝟔) 
𝑀𝑊
𝑡ℎ𝑒𝑜𝑟. = (𝑀𝑊
𝑡ℎ𝑒𝑜𝑟. 𝑜𝑓 𝐻𝐵1 − 𝐻𝐵4(𝐿𝑃1)) + (𝑛 × 𝑀𝑊  𝑜𝑓 𝑂𝐸𝐺𝑀𝐴 × 𝐶𝑜𝑛𝑣. )(𝟓. 𝟕) 
Table 5.3. Molecular weight calculated by NMR and GPC and DLS data for hyperbranched cores 
and star-hyperbranched polymers 1-4 as well as diblock polymer 1 
Name 
Conv.a 
[%] Mn
theo. Mnb Mwb 
PDIb 
(Mw/Mn) 
Mnc SLS 
 % g/mol - g/mol 
HB1 99 4,900 5,900 13,200 2.24 82,000 
HB2 99 9,500 14,000 25,500 1.82 145,000 
HB3 96 18,100 11,500 19,000 1.65 165,000 
HB4 90 33,700 17,400 31,500 1.81 160,000 
LP1 92 8,800 6,600 8,200 1.24 - 
SHB1 95 27,700 31,500 65,100 2.07 380,000 
SHB2 96 32,500 23,800 53,000 2.23 366,000 
SHB3 96 41,100 21,300 43,200 2.03 259,000 
SHB4 96 56,700 21,400 39,100 1.83 244,000 
DB1 92 30,900 23,200 29,500 1.27 - 
Mntheo = theoretical number average molecular weight of linear segments between branching points; 
a Determined by 1H NMR spectroscopy, b determined by SEC in THF against PS standards, c deter-
mined by SEC online static light scattering in THF 
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Figure 5.5. GPC graphs of hyperbranched cores (dotted line) and star hyperbranched polymers (solid 
line) as well as the linear analogue LP1 and DB1 in THF. a) HB1 and SHB1; b) HB2 and SHB2; c) 
HB3 and SHB3; d) HB4 and SHB4 and e) LP1 and DB1. 
Comparison of the GPC curves of hyperbranched cores and star-hyper-
branched polymers after extension (Figure 5.5.) showed the same effect as had already 
been observed in the DLS data in THF (Table 5.2) i.e. that with increasing DEAEMA 
units the branching decreases. In Figure 5.5 this can be observed through the increased 
difference in retention times between HB1 and SHB1 (Figure 5.5.a) compared to HB4 
and SHB4 (Figure 5.5.d). Another indicator for branching is the broad dispersity 
(PDI). Perrier et. al. 8 found that a smaller dispersity (PDI) indicates less branching. 
Comparison between LP1 (PDI = 1.26) and HB1-HB4 (PDI ranging from 1.66 to 
2.22) strongly suggests that the highest branching corresponds to HB1. In addition, 
HB1 exhibits bimodal distribution (Figure 5.5.a) while HB2-HB4 displayed mono-
modal distributions. In the next step star hyperbranched polymers SHB1-SHB4 and 
diblock polymer DB1 were tested for pH responsive behaviour.  
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5.3.2. pH responsive behaviour 
Studies found that stimuli responsiveness of hyperbranched polymers is di-
rectly influenced by branching.5, 20 Davis et. al. 20 found that with varying the degree 
of branching, they could directly influence the cloud point temperature of temperature 
responsive HBPs based on PEG-methacrylates. For this reason, it was decided to in-
vestigate the pH dependent behaviour in relation to core constitution and branching 
of a pH responsive star hyperbranched polymer. De et. al. 20 showed that a hyper-
branched star polymer with pH responsive core of amino acid-based monomers 
showed interesting size changes with changing pH.2 However, no systematic study 
was done on these polymers. Figure 5.6. shows the size changes of star hyperbranched 
polymers SHB1-SHB4 in dependence of pH values. Table 5.4. gives an overview of 
the hydrodynamic radius at pH values under 5 and 7 and above 8. 
Table 5.4. DLS data of SHB1-SHB4 and DB1 in H2O at between pH values of 4 to 9.  
Name 
Dh [nm] 
pH ≤ 5 
Dh [nm] 
pH = 6-6.5 
Dh [nm] 
pH ≥ 8 
 nm 
SHB1 54 52 66 
SHB2 58 39 81 
SHB3 44 47 64 
SHB4 48 48 66 
DB1 24 54 54 
In Figure 5.6.a SHB2 is compared to the analogues DB1 polymer. As expected 
the diblock polymer showed a size of 24 nm at pH 4 till 6 and at higher pH (7) values 
the size increased to 54 nm. At low pH values the tertiary amine of DEAEMA is 
protonated and both blocks are soluble in water. Above a pH of 7 i.e. around the pKa 
of DEAEMA of 7.3 21 the DEAEMA block gets deprotonated and hence hydrophobic 
and the polymers assemble to micellar structures (Figure 5.6.a). SHB2 exhibits sizes 
of around 58 nm below pH 5, where the DEAEMA core is fully protonated and as 
such swollen. Cross-linking leads to the retention of the branched polymer architec-
ture (immobilization of linear DEAEMA blocks). The swelling of the DEAEMA core 
is then a direct consequence of the positive charges of the protonated nitrogen’s re-
pelling each other. Between pH 6 and 7 a decrease of the particles to sizes to 39 nm 
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could be observed (Table 5.4). In this pH range the DEAEMA core is partially proto-
nated i.e. enough to stabilise unimolecular particles and not enough for swelling of 
the core. An increase in pH above 7 leads to the full deprotonation of the core. The 
DEAEMA units return to being completely hydrophobic. Large structures of around 
81 nm were observed. This has been attributed to the formation of `Star-Hyper-
branched’-Micelles i.e. at high pH the core is so hydrophobic that stabilisation is 
achieved by self-assembly of multiple star hyperbranched polymers. These structures 
had previously been observed by Summerlin et. al. in thermoresponsive polymers.4 A 
schematic representation of this process is shown in the inlet in Figure 5.6.a. Compar-
ison to SHB1, SHB3 and SHB4 (Figure 5.6.b and Table 5.4) showed that swelling 
and shrinkage between pH 5 and 7 could be observed in SHB1 too. However, with a 
size change of 54 to 52 nm the effect was not very pronounced. This is probably a 
consequence of the denser crosslinking and smaller core. SHB3 and SHB4 exhibit no 
shrinking at pH 6. This was theorised to be due to the low crosslinking. Hence, SHB3 
and SHB4 behaved more akin to a diblock.  
 
Figure 5.6. Changes in hydrodynamic diamter in dependences of pH of a) SHB2 and DB1 and b) 
SHB1, SHB3 and SHB4. 
5.3.3. Schizophrenic assembly in aqueous solutions 
Poly(oligo (ethylene glycol mono-methyl ether) methacrylate (p(OEGMA)) is 
known to possess an LCST.23,24 When both blocks of a polymer can be switched re-
versibly from hydrophobic to hydrophilic by different stimuli, schizophrenic assem-
bly is a possibility. Schizophrenic micellization, describes the capability of a polymer 
to exist in aqueous medium in three different states, namely conventional micelles, 
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molecular dissolved chains and reverse micelles.25,26 SHBs were tested for schizo-
phrenic assembly by heating aqueous polymer solutions of SHB1 – SHB4 and DB1 
at pH 4 to 75 °C. NaOH was subsequently added to increase the pH to 9, while keeping 
the temperature at 75 °C, the solution was then cooled back to 25 °C. At constant 
temperature the pH was then decreased back to 5. The same was repeated in reserve 
to show the reversibility of the process. All sizes were recorded by DLS and the results 
are shown in Table 5.5 and Figure 5.7.  
As had been observed before (Table 5.4 and Figure 5.6) unimolecular polymer 
nanoparticles were found at pH 4.5 and 25 °C, while star hyperbranched micelles were 
observed above pH 9 and 25 °C. When the aqueous solutions at pH 4.5 were heated 
above the LCST of p(OEGMA), i.e. 75 °C, structures between 474 nm (SHB2) and 
135 nm (SHB4) were observed. These aggregates were stable even after prolonged 
time at 75 °C, while aggregates formed at pH 9 and 75 °C were significantly bigger 
and increased in size over time. This led us to believe that at pH 9, where both blocks 
are insoluble, aggregates of the polymer are formed which slowly precipitated out of 
solution. At pH 4.5 on the other hand, the DEAEMA core block is soluble and the 
formed aggregates can be stabilised in solution.    
 
Table 5.5. DLS data of aqueous solutions SHB1 – SHB4 and DB1 at different pH values and Tem-
peratures. 
Name 
Dh 
pH = 4.5 
T = 25°C 
Dh 
pH = 4.5 
T = 75°C 
Dh 
pH = 9 
T = 25°C 
Dh 
pH = 9 
T = 75°C 
 nm 
SHB1 54 369 66 Insoluble 
SHB2 58 474 81 Insoluble 
SHB3 44 135 64 Insoluble 
SHB4 48 196 66 Insoluble 
DB1 24 356 54 Insoluble 
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Figure 5.7. Plotted DLS data of a) SHB1; b) SHB2; c) SHB3; d) SHB4 and e) DB1 at pH 4.5 and 
25 °C (bold line), pH 4.5 and 75 °C (double line) and pH 9 and 25 °C (dotted line).  
Figure 5.8. shows the aqueous solutions of SHB2 at pH 4.5 and pH 9 at 25 °C 
and 75 °C respectively. As expected for an unimolecular dissolved polymer, the solu-
tion was clear at pH 4.5 and 25 °C. At pH 9 and 25 °C the solution was opaque as is 
typical of a solution containing micelles. Heating the solution at pH 4.5 up to 75 °C 
turned the solution slightly less opaque and no precipitation could be observed. When 
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the solution at pH 9 was heated above the LCST, the whole solution turned milky 
white and precipitate could be seen.    
 
Figure 5.8. Aqueous solutions of SHB2 at different Temperatures and pH values.   
Armes et. al. 27 described the formation of different structures in block-selec-
tive solvents as a function of the inherent curvature of the molecule. The curvature 
can be estimated via the following equation 
𝑝 =
𝑣
𝑎0𝑙𝑐
         (𝟓. 𝟖) 
with p = packing parameter, v = volume of hydrophobic chains, ao = optimal area of 
head group and lc = lengths of chains of hydrophobic tail.  
They postulated that when p ≤ 1/3 (High curvature) polymers self-assembled 
to micelles, between 1/3 ≤ p ≤ 1/2 (medium curvature) cylindrical micelles were ob-
served and between 1/2 ≤ p ≤ 1 (low curvature) polymersomes were obtained.  
Although this model best fits the behaviour of linear, amphiphilic diblock co-
polymers and does not account for crosslinking, it can still be used in this research to 
discuss possible structures for pH 9, 25 °C and pH 4, 75 °C. At pH 9 and 25 °C the 
hydrophobic core of the star hyperbranched polymers ‘tightens’. Hence, v and lc de-
crease, while at the same time the OEGMA block straightens and ao increases. The 
curvature decreases to less than 1/3 and star hyperbranched-micelles form (Table 
5.5.).  At pH 4 and 75 °C the DEAEMA block becomes hydrophilic due to protona-
tion, while OEGMA becomes insoluble, making DEAEMA the new head group. 
However, because of the low molecular weight, especially in SHB1, SHB2 and DB1, 
158 
 
the area of the headgroup does not increase much in size. The OEGMA block, now 
the hydrophilic part, collapses above the LCST. Yet, it was theorised, on the basis of 
the size of the aggregates, that due to the relatively high molecular weight of the 
OEGMA block, steric hindrance keeps the block from folding tight enough to form 
inverse micelles. Unfortunately, because of the elevated temperatures needed, no 
Cryo-TEM images could be obtained. In SHB3 and SHB4 the observed structures at 
pH 4 and 75 °C were significantly smaller at 135 nm and 196 nm respectively. It was 
assumed that, because of the longer DEAEMA chain, the optimal area of the head-
group increased and the packing parameter decreased, which might have led to the 
formation of inverse micelles. From this data, the following structures for SHB1, 
SHB2 and DB1 were proposed (Figure 5.9). 
 
Figure 5.9. Different self-assembled structures of aqueous solutions of SHB1, SHB2 and DB1 at dif-
ferent pH values and temperatures.  
Subsequently it was investigated if the varying core structures had any influ-
ence on the LCST. To that end DLS of aqueous samples of SHB1-SHB4 and DB1 at 
pH 4.5 were measured. These samples were heated stepwise and Z-average size data 
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and count rate was recorded every 0.2 °C. The results are shown in Figure 5.10. Table 
5.6. lists the obtained LCSTs i.e. where the Z-Average as well as the count rate spike 
indicating the transition from hydrophilic to hydrophobic. 
 
Figure 5.10. DLS data of a) Size against temperature at pH 4.5 and b) Count rate against temperature 
at pH 4.5. 
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Table 5.6. LCSTs of SHB1-SHB4 and DB1 at pH 4.5 derived from DLS data of Z-Average and 
count rate 
Name LCSTZ-Average LCSTCount rate 
 °C 
SHB1 68.0 68.0 
SHB2 67.0 66.8 
SHB3 72.0 72.0 
SHB4 72.4 72.6 
DB1 66.0 65.8 
It was found that cross-linked polymers exhibited a slightly higher LCST than 
non-cross-linked structures e.g. DB1 = 66 °C and SHB2 = 67 °C, this is in direct 
contrast to what Davis et. al. 20 found when they studied a system of poly(di(ethylene 
glycol) methacrylate-co-oligo(ethylene glycol) methacrylate-co-ethylene glycol di-
methacrylate) p(DEGMA-co-OEGMA-co-EGDMA). Their system however, did not 
possess a second, non-temperature sensitive block. SHB3 and SHB4 exhibited a sub-
stantially higher LCST of around 72 °C at which point the increase of count rate as 
well as Z-Average size was significantly lower than previously observed in SHB1-
SHB4 and DB1. This was attributed to the high molecular weight of the DEAEMA 
block increasing the hydrophilicity.  
 
Figure 5.11. DLS data of a) SHB1-SHB4 and DB1 at 25, 35, 45, 55, 65 and 75 °C at pH 4.5 and b) 
SHB2 and DB1 at 75 °C and pH 5, 4, 3 and 2.  
To ensure that the observed structures were stable over time at the recorded 
temperatures, aqueous solutions of SHB1-SHB4 and DB1 at pH 4.5 were heated from 
25 to 75 °C in steps of 10 °C and kept at each temperature for 30 minutes after which 
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size data was recorded for another 30 minutes. The results are plotted in Figure 5.11. 
a.  
The DLS data measured proved the previous observations. For SHB1, SHB2 
and DB1 unimolecular structures were observed between 25 and 65 °C. After 75 °C 
the size increased dramatically to 350 – 450 nm, which correspondents well to previ-
ous observations in Figure 5.10. For SHB3 and SHB4 smaller sizes of 250 and 150 
nm respectively could be detected. For SHB3 the transition could be measured at 
65 °C as had been shown before, while the size increase in SHB4 started earlier at 
55 °C. 
As a further step, size changes as a function of pH was investigated. To that 
end, aqueous solutions of SHB2 and DB1 were measured at pH 2,3,4 and 5 and at 
75 °C. The results are shown in Figure 5.12.b. It was found that for both polymers 
sizes were stable in between pH 5-3, with DB1 being consistently smaller than SHB2. 
When the pH changed to pH 2, the sizes decreased from 380 to 200 nm for DB1 and 
450 to 280 nm for SHB2. A possible explanation is that a too acidic environment 
might have led to a disassembly of the structures.   
After careful consideration of the presented data, SHB2 was chosen to inves-
tigate drug encapsulation and release of a water insoluble drug, because of its favour-
able size changes in dependence of pH. 
5.3.4.  Drug encapsulation and triggered release 
SHB2 and DB1 were subsequently investigated for their encapsulation and pH 
dependent release profiles of indomethacin (IMC), a water insoluble drug. To that end 
indomethacin and polymer SHB2 were dissolved into ethanol in a ratio of 1:2 and the 
same amount of DI water was added. After the ethanol was evaporated off, UV/Vis 
was measured of the aqueous solution to obtain the percentage of encapsulated drug. 
The results are shown in Figure 5.12. The inlet photo shows the control solution of 
SHB2 in water, indomethacin evaporated into water without polymers, indomethacin 
and SHB2 in a ratio of 1:2 in water at pH 6.5 and indomethacin and SHB2 in a ratio 
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of 1:2 in water at pH 4.5.
 
Figure 5.12. UV/Vis curves in DI water of SHB2 and indomethacin (2:1) (blue line); DB1 and indo-
methacin (2:1) (yellow line) and indomethacin without polymer (dotted line). The inlet shows the so-
lutions of SHB2 and indomethacin at different pH values and polymer and drug control solutions.  
The UV/Vis data showed that without polymer present no indomethacin was 
dissolved in water. 100 % of IMC could be encapsulated into SHB2, while only 47 % 
of indomethacin had been encapsulated into DB1, which correspondents to 25 wt %, 
which is often found for micelles formed from linear polymers.28-30 When the pH 
dropped to 4.5 precipitated indomethacin was observed (Inlet Figure 5.12). Next, in-
domethacin release from SHB2 and DB1 at pH 4.5 and pH 6.5 was measured. The 
plotted data is shown in Figure 5.13.  
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Figure 5.13. Release data of SHB2 (blue) and DB1 (yellow) at pH 4.5 (bold lines) and pH 6.5 (dotted 
line). 
The release profiles of SHB2 and DB1 were measured over 30 hours at pH 4.5 
and pH 6.5. At pH 4.5 an initial burst release of indomethacin of 5 % and 30 % in the 
first half hour for SHB2 (blue bold line) and DB1 (yellow bold line) respectively was 
observed. After another hour, 21 % indomethacin had been released from SHB2 and 
40 % from DB1. After 2 hours a slow, continues release of indomethacin from SHB2 
of 3-4% per hour was observed, until 97 % indomethacin had been released. The re-
lease profile for DB1 on the other hand, showed that after 6 hours 75 % of the drug 
had already been released, after which the release significantly slowed down. At 30 
hours only 90 % indomethacin could be detected in solution, while the rest remained 
encapsulated in DB1. The core of SHB2 possesses cavities in which actives can be 
loaded at neutral pH. At low pH the core expands, and the indomethacin molecules 
slowly diffuse out. The result is a slow, continues, controlled release. Micelles formed 
from linear, non-cross-linked polymers (DB1) on the other hand, ‘burst’ apart when 
the pH decreases. The control experiments at pH 6.5 show an initial burst release of 6 
% and 22 % for SHB2 (dotted blue line) and DB1 (yellow dotted line) respectively 
after pH adjustment. After 30 h, 10 % (SHB2) and 26 % (DB1) indomethacin had 
leached out, hence at pH 6.5 no significant release was detected. This data proved that 
the indomethacin release was triggered by lowering the pH. 
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The measured data showed that at lower pH, an encapsulated active could be 
released. This would be adventitious for a triggered release of cancer drugs into the 
cell, due to a lower pH in the endosome and lysosome. While it is possible for polymer 
nanoparticles to utilise the EPR effect to diffuse into a malignant cell, additional active 
targeting would be favourable. This can be achieved by functionalising the surface of 
the polymer nanoparticles.  
5.3.5.  End-group cleavage and functionalisation/ gelation 
Using RAFT polymerisation, post-polymerisation modification is easily avail-
able by reducing the trithiocarbonate group of the Z-group to a thiol.31 This enables 
the use of thiol-ene `click` chemistry. Different routes can be envisaged to obtain a 
thiol end-group, e.g. radical induced reduction, thermal elimination, reaction with a 
nucleophile.32 In this work aminolysis was used to obtain a thiol end-group, following 
the example of Summerlin et. al. 33, because of the mild reaction conditions. Figure 
5.14.a shows a scheme of the synthesis on the example of SHB2. The reaction was 
followed by UV/Vis.34  
 
Figure 5.14. a) Schematic representation of the aminolysis reaction of SHB2 to SHB2-SH and UV/Vis 
spectra pre- and post-aminolysis reaction of b) DB1 and c) SHB2 measured in THF.  
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Figure 5.14.b and c shows the measured UV/Vis spectra in THF pre- and post-
aminolysis of DB1 and SHB2 respectively. Pre-reaction the UV/Vis spectra showed 
a strong signal at 310 nm. This was assigned to the trithiocarbonate group of the 
RAFT-transfer agent and can be found in both the spectra for DB1 and SHB2 pre-
reaction. After the reaction the signal disappeared (yellow and blue dotted lines), due 
to the loss of the conjugated system. This proved that the reaction had been successful, 
and SHB2-SH and DB1-SH were obtained. To confirm that no disulphide bonds 
formed during the reaction, GPC was measured. No size change could be detected. 
SHB2-SH was consequently reacted with N-(5-Fluoresceinyl)maleimide, a 
fluorescent dye, by thiol-ene ‘click’ chemistry. A fluorescent dye was chosen because 
it allowed the easy following of the reaction by UV/Vis as well as give a visual con-
firmation of a successful reaction. The reaction could be carried out at room temper-
ature and non-inert conditions, under the exclusion of light. After stirring overnight, 
the product was purified by dialysis against DI water for 24 h. Freeze-drying afforded 
the product as a yellow powder. Figure 5.15.a shows a schematic representation of the 
thiol-ene ‘click’ reaction between SHB2-SH and N-(5-Fluoresceinyl)maleimide to af-
ford SHB2-dye.  
 
Figure 5.15. Schematic representation of the thiol-ene ‘click’ reaction between SHB2-SH and FM to 
afford SHB2-dye 
Figure 5.16 shows the UV/Vis spectra of SHB2-dye, SHB2 and SHB2-SH 
measured in water. Before aminolysis (bold line) a small shoulder at 310 nm indicates 
the presence of the trithiocarbonate group bond. After aminolysis the shoulder disap-
peared (dotted line), indicating the successful reduction to a thiol. The double line 
shows the product after the reaction with the fluorescent dye. A new sharp signal at 
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500 nm was clearly observed. The excitation wavelength for N-(5-Fluoresceinyl)ma-
leimide has been stated as 490 nm in buffer solution (0.1 M Tris pH 8.0) by the ven-
dor.35 This corresponds well to the measurements in DI water and proves that the 
reaction had been successful, and this simple reaction could be used to obtain surface 
functionalized hyperbranched polymers.  
 
Figure 5.16. UV/Vis spectra of SHB2 pre-aminolysis (bold line), SHB2-SH post-aminolysis (dotted 
line) and SHB2-dye after thiol-ene ‘click’ reaction (double line) in DI water.  
Summerlin et. al. 33 described the synthesis of temperature sensitive, symmet-
rical triblock polymers by RAFT with a labile trithiocarbonate linkage in the midpoint 
of each chain. These polymers were able to form reversible hydrogels i.e. networks of 
polymer chains that are highly absorbent to water, by temperature changes. Cleavage 
of the trithiocarbonate bonds to thiols led to free-flowing micellar solution of diblock 
polymers above the LCST and the formation of gels under oxidative conditions. Hy-
drogels are highly interesting for pharmaceutical applications, due to their high po-
rosity, which can easily be tuned by the cross-linking density and flexibility similar 
to natural tissue. Actives can be loaded into the gel matrix which are then able to 
diffuse out when the gel swells in water.36,37  
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The formation of hydrogels using SHB2 was subsequently investigated. Fig-
ure 5.17.a shows a schematic representation of the gelation of SHB2-SH under oxi-
dative conditions.  
 
Figure 5.17. a) Schematic representation of the gelation of SHB2-SH under oxidative conditions and 
b) Vial inversion test of 5 wt % gels of DB1, DB1-SH, SHB2 and SHB2-SH at pH 7. 
 
Figure 5.17.b shows photographs of 5 wt % gels of SHB2-SH and DB1-SH, 
as well as the control experiments SHB2 and DB1 at pH 7. At 5 wt % gels could be 
formed of SHB2-SH, while even at a concentration of 10 wt % no gels could be 
formed using DB1-SH. This was attributed to the cross-linked nature of the hyper-
branched polymers (Figure 5.17.a). Control experiments with SHB2 and DB1 showed 
that when the trithiocarbonate bond is still present no gel formation took place (Figure 
5.17.b).  
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5.4.  Conclusion  
Up to this point we primarily focused on the formation of drug nanoparticles 
by bottom-up techniques. However, while the drug nanoparticles obtained in Chapter 
2 and 3 showed prolonged storage ability in suspension and in solid form, the nano-
suspensions obtained in Chapter 4 tended to agglomerate and precipitate after 24 
hours. We theorised that this was mainly due to the changed polymer state from solid 
to viscous fluid. These types of polymers are, for that reason, more often used as 
nanocarriers for drug encapsulation and release, especially as an alternative to micel-
lar carrier systems, which have been known to premature release their cargo in the 
bloodstream, due to the critical micelle concentration. Cross-linking circumvents this 
problem. Thus, this Chapter focused on the design and optimization of a hyper-
branched polymer system for encapsulation and release of water insoluble actives.  
DEAEMA was chosen as the core monomer to facilitate pH triggered struc-
tural changes, which can be used to trigger release at specific sites in the body.13 A 
series of hyperbranched polymers with varying DEAEMA block lengths were suc-
cessfully synthesised via RAFT polymerisation to avoid the use of heavy metals. Hy-
perbranched cores were chain-extended with OEGMA to form star hyperbranched 
polymers. A diblock polymer of the ratio DEAEMA:OEGMA 50:80 was synthesised 
to serve as a comparison. Increasing the ratio of DEAEMA:CTA, led to decreased 
branching and number of arms. This trend had a direct influence on the pH sensitive 
behaviour. Hyper star polymers with cores of 25 (SHB1) and 50 (SHB2) DEAEMA 
units showed core expansion below pH 6, after which the core contracted to form star 
hyperbranched micelles at high pH.  
OEGMA possesses an LCST. Hence, star hyperbranched polymers were tested 
for ‘schizophrenic’ self-assembly. Polymers SHB1, SHB2 and DB1 showed interest-
ing transitions to assembled structures around 500 nm at low pH and elevated temper-
ature. SHB2 was chosen for further studies because of its favourable behaviour at 
different pH values.  
Initially, the encapsulation ability of hyperbranched star polymers compared 
to conventional diblock polymers was studied. A high drug loading ratio of 1:2 
(drug:polymer) was chosen and it was observed that by using SHB2 twice the amount 
of IMC could be encapsulated compared to a conventional diblock polymers. IMC 
release was recorded at pH 4.5 and 6.5 from SHB2 and DB1 over a period of 30 h. 
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DB1 showed a burst release at pH 4.5 in the first hour and fast release over a period 
of 7 h, after which the release slowed down. After 30 h no complete release had been 
observed. Release profiles of SHB2 at pH 4.5 in comparison showed a small initial 
release of indomethacin, which was attributed to the change in pH. After the first hour 
a steady and slow release of indomethacin was observed that continued till, after 30 
h, all active had been released. Release profiles at pH 6.5 both showed initial burst 
release after pH adjustment followed by drug ‘leaching’, confirming that the release 
is triggered at low pH values. Micellar drug carriers have been known to release their 
cargo in bursts after the external stimuli is applied. As such drug release often reaches 
100% after a few hours.39-41 While this might be desirable for some actives, prolonged, 
continues and slow drug release as was observed using HBPs, would be favourable 
for patients with chronic illnesses that require regular intake of drugs to decrease the 
daily intake and enhance patient comfort.  
To increase the specificity of drug delivery, active targeting can be employed 
i.e. the surface of the polymer can be equipped with targeting ligands. The scope of 
surface modification was probed by modifying SHB2 with a fluorescent dye. To that 
end the trithiocarbonate bond was reduced to a thiol bond via aminolysis. This thiol 
bond was then successfully used to ‘click’ on N-(5-Fluoresceinyl)maleimide, proving 
that star hyperbranched polymers could readily be surface modified by thiol-ene 
‘click’ chemistry. This opens the possibility to use star hyperbranched polymers for 
active targeting in drug delivery or as a multifunctional platform for drug delivery and 
bioimaging.  
Branched and star polymers have been used to form hydrogels for drug deliv-
ery. For this reason, star hyperbranched polymer SHB2 was tested for the ability to 
form hydrogels. The obtained thiols were used to form disulphide bonds under oxida-
tive conditions. It was possible to successfully form gels at 5 wt % concentration using 
SHB2-SH, while no gels could be formed using DB1-SH even at concentrations of 
10 wt %.  
In summary a versatile, easily synthesised polymer platform was obtained and 
systematically studied for drug encapsulation and release. Compared to conventional 
micelles, a favourable controlled and slow release could be measured. The investi-
gated polymer platform is also promising for active targeting by simple surface mod-
ification.  
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Summary and Outlook 
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6.1. Summary 
(Hyper)Branched polymers were investigated throughout this thesis for their 
potential to be employed in encapsulation and nanodrug formulation as favourable 
alternatives to established additives i.e. surfactants, liposomes and block copolymers 
which are currently used in the pharmaceutical industry. 
In Chapters 2 and 3, we synthesised branched polymers of linear, low molec-
ular weight PEG and varying core monomers, i.e. PNIPAm, BMA, and Styrene us-
ing conventional, radical polymerisation.  
In Chapter 2, core-shell branched polymers were tested for their ability to 
stabilise emulsions, and for their use in emulsion freeze-drying, a novel bottom-up 
technique used to obtain nanoparticles of Indomethacin (IMC) and Oil Red O (OR). 
The branched polymers acted as a stabilising scaffold against agglomeration after 
the freeze-drying process. After successfully obtaining indomethacin and oil red 
nanoparticles via emulsion freeze-drying, the process was repeated on triclosan, an 
antimicrobial drug. The obtained triclosan nanoparticles were tested against Candida 
albicans, an opportunistic, pathogenic yeast, where a 6-fold increase in activity was 
found compared to non-processed triclosan.  
In Chapter 3, drug nanoparticles were formed via a simple solvent evapora-
tion technique using the lightly crosslinked polymer PEG135-b-(PNIPAm50-co-
EDAm2n)-b-PEG135 (n = 0.3; 0.6). The influence of solvent, active, pressure and, 
temperature was investigated. Ethanol and ketoprofen were found to be the best 
combination of solvent and active for the process and were used for kinetic studies. 
Long-term stability, and the possibility to obtain small particle sizes, independent of 
pressure and temperature applied during the process was successfully demonstrated. 
PXRD, Cryo-TEM, and DLS data was subsequently used to propose a mechanism. 
Dissolution measurements indicated a clear increase in dissolution of the obtained 
ketoprofen nanoparticles compared to non-processed ketoprofen.  
In Chapter 4, branched polymers of oligo(ethylene glycol) methyl ether 
methacrylate (OEGMA) and butyl methacrylate (BMA) with varying core composi-
tions were synthesised by atom-transfer radical-polymerisation (ATRP) and tested 
for their ability to stabilise drug nanosuspension. ATRP was used to afford better 
polymerisation control compared to conventional polymerisation used in Chapter 2 
and 3. BMA exhibits upper critical solution temperature (UCST) behaviour in meth-
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anol and unimolecular polymer nanoparticle solutions could be obtained by heating 
through the UCST without the need for a dialysis process. The UCST was subse-
quently used to form drug nanosuspensions of water insoluble drugs. Nanosuspen-
sions with high drug loading, i.e. up to 8 w/v %, small PDI and sizes below 460 nm 
were successfully obtained.  
In Chapter 5, a polymer platform for encapsulation and targeted release was 
designed and optimised. A series of pH responsive star hyperbranched polymers of 
the composition p(OEGMA)80-b-p(DEAEMAx-co-DEGDMA2) with increasing x 
was synthesised via reversible addition−fragmentation chain-transfer polymerisation 
(RAFT). The series was investigated for pH responsive behaviour in dependency of 
core composition i.e. shrinkage and expansion, and schizophrenic micellization. The 
polymer with the most favourable core composition was subsequently investigated 
and compared to a linear diblock copolymer analogue, for the encapsulation and pH 
triggered release of indomethacin. Increased encapsulation efficiency and prolonged, 
continuous release, instead of burst release, could be observed compared to the di-
block analogue. The possibility of surface modification for active targeting was in-
vestigated. As a proof of concept, a fluorescent dye, N-(5-Fluoresceinyl)maleimide, 
was successfully ‘clicked’ on via thiol-ene click chemistry. Thiol end-group carrying 
polymers were successfully used to form gels of hyperbranched polymers via disul-
phide bond formation  
In summary, different kinds of branched polymers were synthesised by con-
ventional radical polymerisation, as well as RDRP, and their potential to be used in 
drug delivery of water insoluble drugs was studied.  
It was demonstrated that by finely tuning the physical properties of the pol-
ymers, a plethora of applications are possible. Branched polymers could be used for 
the formation and stabilisation of solid drug nanoparticles by two different bottom-
up techniques, i.e. emulsion freeze-drying, and solvent evaporation. Enhanced disso-
lution, bioavailability, and activity in-vitro compared to non-processed water insolu-
ble drugs was successfully shown. Both bottom-up techniques using branched pol-
ymers investigated here, were shown to be good alternatives to current techniques 
applied in the pharmaceutical industry for producing drug nanoparticles. Using 
RDRP, a branched polymer platform was designed, in which every component, i.e. 
core, arms, and surface, can easily be modified. Due to the possibility to isolate and 
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store every step of the synthesis, batches of hyperbranched cores could be synthe-
sised and ‘grown’ out with a wide variety of monomers to obtain a range of poly-
mers with different physical and chemical characteristics. In this thesis, hyper-
branched polymers with a cross-linked, pH responsive core were successfully used 
to release a cargo in acidic environments and presented a favourable alternative to 
micellar carrier to circumvent issues such as burst and premature release. 
6.2. Outlook 
Synthesising branched polymers by a ‘core’-first method makes it possible to 
design every part of the branched polymer, i.e. core, arms, and surface to specifical-
ly fit certain needs. As such, further studies should be done using different core 
compositions to investigate the interactions of different water insoluble actives with 
the core to further optimise encapsulation and release as well as drug nanoparticle 
formation. Along with the investigation of the interaction between core and actives, 
stimuli responsive behaviour and release should be studied further. While a respon-
sive core-forming monomer was used in this work to endow branched polymers with 
environmental responsiveness, i.e. core contraction and expansion, further studies on 
stimuli responsive cross-linkers, e.g. cross-linkers that possess disulphide bonds that 
would be reduced to thiols in a reductive environment, would be of interest for tar-
geted drug delivery. Pre- or Post-modification of the Z-group of the RAFT-CTA to a 
reactive functionality can also be utilised to endow hyperbranched polymers with 
target specific ligands. These ligands can easily be chosen to fit specific proteins on 
maligned cells. Using this lock-key principle, it was shown to be possible to de-
crease the amount of drug needed in the treatment of cancer. Which in turn, would 
enhance patient comfort and toxic side effects of treatment. To demonstrate the dual 
ability of hyperbranched polymers for active targeting and stimuli responsive drug 
release, hyperbranched polymers should be endowed with targeting ligands and in-
vitro studies should be conducted.  
  
 
 
 
„Alles hat ein Ende nur die Wurst hat zwei"  
German proverb 
